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Abstract 
 
Rooibos (Aspalathus linearis) has been shown to have various health benefits including 
antidiabetic, lipid-lowering, and hepatoprotective properties. Although anecdotally Rooibos 
consumption is regarded as safe, recently, two case studies have associated chronic 
consumption of Rooibos with conventional prescription medications, such as atorvastatin, with 
hepatotoxicity. The cholesterol-lowering drugs, statins, act by competitively inhibiting 
hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, a rate-limiting enzyme in 
cholesterol synthesis. Although rare in occurrence, statins are potentially hepatotoxic. The 
safety of the concurrent use of Rooibos and statins thus needs to be elucidated. 
This study aims to investigate the interaction between the potential hepatoprotective effects 
of Rooibos and statin-induced hepatotoxicity using an in vitro C3A liver cell model.  
C3A liver cells, in both normal and hyperlipidaemic conditions, were exposed to atorvastatin 
(ATV; 10 µM and 25 µM) and Afriplex GRT™ (green Rooibos extract; 0.01 mg/mL and 0.1 
mg/mL) and a combination thereof. Pre-treatment with palmitate (500 µM) for 24 hours was 
used to induce a hyperlipidaemic condition in vitro. The effects of the co-treatment on cell 
viability, oxidative stress, apoptosis, mitochondrial integrity and cellular ROS production were 
assessed in a C3A liver cell culture model. In addition, 3D culture was used to produce C3A 
liver spheroids, and the effect of the treatments in a chronic culture was then assessed. 
GRT was not cytotoxic at any of the concentrations tested, whereas ATV showed time- and 
concentration-dependent cytotoxicity in C3A cells. A significant increase in ROS production 
was observed in C3A cells exposed to 25 µM ATV and palmitate (353.10% ± 262.70 vs. 
1431.00% ± 504.2). Similar results were seen following ATV and GRT combination therapy 
(845.00% ± 589.60 vs. 1493.00% ± 278.4). Under hyperlipidaemic conditions, ATV induced 
significant increases in apoptosis (19.50% ± 3.56 vs. 52.83% ± 7.14) which was not 
ameliorated by GRT co-treatment (13.83% ± 2.79). The results of the 3D culture showed 
complementary results. Treatment with palmitate and ATV was toxic to the spheroids and 
treatment with GRT was unable to attenuate this toxicity. A decrease in cellular ATP was found 
in the ATV and ATV+GRT treated spheroids (1.45 AU/µm3 ± 1.00, and 3.79 AU/µm3 ± 2.32, 
respectively, vs control, 161.02 AU/µm3 ± 55.26) as well as decreased glucose utilisation 
calculated from the increased remaining glucose in the treatment media (91.83% and 94.68%, 
respectively, vs control,100%).  
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The culmination of experiments showed that ATV was hepatotoxic. This effect was 
exacerbated by exposing the cells to palmitate intended to mimic a hyperlipidaemic condition. 
GRT co-treatment did not show any modulating effects on ATV-induced hepatotoxicity under 
the acute or chronic conditions tested.  
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Opsomming 
 
Rooibos (Aspalathus linearis) besit verskeie gesondheidsvoordele insluitend antidiabetiese, 
lipiedverlagende eienskappe en bied beskerming teen lewertoksisiteit. Alhoewel die verbruik 
van Rooibos anekdoties as veilig beskou word, het twee gevallestudies onlangs 
hepatotoksisiteit, geassosieer met die gesamentlike gebruik van Rooibos met konvensionele 
kroniese voorskrifmedisyne, insluitend die statien, atorvastatien. Die cholesterolverlagende 
statiene, is mededingende inhibeerders van hidroksielmetielglutaryl-koënsiem A (HMG-CoA) 
reduktase, 'n tempo-beperkende ensiem in cholesterolsintese. Alhoewel dit selde voorkom, is 
statiene soms hepatotoksies. Die veiligheid van rooibos en statiene se gelyktydige gebruik 
moet dus getoets word. 
Hierdie studie het ten doel om die potensiële beskermings-interaksie tussen ‘n aspalatien-ryk 
groenrooibos ekstrak, Afriplex GRT™ (GRT) en statien-geïnduseerde hepatotoksisiteit in ‘n 
C3A lewerselkultuur model te ondersoek. 
C3A lewer selle, onder beide normale en hiperlipidaemiese toestande, is behandel met 
atorvastatien (ATV; 10 µM en 25 µM) en GRT (0.01 mg/mL en 0.1 mg/mL) asook 'n kombinasie 
daarvan. ‘n Voorbehandeling met palmitaat (500 µM) vir 24 uur is gebruik om 'n 
hiperlipidemiese toestand in vitro te veroorsaak. Die gevolge van die mede-behandeling op 
sel- lewensvatbaarheid, oksidatiewe stres, apoptose, mitochondriale membraan-integriteit en 
sellulêre ROS-produksie is in C3A-lewerselkultuur ondersoek. Daarbenewens is 3D selkultuur 
gebruik om C3A lewersferoïede te produseer, om die kroniese effek van die behandelings op 
lewer weefsel na te boots. 
GRT was nie sitotoksies by die konsentrasies wat getoets is nie, terwyl ATV tyd- en 
konsentrasie-afhanklike sitotoksisiteit in C3A-selle getoon het. 'n Beduidende toename in 
ROS-produksie is waargeneem in C3A-selle wat aan 25 µM ATV en palmitaat (353.10% ± 
262.70 vs. 1431.00% ± 504.2) blootgestel was. Soortgelyke resultate is waargeneem met 
ATV- en GRT-kombinasie terapie (845.00% ± 589.60 teen 1493.00% ± 278.4). Onder 
hiperlipidemiese toestande het ATV beduidende toenames in apoptose (19.50% ± 3.56 
teenoor 52.83% ± 7.14) veroorsaak wat nie deur GRT-mede-behandeling verbeter is nie 
(13.83% ± 2.79). Die resultate van die 3D-kultuur het komplementêre resultate getoon. 'n 
Afname in sellulêre ATP is gevind in die ATV- en ATV + GRT-lewersferoïede (1.45 AU/µm3 ± 
1.00 en 3.79 AU/µm3 ± 2.32, onderskeidelik). Glukoseverbruik is ook verminder, soos bereken 
uit die oorblywende glukose in die behandelingsmedia (91.83% en 94.68%, onderskeidelik). 
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Behandeling met palmitaat en ATV was toksies vir die lewersferoïede en behandeling met 
GRT kon nie hierdie toksisiteit ophef nie. 
Die resultate van die eksperimente het getoon dat ATV hepatotoksies was. Hierdie effek is 
vererger deur die selle aan palmitaat bloot te stel, wat gebruik was om 'n hiperlipidemiese 
toestand na te boots. Die GRT-medebehandeling was oneffektief om die selle teen die ATV-
geïnduseerde hepatotoksisiteit onder die akute of kroniese toestande te beskerm. 
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1 Introduction 
 
Aspalathus linearis, also known as Rooibos, is a shrub indigenous to South Africa, and is 
recognised for its health benefits. Rooibos has been shown to have beneficial effects on 
metabolic diseases, including having antidiabetic (Son et al, 2013) and lipid-lowering 
properties (Beltrán-Debón et al, 2011). Furthermore, Rooibos has been shown to confer 
hepatoprotective properties (Uliĉná et al, 2003; Kucharská et al, 2004; Ajuwon et al, 2013; 
Canda et al, 2014) in multiple studies. The unabated pandemic of metabolic disease and 
associated co-morbidities has fuelled the demand for alternative and complementary 
medicines, which are perceived to be effective without adverse side-effects.  
 
Pharmaceutical agents, although clinically proven to be effective, are often associated with 
side-effects. Currently, the increase in public health awareness has caused an increase in the 
use of alternative therapeutic options to treat chronic conditions, either in conjunction with 
prescription medicines or as an alternative treatment, often without consulting health 
practitioners. Given the growing popularity in the use of natural health products to enhance 
health, the likelihood of supplementing chronic prescriptions with natural medications is 
increasing. However, information on the safety of combining natural products and 
pharmaceutical products is sparse and the potential for herb-drug interactions is becoming a 
serious concern. Research into potential herb-drug interactions is therefore becoming 
increasingly urgent. 
 
Atorvastatin is considered a “blockbuster drug” as the best-selling prescription drug in history, 
with lifetime sales of USD 148 744 million between 1996 and 2016 (editorial in The Lancet, 
2011; Forbes, 2013). Statins are a major chronic prescription worldwide and are administered 
to lower increased cholesterol levels in patients who are at increased risk of developing 
cardiovascular disease. They act by competitively inhibiting hydroxymethylglutaryl-coenzyme 
A (HMG-CoA) reductase, the first and key rate-limiting enzyme of the cholesterol biosynthetic 
pathway (Björnsson et al, 2012).  As with all chronic and prescription medication, the risk for 
the development of side-effects exists. Although rare, statin usage has resulted in serious 
side-effects in some patients, the most severe of which include new-onset diabetes, myalgia 
and myopathy, as well as the potential of rhabdomyolysis or hepatotoxicity. The presence of 
these side-effects or even the potential thereof, often causes patients to cease statin treatment 
and pursue alternative treatment options. Up to 32% of patients on statins cease taking the 
drug within the first six months. The changing of one’s diet, for example, may act as a 
preventative measure. However, this alone is unlikely to significantly improve one’s 
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cardiovascular risk-profile and prevent the necessity of statin treatment in the long run. 
Similarly, in order to lessen the statin dosage and mitigate the risk of side-effects, patients 
may be self-medicating with supplements that exert their own health and risk-profile 
modulating effects, Rooibos supplementation, as an example. 
 
Several natural products, including Rooibos, have been shown to infer metabolic 
benefits.  Findings by the Biomedical Research and Innovation Platform at the South African 
Medical Research Council have demonstrated that an aspalathin-enriched unfermented 
Rooibos extract (GRT) improves glycaemia and dyslipidemia in various diabetic models 
(Mazibuko et al, 2013; Dludla et al, 2014; Mazibuko et al, 2015; Johnson et al, 2016), including 
non-human primates. Controversially, two case studies exist that show that supplementing 
maintenance treatment of rituximab and daily administration of prednisolone with Rooibos 
(Sinisalo et al, 2010), or a Rooibos and Buchu combination in conjunction with oral steroids 
as well as long-term atorvastatin use (Engels et al, 2013), have been associated with the 
development of hepatotoxicity. This highlighted the gap in knowledge of whether or not 
Rooibos increases the risk of adverse herb-drug interactions. However, pre-clinically it has 
been shown that Rooibos is hepatoprotective against chemically-induced hepatotoxicity and 
hepatic injury (i.e. through administration of CCl4-, LPS, or t-BHP). It is unknown whether or 
not this hepatoprotective effect can be conferred in the case of ATV-induced toxicity. It is 
therefore important to understand whether these interactions could pose an added risk for 
hepatotoxicity, or, contrastingly, whether Rooibos is able to ameliorate ATV-induced 
hepatotoxic damage. 
 
To address this, a combination of aspalathin-enriched Rooibos and ATV treatment was used 
to assess whether the ATV-induced hepatotoxicity could be ameliorated by the 
hepatoprotective effects of GRT. In terms of clinical and therapeutic relevance, both acute and 
chronic models were assessed, by using 2D and 3D culture of liver cells, respectively.  
 
The use of conventional cell culture allows for the assessments of mechanistic and acute 
effects of a treatment on a cell line. The present study assessed cell viability using an MTT 
assay, mitochondrial integrity in terms of ROS production, using a DCF assay, and 
mitochondrial membrane potential, using a JC-1 dual emission stain assessed using flow 
cytometry. Secondly, markers of apoptosis were assessed: annexin V/PI staining, assessed 
with flow cytometry, showed the differentiation between viable, and early and late apoptotic 
cells, while a caspase 3/7 assay showed the activation of the apoptotic pathway. All of these 
parameters were assessed in the normal and a palmitate-induced hyperlipidaemic condition. 
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This study further investigated the usefulness of using a 3D culture model to assess the 
potential of chronic or accumulative toxicity of ATV and co-treatment with GRT. The value of 
this experimental approach is two-fold. Firstly, although the technique is still in its experimental 
or developmental phase, it is intended to act as an intermediate between in vitro and in vivo 
studies and is ethically justified as it potentially reduces the number of animals used for 
pharmaceutical and cosmeceutical experimentation. Secondly, rodents, such as mice and 
rats, lack certain human isozymes of important drug metabolising enzymes such as CYP3A4 
which is a primary metabolising enzyme for both ATV and GRT. Cell lines, such as 
HepG2/C3A, are used to produce liver spheroids. The spheroids produced are representative 
of human liver tissue (see Chapter 5: Results: 5.9 Transmission electron micrographs) as they 
are a long-term culture that avoids cell passaging. As the cell lines are human-derived, human 
metabolising enzymes are expressed, offering the opportunity for demonstrating herb-drug 
interactions relevant to hepatotoxicity 
 
Initial cytotoxicity was performed on GRT and ATV, illustrating the effects of the treatments on 
the cells at a range of dosages. The concentration selection for GRT was literature-relevant 
(Muller et al, 2012; Mazibuko et al, 2013; Mazibuko et al, 2015), while the dose selection of 
ATV was chosen as concentrations below the calculated mitochondrial dehydrogenase activity 
IC50 values of ATV, with the lower dose being non-toxic and the higher dose being significantly 
toxic after 24 hours.  
 
Palmitate pre-treatment was added to the study design in order to induce a hyperlipidaemic 
condition in vitro. The presence of these metabolic alterations leaves the liver cells more 
susceptible to further injury than normal/untreated liver cells (Koh et al, 2011). The palmitate 
concentrations selected (500 µM) was within a literature-relevant range (Mazibuko et al, 2015; 
Abu-Baker & Tan, 2017; Zezina et al, 2018). Further, the palmitate concentration was 
indicative of a severe dyslipidaemic state, rendering the cells extensively vulnerable to 
additional injury by ATV. 
 
Mitochondrial stress and dysfunction, and oxidative stress are closely linked and form a feed-
forward relationship: increased mitochondrial stress results in increased ROS generation and 
oxidative stress, and vice-versa. The ROS-induced cytotoxic environment created, results in 
the initiation of apoptosis, the cleavage of executioner caspases and, ultimately, cell death. 
Mitochondrial membrane potential was assessed using a JC-1 assay, which was confirmed 
with a DCF assay assessing ROS generation. Positive results in these assays were confirmed 
in terms of apoptosis activation, with specific consideration on membrane integrity (annexin 
V/PI staining) and caspase activation. 
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As mentioned previously, 3D cell culturing is a culturing technique that allows for chronic, long-
term assessment of treatments on specialised human-derived cells. In this single 
observational study, the focus was on creating a microgravitational environment for C3A liver 
spheroids whereby the environment created in the acute model could be extrapolated and 
applied to a chronic culturing setting. The microwell base of the wells of the AggreWell™ plates 
allows for the reproducible formation of 3D cell clusters in large quantities per well. As such, 
multiple spheroids are used and sampled per treatment and time point assessed, yielding 
multiple technical repeats within a single experimental repeat.  
 
Assessment of basic functional parameters was demonstrative of the effects of treatment on 
the spheroids. Average diameter measurements and ultrastructural morphology confirmed 
changes in spheroid and cellular integrity. These results were correlated with the assessment 
of glucose utilisation, cellular ATP, and adenylate kinase which indicates the alterations in 
cellular functioning.  
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2 Literature Review 
 
2.1 Rooibos 
 
Aspalathus linearis, or Rooibos, (English: “red bush”) is a legumous fynbos shrub indigenous 
to the Cederberg region in the Western Cape Province of South Africa (Figure 2.1.1). Typically 
fermented and brewed as a tea, Rooibos gets its characteristic ‘red’ look from the 
‘fermentation’ (oxidation) process. Customarily, fermented leaves and stems are used to 
produce a mild tasting tisane, free of caffeine, containing few tannins, while being rich in 
polyphenolic compounds. Compared to its fermented counterpart, unfermented, or ‘green’, 
Rooibos contains higher concentrations of polyphenolic compounds, including aspalathin, a 
dihydrochalcone C-glucoside exclusive to this plant species (Uliĉná et al, 2003; McKay & 
Blumberg, 2007).  
 
Rooibos, as a tea, first became a commodity in 1904 through marketing by a Clanwilliam 
merchant, Benjamin Ginsberg. Ginsberg acquired the tea from Khoi descendants who had 
been crudely processing the stems and leaves during the warm summer months (Joubert & 
De Beer, 2011). 
 
 
Figure 2.1.1: Production areas of Aspalathus linearis in and around the Greater Cederberg Biodiversity 
Corridor (map supplied by SARC). (Adopted from Joubert & De Beer, 2011). 
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Figure 2.1.2: Rooibos plantation in the Clanwilliam area. (A) Seeding plantation; (B) Seedlings ready for 
transplantation; (C) Full-grown Rooibos plantation. (Images supplied by S. Bowles). 
 
2.1.1 Biological Characteristics 
 
Scientific evidence confers multiple health benefits to Rooibos, such as anti-inflammatory (Lee 
& Bae, 2015), antioxidant (Joubert et al, 2004), hepatoprotective (Kucharská et al, 2004; 
Ajuwon et al, 2014; Canda et al, 2014), lipid-lowering (Bursill et al, 2007; Marnewick, et al, 
2011), anti-diabetic (Son et al, 2013), and hypoglycaemic (Kawano, 2009; Johnson et al, 2016) 
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effects. These health benefits are contributed widely to the presence of various polyphenolic 
compounds (Ulicná et al, 2003; McKay & Blumberg, 2007; Ajuwon et al, 2013) (Table 2-1).  
 
 
Structures Compounds Green (n=3) 
Fermented 
(n=3) 
 
 
Dihydrochalcones  
aspalathin (R1=OH; R2=C-glucosyl)  
nothofagin (R1=C-glucosyl; R2=OH) 
 
 
 
2.559±0.699 
0.251±0.230 
 
 
0.421±0.017 
0.040±0.022 
 Flavones  
orientin (R1=C-glucosyl; R2,R4=OH; R3=H)  
iso-orientin (R1=H; R2,R4=OH; R3=C-
glucosyl)  
vitexin (R1=C-glucosyl; R2=OH; R3,R4=H)  
isovitexin (R1,R4=H; R2=OH; R3=C-
glucosyl)  
luteolin (R1,R3=H; R2,R4=OH) 
luteolin-7-O-β-D-glucoside (R1,R3=H; 
R2=O-glucosyl; R4=OH)  
chrysoeriol (R1,R3=H; R2=OH; R4=OCH3) 
 
 
0.263±0.087  
 
0.450±0.163  
0.042±0.020  
 
0.049±0.029 
0.007±0.006  
 
0.015±0.008  
0.003±0.001 
 
 
0.202±0.026  
 
0.329±0.049  
0.035±0.009  
 
0.035±0.012 
0.010±0.005  
 
0.015±0.008  
0.007±0.002 
 
 
Flavonols  
quercetin (R1=H; R2,R3=OH) 
hyperoside (R1=H; R2=OH; R3=O-
galactosyl)  
rutin (R1=H; R2=OH; R3=O- rutinosyl) 
 
0.001±0.001  
 
0.021±0.012  
0.245±0.141 
 
0.010±0.001  
 
0.016±0.015  
0.173±0.016 
 
 
It has been well documented that the many polyphenols naturally occurring in plant extracts, 
such as tea extracts, act complementarily with one another to exert beneficial effects (Singh 
et al, 2009). The composition of flavonoids in Rooibos is predominantly dihydrochalcones, 
flavonols, and flavones, with the two most notable flavonoids in Rooibos being aspalathin, and 
nothofagin; the two bioactive dihydrochalcones (McKay & Blumberg, 2007; Gelderblom et al, 
2017). Aspalathin is a dihydrochalcone C-glucoside, to date, found uniquely in Aspalathus 
species. Nothofagin, a rare dihydrochalcone C-glucoside, is the 3-deoxy analogue of 
aspalathin and is present in Rooibos in lower quantities than aspalathin, and has only been 
Table 2-1: Contents of major phenolic compounds in green and fermented Aspalathus linearis plant 
material (means±SD; g/100 g dry matter). (Adapted from Joubert & De Beer, 2011) 
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previously reported to have been found in the bark of a Chinese medicinal plant, Schoepfia 
chinensis (Huang et al, 2008), and Nothofagus fusca (Hillis & Inoue, 1967) (McKay & 
Blumberg, 2007; Joubert & de Beer, 2011; Lee & Bae, 2015) 
 
A study by Marnewick, et al, (2011) showed that dietary intervention with Rooibos modulates 
serum lipid profiles in humans, with results supporting studies by Bursill et al (2007) and Koo 
and Noh (2007), describing the low-density lipoprotein (LDL)-lowering capabilities of phenolic-
rich beverages. It is unclear if the mechanism of action proposed included upregulation of LDL 
receptors, or inhibition of cholesterol synthesis and lipid absorption (Marnewick, et al, 2011). 
Irrespective of the mechanism, such findings contribute to the likelihood of concomitant 
therapy of chronic medication by phytotherapeutic supplements. One such chronic 
medication, particularly in terms of targeting dyslipidaemia, is statins.  
 
2.2 Metabolic Perturbations 
 
Endogenous antioxidant systems defend the body under conditions of oxidative stress. It has 
been confirmed that antioxidant defense systems participate in hepatoprotection in these 
instances, however the exact mechanisms thereof have not yet been fully elucidated (Degli 
Esposti et al, 2012; Li et al, 2015). Several models have shown where Rooibos exerts 
hepatoprotective effects (McKay & Blumberg, 2007; Ajuwon et al, 2013), and that the 
antioxidant potential of Rooibos extracts and infusions depends on its total polyphenolic 
profile, which is subject to method of preparation batch-to-batch variability of the plant material 
(McKay & Blumberg, 2007).  
 
Lee and Bae (2015) assessed the effect of intravenous treatment with nothofagin and 
aspalathin on lipopolysaccharide (LPS)-mediated vascular inflammatory responses. 
Aspalathin and nothofagin were found to inhibit LPS-mediated expression of Toll-like receptor 
4 (TLR4) as well as protecting the cellular barrier integrity, confirmed both in vitro and in vivo. 
Nothofagin exhibited reduced LPS-mediated inflammatory inhibitory ability compared to 
aspalathin. The difference in their antioxidant capabilities is postulated to be as a result of the 
conformational differences between the polyphenols, and nothofagin’s lack of the catechol 
moiety. Nothofagin’s decreased anti-inflammatory effectiveness as compared to its aspalathin 
counterpart is in agreement with other studies. Irrespective of the differences, both nothofagin 
and aspalathin are considered potent antioxidants and consequently both may be regarded 
as potential therapeutic agents in treating severe vascular inflammatory diseases (Lee & Bae, 
2015). 
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There are many adaptive mechanisms employed by cells to promote survival in stressful 
situations (Yang et al, 2000). A compensatory mechanism – the unfolded protein response 
(UPR) cascade – is activated in the endoplasmic reticulum (ER) under nutrient excessive 
conditions, such as overwhelming fatty acid content in a cell, or hypoxia. The ER is the sensor 
of nutrients and cholesterol, as well as being crucial in de novo protein synthesis and protein 
folding. Changes in the redox state, calcium concentration alterations sensed by the ER, or 
accumulation of unfolded or misfolded proteins in the ER lumen are all possible triggers of the 
UPR (Wei et al, 2006; Wei et al, 2007; Schenk et al, 2008). Often in liver injury and disease, 
the ER stress is too great for the UPR to overcome, activating caspase activity and apoptosis 
(Wang et al, 2006; Wei et al, 2007). The chronic exposure to apoptotic stresses results in 
cellular adaptations which may, in fact, potentiate necrosis (Yang et al, 2000). One such 
modification is the increase in uncoupling protein-2 (UCP-2) expression, which leads to 
increased mitochondrial electron transport and decreased mitochondrial membrane integrity. 
The partial uncoupling of the mitochondrial membrane by UCP-2 and the consequent 
decrease in adenosine triphosphate (ATP) synthesis renders the cells particularly susceptible 
to further insult. Because of the already compromised nature of the cells, the addition of a 
stressor may cause necrosis, despite not being severe enough to do so in healthy cells (Yang 
et al, 2000). 
 
Chronic exposure to oxidative stress, as a result of chronic hyperlipidaemic conditions, 
contributes to mitochondrial adaptations (Yang et al, 2000). Zezina et al (2018) suggests that 
in macrophages, mitochondrial fission is a protective adaptation in response to fatty acid 
overexposure, as opposed to being caused by fatty acids. The fragmentation of the 
mitochondrial network allows for the decrease in mitochondrial reactive oxygen species (ROS) 
production. Yang et al (2000) showed that mitochondria of fatty livers produce increased levels 
of O2- and H2O2, supporting the notion that chronic ROS production and consequent oxidative 
stress contributes to mitochondrial modifications and dysfunction in fatty livers of ob/ob 
C57BL/6 mice compared to their lean controls. The same study went on to suggest that, given 
the similarities between their results and tumour necrosis factor α (TNF-α)-induced apoptosis 
as well as nuclear factor kappa-light-chain-enhancer of activated B cells (NFB) activation and 
the consequent increase in anti-apoptotic genes such as B-cell lymphoma 2 (Bcl-2) and B-cell 
lymphoma extra-large (Bcl-XL), and increased ROS production in the hepatocytes shows a 
paradoxical effect. The combination of the activation of these two mechanisms by H2O2 seem 
to balance one another out, leaving the hepatocytes vulnerable to future insult, but viable 
under normal conditions (Yang et al, 2000). 
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The unusual balance between pro- and anti-apoptotic markers found by Yang et al (2000) was 
also found by Selzner et al (2000). Activation of the apoptotic pathway was dysfunctional in 
fatty Zucker rats compared to their lean controls, evident by the significantly decreased levels 
of the apoptotic mediators caspase-8, caspase-3, and cytochrome c. As caspase-8 is an early 
marker of the apoptotic pathway, its inactivity shows an impairment in the activation of the 
cascade. However, there was extensive necrotic cell death in the fatty rats, suggesting a 
preference of necrosis in fatty rats when exposed to a stressor as opposed to apoptosis which 
is found in the lean controls. Further, despite the high levels of apoptosis in the lean controls, 
there was still an increased propensity for viability, whereas the high levels of necrosis in the 
fatty rats resulted in a high rate of mortality, emphasizing the irreparable damage caused by 
necrosis (Selzner et al, 2000). Taken together, these results show that, in fatty livers, necrosis 
is the major mechanism of cell death when exposed to an insult. 
 
Chronic oxidative stress and the resulting mitochondrial, and deoxyribose nucleic acid (DNA) 
damage, as well as apoptotic changes in different organ systems, could lead to multiple organ 
failure (Soory, 2009; Degli Esposti et al, 2012). As such, cellular dysfunction serves as a 
contributing factor in the pathogenesis of the majority of liver pathologies as well as 
degenerative diseases such as cancer, cardiovascular disease, diabetes, and 
neurodegenerative disorders (Cesaratto et al, 2004; Degli Esposti et al, 2012). Observational 
studies have shown that an inverse relationship exists between the consumption of diets rich 
in flavonoids and cellular damage via direct radical scavenging of reactive species, chelating 
metal ions, or challenging enzymatic systems responsible for free radical production (McKay 
& Blumberg, 2007; Calitz et al, 2015).  
 
A study by Kucharská et al (2004) compared the liver antioxidant capabilities, redox state of 
coenzyme Q9, and oxidative stress in rats exposed to Rooibos tea for 7 days before carbon 
tetrachloride (CCl4-)-induced liver damage. The synthetic antioxidant N-acetyl-L-cysteine 
(NAC) was used as a positive control for comparison. Ubiquinone (coenzyme Q or CoQ; 
specifically, the dominant isoform CoQ9 in rodents and CoQ10 in humans) is involved in the 
mitochondrial respiratory chain (electron transport chain; ETC), and its reduced form (CoQ9H2) 
is a potent lipid-soluble antioxidant, synthesised in the liver. Apart from restoring CoQ9H2 in 
rats, to levels comparable to those of healthy controls, the Rooibos treatment was also shown 
to prevent lipid peroxidation more effectively than NAC. Kucharská et al (2004) therefore 
suggested that antioxidant treatment is important for the prevention of liver disease, however 
treatment with natural antioxidants, such as Rooibos, may be more beneficial than the use of 
synthetic antioxidants. 
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2.2.1 Rooibos Treatment and Lipotoxicity 
 
Ageing and diabetes have both been shown to cause the accumulation of glycated proteins in 
several tissues in the body. Kinae et al (1994) showed that Rooibos extract and polyphenol 
supplementation decreased advanced glycation end-product (AGE) production in human 
serum albumin, inferred to be as a result of the radical scavenging capabilities of Rooibos 
polyphenols (Kinae, et al, 1994; Kawano, 2009; Son et al, 2013).  
 
The presence of the enzymes alanine transaminase (ALT) and aspartate transaminase (AST) 
in serum are well-established markers of hepatocellular damage. This is because they are 
found in abundance within hepatocytes and in low levels everywhere else in the body. As a 
result, the leakage of these enzymes into the serum occurs when hepatocytes are damaged 
or injured. The ratio of serum AST/ALT is also used as an indicator of hepatic fibrosis and the 
extent of fibrosis-related hepatic disorders (Giboney, 2005). Monsees and Opuwari (2017) 
showed that ALT levels in rats were significantly decreased compared to healthy controls 
when treated with unfermented Rooibos, while AST levels were significantly increased, in rats 
treated with fermented Rooibos, compared to healthy controls. It was concluded that Rooibos 
maintains serum, kidney, and liver antioxidant levels and that no adverse reactions were 
observed in vivo in female rats subjected to 21 days of exposure to Rooibos as the sole 
substitute for water. Further, it was suggested that Rooibos may have oestrogenic potential 
and, pending further confirmation, may have positive effects on female fertility (Monsees & 
Opuwari, 2017). 
 
Beltrán-Debón et al (2011) assessed the continuous administration of an aqueous Rooibos 
extract on male low-density lipoprotein receptor deficient (LDLr-/-) mice. This model was 
chosen as it has been shown to be a representative model of aspects of intense metabolic 
alterations typical of metabolic syndrome in humans (Rodríguez-Sanabria et al, 2010). 
Beltrán-Debón et al (2011) demonstrated that lipoprotein metabolism was significantly altered 
by consumption of an aqueous Rooibos extract, resulting in distinct lipid-lowering effects. This 
effect was strictly diet-related. The study showed that mice fed a high fat diet that received the 
Rooibos extract showed significant reductions in serum triglycerides, cholesterol, and free 
fatty acids. The triglyceride reduction was found in very low-density lipoproteins (VLDL), while 
the cholesterol reduction was evident in all lipoprotein particles. These results suggested that 
possible molecular targets of Rooibos polyphenols are located mainly in the liver and adipose 
tissue. Further assessment of both tissues, however, showed that an aqueous Rooibos extract 
significantly activated the AMP-activated protein kinase (AMPK) in the liver but not in the 
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epididymal white adipose tissue (eWAT), irrespective of the type of diet (Beltrán-Debón et al, 
2011). 
 
Under normolipidaemic conditions, there is a homeostatic balance between lipids, their 
oxidation, and transport, whereas dyslipidaemia results in increased concentrations of free 
fatty acids in circulation. Increased levels of circulating free fatty acids contributes to the 
pathogenesis of cardiovascular disease, atherosclerosis, metabolic syndrome, and obesity 
(Feldstein et al, 2004; Wei et al, 2006; Wei et al, 2007; Li et al, 2008). It has been shown that 
increased levels of saturated fatty acids, specifically, a likely cause of lipotoxicity, is a risk 
factor for serious metabolic disease, including T2DM (Feldstein et al, 2004; Wei et al, 2006; 
Wei et al, 2007; Li et al, 2008). One of these saturated fatty acids is hexadecanoic acid, 
otherwise known as ‘palmitate’ or ‘palmitic acid’, which is the first fatty acid produced during 
fatty acid synthesis.  
 
 
 
Figure 2.2.1: Chemical structure of palmitate. 
 
Lipotoxicity, the impairment of normal cellular functioning occurs due to an imbalance between 
the rate of lipid production and influx and the rate of lipid expenditure. Diets rich in saturated 
fats have been shown to increase LDL and total cholesterol levels (Alkhouri et al, 2009; Unger 
et al, 2010). Free fatty acids enter hepatocytes passively, or actively through fatty acid 
transport proteins (FATPs), such as fatty acid translocase, also known as CD36. Once in the 
cell, fatty acids are converted to different types of lipids for storage, the most neutral of which 
is triacylglycerol. Fatty acids can also be converted to ceramides, diacylglycerol, or fatty acyl-
CoAs, all of which are considered lipid intermediates and can alter normal cellular functioning 
and ultimately cause lipotoxicity (Schenk et al, 2008; Alkhouri et al, 2009; Unger et al, 2010; 
Alkhouri et al, 2011).  
 
Excess free fatty acid storage in tissues other than adipose tissue may trigger the activation 
pathways that have deleterious or destructive effects, such as inflammation, insulin resistance, 
and excessive fibrosis. Accumulation of free fatty acids in liver cells (steatosis), for example, 
plays a role in Non-Alcoholic Fatty Liver Disease (NAFLD). Further, the extent of lipotoxicity 
is determined by the type of fatty acids present as opposed to their quantity. In hepatocytes, 
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liver damage and apoptosis occur as a result of an imbalance in the ratio of monounsaturated 
fatty acids and saturated fatty acids (Nehra et al, 2001; Wei et al, 2006; Alkhouri et al, 2009; 
Akhmedov & Berdeaux, 2013). The excess of fatty acids cause cell damage and death through 
any of several mechanisms, such as apoptosis pathway activation, death receptor activation, 
or initiating a cellular stress response in the endoplasmic reticulum (Wei et al, 2006; Li et al, 
2008; Schenk et al, 2008; Alkhouri et al, 2009; Akhmedov & Berdeaux, 2013). 
 
A study by Marnewick, et al, (2011) showed that dietary intervention with Rooibos modulates 
serum lipid profiles in humans, with results supporting studies by Bursill et al (2007) and Koo 
and Noh (2007), describing the LDL-lowering capabilities of phenolic-rich beverages. It is 
unclear of the mechanism of action; however proposed mechanisms include upregulation of 
LDL receptors, or inhibition of cholesterol synthesis and lipid absorption (Marnewick, et al, 
2011). Irrespective of the mechanism, such findings contribute to the likelihood of concomitant 
therapy of chronic medication by natural and herbal supplements. One such chronic 
medication, particularly in terms of targeting dyslipidaemia, is statins.  
 
2.3 Herb-Drug Interactions 
 
A review by Awortwe et al (2018) illustrated that the majority of the cases recorded in the study 
showed patients taking statins and/or warfarin for the treatment of cardiovascular 
complications reported clinically significant complications after concomitant therapy with 
herbal products, including green tea. 
 
Controversially, it is widely accepted that commercially available alternative and 
complementary medicines of natural origin are safe and effective as they have been 
successful in maintaining good health or used for treating certain diseases. There is an 
inherent trust in alternative and complementary medicines, although this trust is often 
misplaced as there is a lack of standardisation and regulation for these products. The lack of 
standardisation and regulatory control for these products is of concern to clinicians. One such 
concern is chemical composition of plants used for formulation of such medicines, as well as 
quality of the product and batch variation due many factors such as: geographical area of 
growth, storage and processing conditions, time of harvest, part of the plant utilised, 
contamination or misidentification, which may contribute to the possibility of herb-drug 
interactions and potential toxicity (Fugh-Berman, 2000; Antwi-Baffour et al, 2014; Gouws & 
Hamman, 2018).  
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A December 2017 report by Research and Markets showed that there is a growing demand 
for alternative and complementary medicine, in part, due to the rising burden of 
noncommunicable diseases and the increasing cost of healthcare, which further drives 
product demand. The report forecast that, by 2025, the global nutraceutical market is projected 
to reach USD 578.23 billion (Research and Markets, 2018). 
 
As part of their endogenous protective mechanisms, many plants produce secondary 
metabolites which may be toxic (Calitz et al, 2015; Gum et al, 2017). The toxic metabolites 
are characterised in general as ‘phytoprotectants’ or ‘phytoanticipins’ and cannot necessarily 
be distinguished from therapeutically relevant ingredients (Calitz et al, 2015). Atropa 
belladonna, commonly known as deadly nightshade, contains tropane alkaloids, used as 
anticholinergics in homeopathic remedies and Food and Drug Administration (FDA)-approved 
drugs. High doses of these alkaloids are neurotoxic (Kwakye et al, 2018) and the European 
Food Safety Authority (EFSA) has placed a warning on Rooibos for pyrrolizidine alkaloid (PA) 
contamination as a potential health risk. A 2017 study by the EFSA Panel on Contaminants in 
the Food Chain (CONTAM) showed that, between the infusions and teas tested, including 
green tea and black tea infusions, Rooibos leaves had the highest concentrations of PA 
(Knutsen et al, 2017). A 2017 study by Van Wyk et al, however, showed that Rooibos does 
not produce any PAs but has been shown to grow in close contact – sometimes even entwined 
– with a weed (Senecio angustifolius) that does. The authors suggested that the shared soil 
is a means by which PAs are transferred to the Rooibos plant, as well as poor discerning 
between the plants at harvest, resulting in Senecio angustifolius contamination of the 
harvested batch of Rooibos (Van Wyk et al, 2017). The toxicity of these secondary metabolites 
depends on the metabolism of natural products by the organism (Gum et al, 2017). There are 
highly conserved biological similarities between taxa of humans and herbivorous insects, such 
as most pathways involving carbohydrate, protein, nucleic acid, and lipid metabolism. As a 
result, some phytochemicals that defend plants against herbivorous insects may also be 
harmful to humans (Calitz et al, 2015).  
 
Similarly to pharmaceutical drugs, alternative and complementary medicines can dose-
dependently be therapeutic or toxic. The potential exists for all ingested substances to interact 
with the same metabolising enzymes, drug transporters, as well as other components of the 
mixture of ingested substances. As a result, concurrent use of herbs may exacerbate, mimic, 
or counteract the effect of pharmaceuticals (Fugh-Berman, 2000) causing herb-drug 
interactions (Awortwe et al, 2018). As co-administration of alternative and complementary 
medicines can alter the pharmacodynamics and pharmacokinetics of the drug and possibly 
culminate in adverse effects, herb-drug interactions have become particularly significant 
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clinically. These interactions could lead to the concentrations of a drug in the tissue being 
either decreased, thereby limiting the efficacy and potentially leading to the failure of the 
treatment, or could be increased, leading to toxicity (Joubert et al, 2008; Gouws & Hamman, 
2018).  
 
2.3.1 Drug and Xenobiotic Metabolism 
 
Xenobiotics are chemical substances found in an organism that are extrinsic to the normal 
metabolism of the organism. Xenobiotics are constantly introduced and eliminated by all life 
forms. They are typically lipophilic, synthetic or naturally occurring, and can be dose-
dependently beneficial or harmful. Beneficial xenobiotics may be used during biological 
processes to provide energy, or even by acting as a precursor in the synthesis of 
macromolecules. However, xenobiotics may also be detrimental to the cell by interfering with 
metabolic pathways, DNA, ribose nucleic acid (RNA), or proteins (Vrbanac & Slauter, 2017). 
These interactions could induce cell damage and even cell death, thereby disturbing normal 
cellular functions and causing the onset of an array of toxic effects (Wetzel et al, 1994; 
Abrahams, 2011).  
 
Numerous metabolic enzymes are responsible for eliminating exogenous and endogenous 
compounds from the body. Phase I and phase II metabolic reactions are catalysed by these 
enzymes. Some of the enzymes responsible for phase I reactions are the enzymes in the 
CYP450 metabolic system, found in the endoplasmic reticulum of gastrointestinal epithelial 
cells and hepatocytes (Na et al, 2011; Thomford et al, 2016). Herbal medicines consist of 
complex phytochemical mixtures which interact and exert multiple synergistic effects (Gum et 
al, 2017; Gouws & Hamman, 2018). The CYP450 enzyme system is vulnerable to induction 
or inhibition by xenobiotics, particularly these complex combinations. The resulting herb-drug 
interactions, often due to enzyme modulation, are of particular importance with respect to 
drugs with a narrow therapeutic window as even a relatively small alteration in blood plasma 
concentrations could cause ineffectiveness, or toxic effects (Budzinski et al, 2000; Gouws & 
Hamman, 2018). 
 
A well-known example of adverse interactions between natural products and drugs, due to 
altered drug bioavailability, is the interaction between grapefruit juice and the drug felopidine 
which, at the time, was an accidental find. The pharmacokinetics of various drugs are altered 
when administered with grapefruit juice, notably calcium channel blockers, antibiotics, and 
statins (Mertens-Talcott et al, 2006). These adverse interactions, specifically herb-drug 
interactions, may occur through either of two significant mechanistic routes: activation of gene 
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transcription, or inhibition of enzyme action (Plant, 2007). The first major mechanism of the 
induction of the grapefruit-drug interaction is due to reduced “first-pass” metabolism by 
inhibition of the intestinal cytochrome P450 isozyme CYP3A4 (Mertens-Talcott et al, 2006). 
 
The metabolism of the majority of therapeutic drugs and xenobiotics relies on the isoenzyme 
CYP3A. This enzyme is of particular interest as it has been shown that Rooibos flavonoids 
selectively induce CYP450 isozymes, notably CYP3A4 which metabolises numerous drugs, 
including statins. It has been shown that expression of CYP3A was upregulated in the 
intestines in rats exposed to two weeks of continuous administration of Rooibos tea, as well 
as a significant decline in the area under the concentration curve (AUC) and Cmax of 
midazolam, a short-acting benzodiazepine derivative known to be a sensitive probe of CYP3A 
function (Matsuda et al, 2007). The induction of CYP3A as a result of exposure to Rooibos 
suggests that, given long-term consumption of Rooibos, the possibility of herb-drug interaction 
should not be overlooked (Matsuda et al, 2007). A similar phenomenon was found by Patel et 
al (2016) when human assessing recombinant CYP inhibition. Fermented and unfermented 
Rooibos extracts were assessed in terms of multiple drug-metabolising CYPs, including 
CYP3A4. It was shown that various polyphenols found in the Rooibos extracts were 
responsible for inhibiting CYP3A4, amongst others, in a time- and dose-dependent manner 
(Patel et al, 2016). These results further confirm the necessity for assessing potential herb-
drug interactions, particularly with CYP3A4-metabolised drugs and nutraceuticals or 
supplements. 
 
Drug transporters work in conjunction with metabolising enzymes for the disposition and 
metabolism of drugs. There are two types of transporters, uptake and efflux, and they are 
found in the intestinal enterocytes, at both the basolateral membrane and apical membrane. 
Efflux transporters are typically found in the brush border apical membrane of enterocytes and 
inhibit the complete absorption of drugs by expelling the metabolites, for example, back into 
the intestinal lumen (Kullak-Ublick et al, 2001; Chan et al, 2004; Ho & Kim, 2005). This results 
in decreased oral bioavailability of the drugs (Chan et al, 2004; Ho & Kim, 2005). Contrarily, 
uptake transporters facilitate the absorption of drugs, increasing their movement from the 
lumen into the enterocytes (Kullak-Ublick et al, 2001; Ho & Kim, 2005). 
 
It is important to consider the effects natural products may have on the enzyme activity, 
however interference at the ATP-binding cassette (ABC) transporter level could also play a 
role in the induction and progression of adverse effects: hepatocellular excretory functions are 
primarily mediated by ABC transporters (Borst & Elferink, 2002; Vrbanac & Slauter, 2017). 
The ABC transport proteins transport substrates against a concentration gradient, utilising 
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ATP as an energy source (Chan et al, 2004). Of note is the ABC efflux transporter, subfamily 
B, member 1 (ABCB1), also known as P-glycoprotein (P-gp), which plays an important 
physiological role in detoxifying toxic metabolites (Bhardwaj et al, 2002; Jodoin et al, 2002; 
Patel et al, 2004; Del Rio et al, 2013; Patil et al, 2014). This efflux transporter’s effects can 
either hinder or help the actions of the xenobiotic or drug. Similarly, the protein bile salt export 
pump (BSEP), expressed on the bile canicular membrane, is the primary facilitator of bile acid 
efflux in hepatocytes. Dysfunction of bile salt transporters is a mechanism by which drug-
induced cholestasis occurs (Vrbanac & Slauter, 2017). Further, drugs and their metabolites 
have been shown to inhibit BSEP activity. The multidrug resistance-associated protein 3 
(MRP3) is involved in the enterohepatic recycling of bile salts and associated with the removal 
of toxic organic anions under cholestatic conditions (Borst & Elferink, 2002). As a result, 
inhibition of liver drug transporters could potentiate adverse effects. 
 
Organic anion transporting proteins (OATPs) belong to the SLC gene superfamily, with the 
OATP1B1 and OATP1B3 (also known as SLCO1B1 and SLCO1B3 respectively) transporters 
being liver-specific. Further, these transporters have been shown to have broad substrate 
specificity, as well as being crucial to hepatic statin uptake (Borst & Elferink, 2002; Vrbanac & 
Slauter, 2017). As such, up- and down-regulation in the activity of these transporters has been 
associated with hepatic injury. Shu et al (2016a) showed that the up-regulation of SLCO1B1 
significantly increased the hepatic metabolism of atorvastatin and consequent hepatotoxicity. 
 
The removal of toxic substances and prevented absorption of these substances is crucial in 
maintaining viability and avoiding adverse effects. However, the absorption of some toxic 
substances is necessary, such as in the case of cytotoxic anticancer drugs used in the 
treatment of malignant tumours, the efflux of which inhibits the treatment’s efficacy. It has also 
been shown that P-gp expression and/or activity can be modulated by herbal constituents, 
affecting drug bioavailability (Bhardwaj et al, 2002; Jodoin et al, 2002; Mertens-Talcott et al, 
2006; Patil et al, 2014). One of the nuclear receptors implicated in the regulation of P-gp 
expression levels as well as xenobiotic metabolising enzymes is pregnane X receptor (PXR) 
(Savas et al, 1999; Ott, et al, 2009). 
 
2.3.2 Rooibos Toxicity 
 
There have been isolated cases where idiosyncratic liver injury has been induced through the 
consumption of herbal products that are presumed to be safe (reviewed by Calitz et al, 2015). 
Yang et al (2010) reported three female patients presenting with acute hepatitis subsequent 
to ingestion of aloe products. Aloe vera, Aloe arborescens, and unspecified aloe extracts were 
Stellenbosch University  https://scholar.sun.ac.za
 22 
 
ingested daily for between 3 and 5 months at doses of between 28.5 mg to 420 mg (Yang et 
al, 2010). Similarly, Lee et al (2014) reported a case whereby a female patient presented with 
acute hepatitis consequent to 4-week ingestion of a gel preparation containing Aloe vera. A 
case study by Kocaman et al (2008) showed a patient, with no history of other medication, 
had treated flu symptoms with 1500 mg/day Echinacea root extract. The patient presented 
with fatigue and jaundice. Hepatitis, cholestasis, and eosinophilic granulocyte and portal 
lymphoplasmocyte infiltration were revealed by a liver biopsy. Within a month of cessation of 
the product, biochemical parameters were restored to within a normal range (Kocaman et al, 
2008).  
 
Sinisalo et al (2010) were the first to report an incidence of Rooibos-induced hepatotoxicity in 
a case study when a patient, on various chronic medications with a diagnosed stable low-
grade B-cell malignancy, without clinical evidence or medical history of autoimmune or viral 
hepatitis or haemochromatosis, presented with elevated ALT and alkaline phosphatase (ALP) 
(Sinisalo et al, 2010). Elevated levels of these enzymes indicate diminishing hepatocellular 
membrane integrity and consequent enzyme leakage; a precursor to liver injury (Clarke & 
Mills, 2006). The patient started consuming Rooibos tea daily, two weeks prior to the test. 
Cessation of Rooibos consumption rectified the ALT and ALP serum levels within a week 
(Sinisalo et al, 2010). Engels et al (2013) reported concomitant use of a combination of 
Rooibos and Buchu tea with oral steroids as well as long-term statin use resulted in drug-
induced liver injury (DILI). Cessation of tea intake proved to ameliorate the DILI, suggesting 
that the tea was possibly the direct cause of the hepatotoxicity. It is, however, note-worthy that 
there have been only two reports of Rooibos tea DILI and that causality was not attributed to 
Rooibos per se. Engels et al (2013) acknowledge that there is limited understanding of the 
medical interactions of herbs by clinicians – a problem which is compounded by the fact that 
patients are not forthcoming with the information about self-medication with herbal 
supplementation consumption (Engels et al, 2013). Similarly, Sinisalo et al (2010) noted that, 
given the excellent safety record of Rooibos tea, the patient may have had an adverse reaction 
to one of the multiple constituents of Rooibos, or that the tea may have been contaminated by 
a hepatotoxic compound – a pyrrolizidine alkaloid, for example. 
 
2.4 Statins 
 
In both primary and secondary prevention of cardiovascular disease (CVD), statins are the 
most commonly used drugs for the management of hypercholesterolemia and other CVD-
associated risk factors, such as high LDL-C (Clarke & Mills, 2006; Björnsson et al, 2012; 
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Björnsson, 2016). Of these, atorvastatin and simvastatin are of the most commonly prescribed 
statins and are second and third most effective in lowering total and LDL cholesterol levels 
respectively (Schaefer & Asztalos, 2006).   
 
The 2018 World Health Organisation’s (WHO) South African Country Profile on 
Noncommunicable Diseases (NCDs) showed that, as of 2017, there are still many unknowns 
in terms of the national implementation of drug therapy to prevent heart attacks and strokes. 
As it stands, the following parameters for South Africa are unknown: “The proportion (%) of 
population with existing CVD or are at high risk for CVD, Type 2 Diabetics, and familial 
hypercholesterolaemia; the proportion (%) of high risk persons receiving any drug therapy and 
counselling to prevent heart attacks and strokes; the proportion of primary health care centres 
reported as offering CVD risk stratification; and [whether South Africa has] reported having 
[national] CVD guidelines that are utilized in at least 50% of health facilities” (Adopted from 
WHO, 2018). 
 
 
Figure 2.4.1: Proportional causes of mortality in the South African population. (Adapted from WHO, 2018). 
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These data show that it is not exactly known to what extent statins are used nationally in a 
South African context. While NCDs are estimated to account for 51% of deaths in South Africa, 
these data are uncertain approximations due to a lack of national NCD mortality data (WHO, 
2018). However, data of various risk factors of NCDs are tabulated (Table 2-2) below: 
 
Table 2-2: Prevalence of risk factors for NCDs in South Africa. (Adapted from WHO, 2018). 
 
Data 
year 
Males Females Total 
Harmful use 
of alcohol 
Total alcohol per capita consumption, 
adults aged 15+ (litres of pure alcohol) 
2016 16 3 9 
Physical 
inactivity 
Physical inactivity, adults aged 18+ 
(%) 
2016 26 48 37 
Salt/Sodium 
intake 
Mean population salt intake, adults 
aged 20+ (g/day) 
2010 7 6 6 
Tobacco use 
Current tobacco smoking, adults aged 
15+ (%) 
2016 33 8 20 
Raised blood 
pressure 
Raised blood pressure, adults aged 
18+ (%) 
2015 24 24 24 
Diabetes 
Raised blood glucose, adults aged 18+ 
(%) 
2014 8 12 10 
Obesity 
Obesity, adults aged 18+ (%) 2016 15 39 27 
Obesity, adolescents aged 10-19 (%) 2016 9 13 11 
Ambient air 
pollution 
Exceedance of WHO guidelines level 
for annual PM 2.5 concentration 
(proportion) 
2016 -  2 
Household 
air pollution 
Population with primary reliance on 
polluting fuels and technologies (%) 
2016 -  15 
 
These risk factors imply that there is a tendency towards a decline in the overall health of the 
South African population, suggesting that, in years to come, there will be an increase in the 
necessity for therapeutic and lifestyle interventions. 
 
2.4.1 Mechanism of Action 
 
The presence of metabolic syndrome and diabetes in patients may result in different effects 
of atorvastatin as compared to patients without these metabolic alterations (Koh et al, 2011). 
Within 2 to 4 hours after administration, the steady-state maximum plasma concentration 
(Cmax) of multiple daily doses of atorvastatin, 2.5 to 80 mg, is 1.95 to 252 µg/L. A review by 
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Lea & McTavish (1997) showed that the area under the plasma concentration time curve 
showed values of between 25.2 to 1293 µg/(h/L). The absolute bioavailability of the drug is 
12%, and is approximately 98% protein-bound in plasma, with a mean elimination half-life of 
about 14 hours (Lea & McTavish, 1997).  
 
Table 2-3: Pharmacokinetic parameter values of atorvastatin acid and lactone in humans following oral 
administration of atorvastatin acid 20 or 40mg. Values are means ± SD, or median (range). (Adapted from 
Lennernӓs, 2003). 
Drug or metabolite Dose (mg) Cmax (µg/L) tmax (h) t½β (h) AUC (µg ↑ h/L) 
Atorvastatin acid 
40 
12.7 ± 7.8 1 (0.5 – 3) 7.8 ± 3.6 61.4 ± 36.2 
Atorvastatin lactone 4.2 ± 2.4 3 (1 – 8) 8.3 ± 4.1 53 ± 27.3 
Atorvastatin acid 
40 
13.4 ± 9.5 1 (0.5 – 3) 7.0 ± 3.7 54.2 ± 24.2 
Atorvastatin lactone 3.8 ± 2.6 3 (1 – 8) 9.2 ± 4.1 51.6 ± 35.1 
Atorvastatin acid 
20 
6.9 ± 3.66 1.8 ± 1.0 13.8 ± 6.4 98.7 ± 48.4 
Atorvastatin lactone 3.6 ± 2.4 3.4 ± 2.5 14.1 ± 7.7 75.1 ± 40.1 
AUC = area under concentration curve (0 - ↓); Cmax = peak plasma concentration; tmax = time to Cmax; t½β = elimination half-life 
 
As with most crucial pathways in the human body, cholesterol synthesis is highly regulated 
and dependent on the modulation of various genomic processes such as transcription, 
translation, and post-transcription. The accepted primary rate-limiting step of the cholesterol 
biosynthesis pathway is at the third enzyme, HMG-CoA reductase (Singh et al, 2009) (Figure 
2.4.2). Statins are drugs used to decrease LDL and cholesterol in humans, achieved through 
the competitive inhibition of hepatic HMG-CoA. This inhibition results in decreased hepatic 
secretion of apolipoprotein (apo) B-100-containing lipoproteins (VLDL and intermediate-
density lipoproteins (IDL)), as well as increased cellular receptor-mediated clearance of apoB-
100-containing lipoproteins, particularly LDL (Schaefer & Asztalos, 2006; Björnsson et al, 
2012; Pal et al, 2015; Björnsson, 2016). Taken together, this inhibition effectively lowers 
triglycerides by up to 40%, LDL by up to 60%, and VLDL cholesterol by up to 50%. Further, 
statins have been shown to increase HDL cholesterol levels by up to 15% without increasing 
the production of the major protein in HDL, apoA-I (Schaefer & Asztalos, 2006).  
 
Stellenbosch University  https://scholar.sun.ac.za
 26 
 
 
Figure 2.4.2: Statins interrupt the enzymatic reduction of HMG-CoA to mevalonate. This inhibition prevents 
synthesis of cholesterol and two isoprenoids, farnesyl pyrophosphate and geranylgeranyl pyrophosphate, which 
post-translationally modify oncogenic proteins. Dashed arrows represent multistep transitions. HMG-
CoA=hydroxymethylglutaryl-coenzyme A. (Adapted from Ahern et al, 2014). 
 
The active metabolites of atorvastatin results in a HMG-CoA reductase inhibition of 20 to 30 
hours (Lea & McTavish, 1997). Post-translational modulation of HMG-CoA reductase results 
in its altered rate of degradation and phosphorylation status. Phosphorylation causes an 
inactivation of the enzyme allowing for rapid environmental- and cellular-dependent 
cholesterol synthesis modulation. The primary kinase involved in the phosphorylation-
mediated inactivation of HMG-CoA reductase is AMPK, the activity of which is subject to the 
phosphorylation of upstream kinases (Singh et al, 2009). Many phenolic compounds activate 
AMPK, including aspalathin (Beltrán-Debón et al, 2011; Mazibuko et al, 2013; Kamakura et 
al, 2015). This inhibitory action has also been shown to inhibit monocyte activation, 
augmenting the vessel wall metalloprotease synthesis as well as the production of pro-
inflammatory cytokines: interleukin (IL)-6, IL-1, and TNF-, consequently diminishing the 
progression of atherosclerosis (Pal et al, 2015).  
 
Cholesterol synthesis is not the only end product of the mevalonate pathway and, as a result, 
its chronic inhibition may have other deleterious effects. Statins have been shown to decrease 
serum CoQ10 levels by up to 40% and, while, daily supplementation with CoQ10 has been 
shown to improve the antioxidant hepatic and serum CoQ10 levels, it is important to consider 
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the fundamental precursor insufficiency (Jiménez-Santos et al, 2014; Deichmann et al, 2016). 
Dysfunction of ubiquinone and the ETC results in decreased ATP generation and 
mitochondrial and cellular functioning. The inhibitory effect of the mevalonate pathway is 
further reaching than just CoQ10 levels as the inhibition also results in decreased dolichol 
production, affecting the fluidity and permeability of phospholipid bilayers (Lodish et al, 2000; 
Li et al, 2006; Deichmann et al, 2016; Wang & Hekimi, 2016). This suggests that the toxicity 
induced by ATV could be isolated to mitochondrial dysfunction and bioenergetic failure. 
 
Independent of their HMG-CoA reductase capabilities, other pleiotropic effects of statins have 
been established and studied (Gum et al, 2017). These effects include immunomodulatory 
and anti-inflammatory capabilities, such as eliminating potential structural remodelling 
(Michalik et al, 2013) and altering leukocyte infiltration associated with tumours in murine 
models (Mira et al, 2013). 
 
2.4.2 Side-effects and Toxicity 
 
Clinically, the most common hepatic side-effects of statin use are displayed by mild-to-
moderate elevations in liver transaminases, particularly ALT and AST (Clarke & Mills, 2006; 
Pal et al, 2015). Atorvastatin usage has been associated with various other side-effects, such 
as the manifestation of cholestatic jaundice, fulminant hepatic necrosis, cirrhosis, hepatitis, 
myalgia, and liver failure (Pal et al, 2015). A high oral daily dose (40 mg to 80 mg) is associated 
with an increased risk of DILI, and dose escalation of ATV has been associated with acute 
liver failure (Björnsson, 2016).  
 
As it is an uncommon occurrence, the exact mechanism of atorvastatin-induced hepatotoxicity 
is yet to be fully elucidated, however progress has been made in establishing elements 
thereof. Shu et al (2016a) showed extensively that CYP3A4 and SLCO1B1 up-regulation 
occurs in a hyperlipidaemic condition in vitro and in vivo. Further, Shu et al (2016a) showed 
that the initial metabolism of atorvastatin to its metabolites, ortho- and para-hydroxy 
atorvastatin, results in massive ROS production which is suspected to be the point at which 
ATV-induced toxicity occurs. Tolosa et al (2015) compared six statins in terms of mitochondrial 
parameters in order to elucidate potential mechanisms of statin-induced hepatotoxicity. 
Following a one hour treatment, atorvastatin showed the lowest mitochondrial toxicity risk of 
six statins. In terms of mitochondrial membrane potential, atorvastatin was shown to induce 
hyperpolarisation. It was also shown that the proposed mechanisms of toxicity include 
mitochondrial superoxide production, and dysregulation of calcium homeostasis. 
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Figure 2.4.3: The general mechanism scheme of oxidative stress induced by various factors on liver 
disease. (Adapted from Li et al, 2015). 
 
Pal et al (2015) showed that statin-induced hepatotoxicity is ROS-dependent and elicited by 
the activation of the intrinsic mitochondria-dependent pathway, ER stress, and MAPK 
activation (Figure 2.4.4). Reactive oxygen species are important and necessary in pathological 
conditions as it causes oxidative stress as well as contributing to retrograde redox signalling 
from the mitochondria to both the nucleus and the cytosol (Pal et al, 2015; Wang et al, 2015). 
In the same study, it was shown that hepatic tissue damage and oxidative stress as a result 
of ATV administration, is dose-dependent (Pal et al, 2015). Furthermore, ROS are known to 
play an integral role in ATV-induced oxidative stress. Increased ROS production causes 
mitochondrial and DNA damage as well as oxidative injury of the cellular membranes (Pal et 
al, 2015; Wang et al, 2015).  
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Figure 2.4.4: Schematic diagram of the ATO induced hepatic tissue toxicity in dose-dependent manner. 
(Adapted from Pal et al, 2015). 
 
2.5 Alternative Models 
 
Even though there are only two reported cases of hepatotoxicity associated with Rooibos, the 
use of herbal supplementation, specifically of Rooibos in South Africa, is high and therefore 
the risk for more cases increases. As such, two rare cases cannot be ignored. 
 
Although there is rigorous and extensive testing of drugs, the extrapolation from in vitro to in 
vivo studies does not necessarily translate. Focus is given to five major CYP450 isozymes 
(CYP1A2, 2C9, 2C19, 2D6, and 3A4) in terms of drug interactions for most first line screening 
studies. This is because over 90% of drugs on the market are metabolised thereby (Gouws et 
al, 2017). Further, successful in vivo studies have failed to translate between species and to 
a clinical trial level. There is also the risk of the trial not translating to a clinical setting as the 
trials are often undertaken by young and healthy individuals (Awortwe et al, 2018). This can 
have dire consequences. One such example is the Investigation of Lipid Level Management 
to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial.  
 
The ILLUMINATE trial was the assessment of one such pharmacological intervention, 
torcetrapib, aimed at inhibiting cholesterol ester transfer protein (CETP), increasing HDL 
levels, and consequently decreasing the risk of future clinical cardiovascular events in high-
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risk patients. The phase III trial was terminated prematurely as the administration of torcetrapib 
increased the risk of morbidity and mortality as opposed to mitigating it (Barter et al, 2007). 
This contributes to the necessity for alternative, safer, more representative research models. 
 
A cholesterol ester is a cholesterol with a fatty acid attached, and accounts for approximately 
70% of all plasma cholesterol. The transfer of cholesterol esters from HDL to apoB-containing 
lipoproteins is instigated by CETP (Figure 2.5.1). Statins have been shown to mildly decrease 
the plasma activity of CETP, however this action is secondary to the reduction of triglyceride-
rich acceptor particles. As such, raising HDL through CETP inhibition has been a therapeutic 
target. Increased HDL levels, combined with decreased LDL levels, would serve as a 
preventative measure by reducing the risk of cardiovascular disease which has been 
associated with low HDL levels (Schaefer & Asztalos, 2006; Barter et al, 2007). 
 
 
Figure 2.5.1: The role of insulin resistance in diabetic dyslipidaemia. Insulin resistance initiates the 
characteristic triad of high triglyceride, low HDL cholesterol and high small dense LDL levels. If the concentration 
of VLDL- transported triglyceride is high, CETP promotes the transfer of LDL cholesteryl ester or HDL cholesteryl 
ester in exchange for triglyceride. Triglyceride-rich HDL cholesterol or LDL cholesterol can undergo hydrolysis by 
hepatic lipase or lipoprotein lipase. Abbreviations: ↑, increased level; ApoA-1, apolipoprotein A-1; ApoB, 
apolipoprotein B; CE, cholesteryl ester; CETP, cholesteryl ester transfer protein; FFA, free fatty acid; HL, hepatic 
lipase; LPL, lipoprotein lipase; SD LDL, small dense LDL cholesterol; TG, triglyceride. (Adapted from Mooradian, 
A. G., 2008). 
 
2.5.1 3D Culture 
 
In vitro primary hepatocyte cultures lose important hepatic functionality during culture. In order 
to overcome this, modified primary liver tumour cells or immortalised cell lines have been 
created which have the advantage of long-term stability, rapid growth, and liver functionality 
(Baquerizo et al, 2015).  
 
Stellenbosch University  https://scholar.sun.ac.za
 31 
 
In terms of research, it has been a concern that hepatocytes – both primary and secondary 
cultures, traditionally used as 2D cultures – do not accurately reflect liver function (Wrzesinki 
et al, 2013; Edmondson et al, 2014; Anton et al, 2015). Passaging cells by trypsinisation is 
particularly strenuous to cultured cells as trypsin is a proteolytic enzyme used to dissociate 
adherent cells from the growth surface. Consequently, Wrzesinki et al (2013) showed that in 
3D culture, hepatocytes, specifically C3A cells, recover fully from trypsinisation after 15 to 18 
days and thereafter remain stable for at least 24 days, indicating their transition from 
exponential growth typical of 2D culture to stable dynamic equilibrium (Wrzesinki et al, 2013; 
Wrzesinki et al, 2014). In dynamic equilibrium, advanced liver functions (such as urea and 
cholesterol synthesis, P450 expression, and cellular organization) are re-established in the 3D 
spheroids and they remain stable models for mid- to long-term assessment of compounds 
(Wrzesinki et al, 2013). Liver spheroids produced by 3D culture allow for the evaluation of 
pharmacodynamics and/or mechanistic biomarkers, which is useful for understanding the 
compounds’ mode of action (Wrzesinki et al, 2013; Edmondson et al, 2014; Anton et al, 2015).  
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3 Aims of Investigation 
 
This study aims to investigate the potential hepatoprotective effects of Rooibos against 
atorvastatin (ATV)-induced hepatotoxicity using an in vitro C3A liver cell model. 
 
Hypothesis 
 
Hypothesis (Ha): Aspalathin-enriched Rooibos extract ameliorates ATV-induced hepatotoxicity 
in a normal or hyperlipidaemic condition 
 
Null hypothesis (H0): Aspalathin-enriched Rooibos extract does not ameliorate ATV-induced 
hepatotoxicity in a normal or hyperlipidaemic condition 
 
Objectives 
• To induce acute hepatotoxicity using atorvastatin in C3A liver cells using time- and 
concentration-dependent assays, in a normal and hyperlipidaemic condition 
• To measure the extent of hepatotoxic damage by assessing apoptosis using flow 
cytometry probing for annexin V as well as a propidium iodide staining, further 
confirmed by a caspase 3/7 assay in 2D culture 
• To determine ATV-induced cellular ROS and mitochondrial integrity changes with and 
without GRT co-treatment using a DCF assay, as well as a JC-1 stain, measured with 
flow cytometry, in 2D culture 
• To determine the hepatoprotective effects of GRT against chronic ATV-induced 
hepatotoxicity using a 3D culture system 
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4 Methodology & Materials 
 
A more detailed description of the preparation of reagents as well as experimental methods 
can be found in Chapter 11: Appendices.  
 
4.1 In vitro culturing of C3A cells in 2D culture 
 
The human-derived hepatocarcinoma cell line C3A (ATCC® HB8065™) was purchased from 
the American Type Culture Collection (ATCC). In order to create a large reserve of 
cryopreserved cells, the cells were passaged and sub-cultured. C3A cells were seeded at a 
density of 11x104 cells per millilitre in 75 cm2 tissue culture flasks and supplemented with 
Eagle’s Modified Essential Medium (EMEM; Lonza, MD, USA), 10% v/v foetal bovine serum 
(FBS; Gibco, catalogue no.: 10500064; ThermoFisher Scientific, Johannesburg, South Africa) 
and 1% v/v L-glutamine (Lonza, MD, USA), the combination thereof hereafter referred to as 
growth medium. Cells were incubated in a RS Biotech Galaxy R CO2 Incubator in humidified 
air at 37°C with 5% CO2 and the culture media was replaced every 2 – 3 days. Cells were sub-
cultured at 70 – 80% confluence. For all experiments, cells were subject to the same culturing 
conditions and reagent concentrations pertaining to cell maintenance.  
 
Palmitate was prepared in ethanol, thereafter palmitate treatment was prepared in growth 
medium with 2 mg/mL BSA (bovine serum albumin; fraction V, BSAV-RO, Roche, Sigma-
Aldrich, Johannesburg, South Africa) and 4.7 g/L sodium bicarbonate (NaHCO3; catalogue 
no.: S3817, Sigma, Stanheim, Germany) and left to conjugate in a water-bath at 37°C for two 
hours (Mazibuko et al, 2013; Mazibuko et al, 2015). 
 
Afriplex GRT™ (Aspalathus linearis (Brum.f) R.Dahlgren) extract was obtained from Afriplex, 
ATV was obtained from Sigma-Aldrich (catalogue no.: PHR1422), and palmitate was obtained 
from Sigma-Aldrich (catalogue no.: P0500). These, and all other chemicals for experimental 
use were of cell culture grade. Stock solutions were prepared in dimethyl sulfoxide (DMSO) 
and final working concentrations of treatments were not more than 0.25% v/v DMSO. 
 
4.2 Acute ATV and GRT cytotoxicity assessment in 2D culture (MTT)  
 
See Chapter 11: Appendices: 11.2. 
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Measuring the activity of various mitochondrial dehydrogenase enzymes allows for the 
assessment of mitochondrial viability as an indication of cell viability. The tetrazolium salt,       
3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT), is reduced in active 
mitochondria from a soluble yellow salt to insoluble purple formazan crystals which can be 
measured spectrophotometrically (Mosmann, 1983). 
 
In order to assess cellular metabolic activity, an MTT cell viability assay (catalogue no.: 
M5655; Sigma, Stanheim, Germany) was used. C3A (ATCC® HB8065™) cells were seeded 
in four 96-well plates (0.32 cm2) (Nest Biotech; Whitehead Scientific, Cape Town, South Africa) 
at a density of 11x104 cells per millilitre in 200 µL growth medium per well. Seventy-two hours 
after seeding, the media was refreshed. One hundred and twenty hours after seeding, culture 
media was aspirated and cells were exposed to a vehicle control (media with 0.25% DMSO 
for palmitate positive and palmitate negative controls), ATV (0.5 µM, 1 µM, 2.5 µM, 5 µM,       
10 µM, 12.5 µM, 25 µM, 50 µM, and 100 µM), or GRT (0.01 mg/mL, 0.02 mg/mL, 0.05 mg/mL, 
0.1 mg/mL, 0.2 mg/mL, 0.25 mg/mL, 0.5 mg/mL, 1 mg/mL, and 2 mg/mL) for 3, 6, 12, and 24 
hours. Treatments were added to EMEM with 0.25% DMSO. Three replicates per 
concentration of ATV and GRT were assessed in three independent experiments. 
 
 
 
 
Figure 4.2.1: Schematic representation of the timeline of the MTT experiments for the optimisation of the 
ATV and GRT concentrations. 
 
For the assay, culture media was aspirated and cells were washed with pre-warmed PBS 
before being incubated with 50 µL 2 mg/mL MTT for 30 minutes at 37°C. Following incubation, 
the MTT was aspirated, 200 µL DMSO and 25 µL Sorenson’s Buffer was added (DMSO lyses 
cells, effectively stopping cellular respiration, while Sorenson’s Buffer is a fixation buffer). 
Spectrophotometric measurements were recorded using a BioTek ELx800 absorbance 
microplate reader at OD570. Cytotoxicity was calculated as a percentage relative to the 
untreated vehicle control group. Results were generated using Gen5 version 1.05 (BioTek 
Instruments, Inc., Winooski, VT, USA). 
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Similarly, an MTT assay was used to assess palmitate cytotoxicity. C3A (ATCC® HB8065™) 
cells were seeded at a density of 11x104 cells per millilitre in a 96-well plate (0.32 cm2) (Nest 
Biotech; Whitehead Scientific, Cape Town, South Africa) in 200 µL growth medium per well. 
Seventy-two hours after seeding, culture media was aspirated and the cells were exposed to 
varying concentrations of palmitate (0 µM, 200 µM, 500 µM, 750 µM) for 24 hours. One 
hundred and twenty hours after seeding, pre-treatment was aspirated and replaced with 
vehicle control (media with 0.25% DMSO for palmitate positive and palmitate negative 
controls), ATV (10 µM or 25 µM), or GRT (0.01 mg/mL or 0.1 mg/mL) for a further 24 hours. 
Treatments were made up in EMEM with 0.25% DMSO. Three replicates per concentration of 
palmitate, ATV, and GRT were assessed in three independent experiments. Cell viability was 
expressed normalised to the vehicle control at 100%. 
 
 
 
Figure 4.2.2: Schematic representation of the timeline of the MTT experiments for the optimisation of the 
palmitate concentration. 
 
4.3 Assessment of induction of the disease condition 
 
See Chapter 11: Appendices: 11.3. 
 
CYP3A4 is responsible for the majority of human drug metabolism, including ATV and, 
interestingly, GRT notwithstanding (Patel et al, 2016). Moreover, it has been shown that the 
hyperlipidaemic disease state results in the upregulation of CYP3A4 (Shu et al, 2016b).  
 
Assessment of the modulation of CYP3A4 enzyme activity was assessed using Western Blot 
analysis. C3A (ATCC® HB8065™) cells were seeded in a clear 6-well plate (9.5 cm2) 
(catalogue no.: CLS3516; Corning® Costar®, Sigma, Stanheim, Germany) at a density of 
11x104 cells per millilitre in 3 mL growth medium per well. Seventy-two hours after seeding, 
culture media was refreshed. Ninety-six hours after seeding, culture medium was aspirated 
and cells were exposed to culture medium, 500 µM palmitate, culture medium and 10 µM 
rifampicin (catalogue no.: R3501, Sigma, Stanheim, Germany), or a combination of 500 µM 
palmitate and 10 µM rifampicin for 24 hours.  
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Figure 4.3.1: Schematic representation of the timeline for CYP3A4 Western blot assessment. 
 
For cell harvesting, 300 µL radioimmunoprecipitation assay (RIPA) lysis buffer supplemented 
with phenylmethylsulfonyl fluoride (PMSF; catalogue no.: 78830; Fluka, Bucharest, Romania) 
was used to lyse the cells. Lysed cells were further homogenised with a Qiagen TissueLyser 
II (Qiagen, Hilden, Germany) before being centrifuged and the supernatant collected and 
stored at -80 °C until further use. A reducing agent compatible and detergent compatible (RC 
DC) protein assay kit (RC DC™ Protein Assay Kit II; catalogue no.: 5000122; Bio-Rad, 
California, United States) was used to determine the protein concentrations of diluted (1:10) 
samples, compared to a BSA standard curve of 0.0 mg/mL, 0.125 mg/mL, 0.25 mg/mL,           
0.5 mg/mL, 0.75 mg/mL, 1.0 mg/mL, 1.5 mg/mL, and 2.0 mg/mL. Absorbance readings were 
recorded using a SpectraMax i3x multi-mode microplate reader (Molecular Devices, LLC, 
Sunnyvale, CA, USA) at OD630. Results were generated on SoftMax Pro 7 software, version 
7.0.2 (Molecular Devices, LLC, Sunnyvale, CA, USA).  
 
Sample buffer (4X SDS Sample Buffer, catalogue no.: 70607; Sigma, Stanheim, Germany) 
mixed with β-mercaptoethanol (Fluka, Bucharest, Romania) was prepared and mixed with     
60 µg protein lysate in a 1:4 ratio. Mini-PROTEAN® TGX™ 12% Precast Gels (catalogue no.: 
4561044; Bio-Rad, California, United States) were placed in a gel electrophoresis tank, filled 
with 1x Tris/Glycine/SDS running buffer (catalogue no.: 1610732; Bio-Rad, California, United 
States). Precision Plus ProteinTM WesternCTM marker (catalogue no.: 1610376; Bio-Rad, 
California, United States) and 60 µg protein sample was loaded onto the gel. A PowerPacTM 
Basic (catalogue no.: 1645050; Bio-Rad, California, United States) was set at 150 V for protein 
gel electrophoresis. Thereafter, proteins were transferred to a nitrocellulose membrane using 
a Trans-Blot® Turbo™ RTA Mini Nitrocellulose Transfer Kit (catalogue no.: 1704270; Bio-Rad, 
California, United States). The transfer sandwich was assembled in a Trans-Blot® TurboTM 
transfer cassette (catalogue no.: 1704150; Bio-Rad, California, United States) and run as a 
Bio-Rad mixed molecular weight transfer for 10 min at 25 V and 2.5 A. Following transfer, the 
success of the protein transfer was assessed with a Ponceau S stain (Ponceau S solution; 
catalogue no.: P7170; Sigma-Aldrich, Missouri, United States), before being counterstained 
with 1 x Tris-buffered saline with 0.1% Tween 20 (TBS-T). The membrane was then blocked 
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in 5% (w/v) skim milk powder/TBS-T at room temperature, before three washes with TBS-T 
followed by overnight incubation in primary antibody (1:500 dilution; CYP3A4 (D9U6N) Rabbit 
monoclonal Ab #13384; Cell Signaling Technology, Anatech Instruments (Pty) Limited, 
Olivedale, South Africa) in 5% (w/v) BSA and TBS-T at 4°C on an orbital shaker. The following 
day, the membrane was washed three times with TBS-T. Thereafter, the membrane was 
incubated in StrepTactin® HRP Conjugate (catalogue no.: 161-0381; Bio-Rad, California, 
United States) and horseradish peroxidase (HRP) conjugated secondary antibody in 2.5% 
(w/v) skim milk powder in TBS-T. The membrane was then washed another three times in 
TBS-T before chemiluminescent detection. The membrane was saturated in Clarity™ Western 
enhanced chemiluminescence (ECL) Substrate (catalogue no.: 1705061; Bio-Rad, California, 
United States) and incubated in the dark before imaging on the Bio-Rad ChemiDoc™ MP 
System (catalogue no.: 12003154; Bio-Rad, California, United States). Image LabTM Software 
(catalogue no.: 1709691; Bio-Rad, California, United States) was used to quantify the protein 
bands and protein expression was normalised to the housekeeping gene, GAPDH, which 
served as the loading control. 
 
4.4 Oxidative stress assessment in 2D culture 
 
See Chapter 11: Appendices: 11.4. 
 
The production of reactive oxygen species (ROS) is considered an integral component of the 
development of statin-induced hepatotoxicity. 2’, 7’-dichlorofluorescin diacetate (DCFDA) is a 
fluorogenic dye that measures ROS production – such as hydroxyls and peroxyls – within the 
cells. DCFDA is initially deacetylated by cellular esterases before undergoing oxidation by 
ROS, resulting in the generation of highly fluorescent 2’, 7’-dichlorofluorescein (DCF) which 
can be determined by means of fluorescence spectroscopy (Kalyanaraman et al, 2012). 
 
Oxidative stress was assessed by means of a DCF stain (catalogue no.: D6883; Sigma, 
Stanheim, Germany). C3A (ATCC® HB8065™) cells were seeded in a black 96-well clear 
bottom plate (0.32 cm2) (Nest Biotech; Whitehead Scientific, Cape Town, South Africa) at a 
density of 11x104 cells per millilitre in 200 µL growth medium. Seventy-two hours after seeding, 
culture media was aspirated and the cells were exposed to 500 µM palmitate treatment 
medium for 24 hours. One hundred and twenty hours after seeding, culture media was 
aspirated and cells were exposed to a vehicle control (media with 0.25% DMSO for palmitate 
positive and palmitate negative controls), ATV (10 µM and 25 µM), GRT (0.01 mg/mL and     
0.1 mg/mL), or a combination thereof (10 µM ATV + 0.01 mg/mL GRT, 10 µM ATV + 0.1 
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mg/mL GRT, or 25 µM ATV + 0.1 mg/mL GRT) for 24 hours. All treatments were added to 
vehicle control medium. ROS production was determined using an end-point fluorogenic DCF 
assay incubated for 30 minutes. Treatments were made up in EMEM with 0.25% DMSO. 
Fluorescent readings were recorded using a SpectraMax i3x multi-mode microplate reader 
(Molecular Devices, LLC, Sunnyvale, CA, USA) at an excitation wavelength of 485 nm and an 
emission wavelength of 535 nm. Results were generated on SoftMax Pro 7 software, version 
7.0.2 (Molecular Devices, LLC, Sunnyvale, CA, USA). Three replicates per treatment were 
assessed in three independent experiments. Reactive oxygen species production was 
calculated relative to cell viability assessed by an MTT assay (catalogue no.: M5655; Sigma, 
Stanheim, Germany), previously described in section 4.2.  
 
 
 
Figure 4.4.1: Schematic representation of the timeline of the DCF experiments. 
 
4.5 Mitochondrial membrane potential assessment in 2D culture 
 
See Chapter 11: Appendices: 11.5.1. 
 
5, 5', 6, 6'-Tetrachloro-1, 1', 3, 3'-tetraethylbenzimidazolylcarbocyanine iodide (JC-1) is a dual-
emission cationic dye that accumulates in polarized mitochondria. JC-1 is either a green 
fluorescent (λex 520 nm) monomer, as a result of low concentrations entering the mitochondria 
due to a low membrane potential, or a red fluorescent (λem 596 nm) aggregate, as a result of 
high concentrations in the mitochondrial matrix due to a high membrane potential. As such, 
mitochondrial membrane depolarization is indicated by decreased aggregate fluorescence, 
and is dependent only on the membrane potential (Reers et al., 1991; Di Lisa et al., 1995). 
 
Mitochondrial membrane integrity was assessed by means of a JC-1 stain (catalogue no.: 
T3168; Sigma, Stanheim, Germany). C3A (ATCC® HB8065™) cells were seeded in a 24-well 
plate (1.9 cm2) (catalogue no.: M8812; Greiner CELLSTAR®, Sigma, Stanheim, Germany) at 
a density of 11x104 cells per millilitre in 1 mL growth medium per well. Seventy-two hours after 
seeding, culture media was refreshed. Ninety-six hours after seeding, 500 µM palmitate was 
used to treat the cells for 24 hours. One hundred and twenty hours after seeding, cells were 
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exposed to a vehicle control (media with 0.25% DMSO for palmitate positive and palmitate 
negative controls), ATV (10 µM and 25 µM), GRT (0.01 mg/mL and 0.1 mg/mL), or a 
combination thereof (10 µM ATV + 0.01 mg/mL GRT, 10 µM ATV + 0.1 mg/mL GRT, or 25 µM 
ATV + 0.1 mg/mL GRT) for a further 24 hours. All treatments were added to vehicle control 
medium. Post treatment, treatment media was aspirated, replaced with 500 µL of 2 µM JC-1 
stain, and incubated at 37°C for half an hour. Mitochondrial membrane potential was assessed 
with flow cytometry, using a BD Accuri™ C6 (BD Biosciences, Johannesburg, South Africa). 
Results were generated using Accuri C6 software (BD Biosciences, Johannesburg, South 
Africa). Two replicates per treatment were assessed in three independent experiments. 
 
 
 
Figure 4.5.1: Schematic representation of the timeline of the JC-1 experiments. 
 
The forward scatter and fluorescent 1 (area) (FL1-A) of the cells was plotted for each 
population of each treatment group. Polygonal gating (P6; Figure 4.5.1) was applied to the 
unstained, untreated control cells as an indication of the dispersion of viable cells.  
 
 
Figure 4.5.2: Representative image of gating applied to forward scatter/fluorescent 1 channel plots. 
Polygonal gating was set around the unstained untreated cell population (P6) as an indication of the dispersion of 
the cell populations.  
 
The colour of the FL-1 and FL-2 channels was compensated accordingly, and quadrant gating 
was applied to the stained untreated cell population, gated in P6. A second, rectangular gate 
(R1) was set around the entire population so as to correct for the inaccuracy of the 
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percentages displayed in the quadrants as a result of the application of appropriate colour 
compensation (Figure 4.5.2). 
 
 
 
Figure 4.5.3: Representative image of gating for JC-1 stain. Quadrant gating was applied to the stained 
untreated cell population. A second gate was applied, R1, to isolate the region of interest for analysis.  
 
The FL-1 and FL-2 channels were compared to each other and the population was set to 
include the population gated in R1, which was already gated to include the population gated 
in P6 (Figure 4.5.3). Quadrant gating was applied around the population. With each treatment, 
there was a shift in the percentage of the total population of JC-1 inactive cells falling in the 
lower right quadrant, which was averaged for three experimental repeats. Further, the mean 
red (FL-2) fluorescence intensity was measured and calculated as a percentage relative to the 
appropriate control and tabulated (Supplementary Data: Table 10-1 and Table 10-2). 
 
 
Figure 4.5.4: Representative image of plot for analysis, following a JC-1 stain. Quadrant gating was set 
around the stained untreated cell population. The percentage of cells in the lower right quadrant was indicative of 
JC-1inactive cells as a result of decreased mitochondrial membrane potential. 
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To generate representative images (Chapter 10: Supplementary Data: Figure 10.1.1), 
palmitate pre-treated cells were imaged on the Nikon Eclipse Ti-S with PRIOR ProScan III 
(NIS Elements AR4.40; Nikon Instruments Inc. Johannesburg, South Africa). 
 
4.6 Viability and apoptosis assessment in 2D culture 
 
See Chapter 11: Appendices: 11.5.2. 
 
One of the earliest indicators of apoptosis is the loss of plasma membrane asymmetry, 
allowing for the translocation of the membrane phospholipid phosphatidylserine (PS) to 
outside the plasma membrane, exposed to the external cellular environment. Annexin V is a 
protein that can be conjugated to fluorochromes while maintaining its high affinity for PS, 
making it a sensitive probe for the assessment of apoptosis by flow cytometry. The 
translocation of PS allows for the distinction of early apoptotic cells as it precedes the loss of 
plasma membrane integrity – a key element of apoptotic cell death. This calls for the 
concurrent use of a vital dye. As such, damaged plasma membranes are permeable and allow 
propidium iodide, a DNA-intercalating agent, into the cells. Therefore, annexin V positive, PI 
negative cells are in early apoptosis, whereas annexin V positive, PI positive cells have 
undergone cell death (Vermes et al., 1995; van Engeland et al., 1996). As such, early and late 
apoptosis were assessed with dual staining of annexin V/propidium iodide (PI) (annexin V: 
catalogue no.: A13199; ThermoFisher Scientific, Johannesburg, South Africa; PI: catalogue 
no.: P4170; Sigma, Stanheim, Germany stain. C3A (ATCC® HB8065™) cells were seeded in 
a 24-well plate (1.9 cm2) (Greiner CELLSTAR®, Sigma, Stanheim, Germany) at a density of 
11x104 cells per millilitre in 1 mL growth medium per well. 
 
Seventy-two hours after seeding, culture media was refreshed. Ninety-six hours after seeding, 
culture media was aspirated, and the cells were exposed to 500 µM palmitate for 24 hours. 
One hundred and twenty hours after seeding, culture media was aspirated and cells were 
exposed to a vehicle control (media with 0.25% DMSO for palmitate positive and palmitate 
negative controls), ATV (10 µM and 25 µM), GRT (0.01 mg/mL and 0.1 mg/mL), or a 
combination thereof (10 µM ATV + 0.01 mg/mL GRT, 10 µM ATV + 0.1 mg/mL GRT, or             
25 µM ATV + 0.1 mg/mL GRT) for 24 hours. All treatments were added to vehicle control 
medium. Apoptosis status was assessed with dual staining of annexin V and PI, incubated at 
37°C for thirty minutes. Flow cytometry was performed using a BD Accuri™ C6 (BD 
Biosciences, Johannesburg, South Africa). Results were generated using Accuri C6 software 
(BD Biosciences, Johannesburg, South Africa). Two replicates per treatment were assessed 
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in three independent experiments. A comparison of the percentages in each viability state was 
tabulated for the normal condition (Supplementary Data: Table 10-3) and the hyperlipidaemic 
condition (Chapter 10: Supplementary Data: Table 10-4). 
 
 
 
Figure 4.6.1: Schematic representation of the timeline of the annexin V/PI experiments. 
 
Gating was applied on the forward scatter/side scatter plots to demarcate the dispersion of 
the healthy population (P1; Figure 4.6.1). 
 
 
Figure 4.6.2: Representative images of gating applied to forward and side scatter plots. Polygonal gating 
was set around the unstained untreated cell population (P1) as an indication of the dispersion of the healthy cell 
population.  
 
Quadrant gating was applied to the stained untreated population, gated in P1. A rectangular 
gate (R1) was set around the entire plot so as to correct for the inaccuracy of the percentages 
displayed in each quadrant as a result of the application of appropriate colour compensation 
(Figure 4.6.2). 
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Figure 4.6.3: Representative image of gating for annexin V/propidium iodide stain. Quadrant gating was set 
around the stained untreated cell population, gated in P1. A rectangular gate (R1) was set around the entire plot, 
correcting for inconsistencies due to colour compensation.   
 
Thereafter, the FL-1 and FL-2 channels were compared and the population was set to include 
the previously R1-gated population, in P1 (Figure 4.6.3). Quadrant gating was applied around 
the population to establish the percentage of cells in each quadrant. 
 
 
Figure 4.6.4: Representative image of gating for annexin V/propidium iodide stain. The percentage of cells 
in each quadrant was indicative of viable cells (lower left quadrant), early apoptosis (upper and lower right 
quadrant), and late apoptosis (upper left quadrant).  
 
The percentage of each population landing in the various quadrants was an indication of the 
following: the lower left (LL) quadrant was an indication of viable cells; the upper and lower 
right (UR and LR) quadrants were an indication of early apoptosis, and the upper left (UL) 
quadrant was an indication of late apoptosis. 
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4.7 Apoptosis assessment in 2D culture 
 
See Chapter 11: Appendices: 11.6. 
 
Caspase 3 and caspase 7 are executioner caspases in the pathway of apoptotic cell death. 
Despite having unique roles to play within the cascade, it has been shown that they are 
indistinguishable in the cleavage of certain fluorogenic peptides. This allows for the fluorescent 
measurement of apoptosis (Walsh et al., 2008). 
 
Late apoptosis was assessed by means of a caspase 3/7 stain (catalogue no.: C10423; 
ThermoFisher Scientific, Johannesburg, South Africa). C3A (ATCC® HB8065™) cells were 
seeded in a black 96-well clear bottom plate (0.32 cm2) (Nest Biotech; Whitehead Scientific, 
Cape Town, South Africa) at a density of 11x104 cells per millilitre in 200 µL growth medium 
per well. Seventy-two hours after seeding, culture media was refreshed. Ninety-six hours after 
seeding, culture media was aspirated, and the cells were exposed to 500 µM palmitate for 24 
hours. One hundred and twenty hours after seeding, culture media was aspirated and cells 
were exposed to a vehicle control (media with 0.25% DMSO for palmitate positive and 
palmitate negative controls), ATV (10 µM and 25 µM), GRT (0.01 mg/mL and 0.1 mg/mL), or 
a combination thereof (10 µM ATV + 0.01 mg/mL GRT, 10 µM ATV + 0.1 mg/mL GRT, or       
25 µM ATV + 0.1 mg/mL GRT) for 24 hours. All treatments were added to vehicle control 
medium. Apoptosis was assessed using a 10 µM caspase 3/7 stain, incubated at 37°C for an 
hour. Fluorescent readings were recorded on a SpectraMax i3x multi-mode microplate reader 
(Molecular Devices, LLC, Sunnyvale, CA, USA) at an excitation wavelength of 502nm and an 
emission wavelength of 530nm every 15 minutes for 60 minutes. Results were generated on 
SoftMax Pro 7 software, version 7.2 (Molecular Devices, LLC, Sunnyvale, CA, USA). Three 
replicates per treatment were assessed in three independent experiments. 
 
 
 
Figure 4.7.1: Schematic representation of the timeline of the caspase 3/7 experiments. 
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4.8 In vitro culturing of C3A cells in 3D culture 
 
See Chapter 11: Appendices: 11.7 
 
For 3D culturing of C3A cells, a protocol described by Wrzesinki et al (2013) was optimized. 
Two 3D bioreactors were assembled and prepared 24 hours before use (Day 0). Briefly, an 
AggreWell™ 800 plate (catalogue no.: 34811, STEMCELL Technologies, Cape Town, South 
Africa) was prepared and stored in an incubator until needed. Cells at 85 – 90% confluence 
were added to the prepared AggreWell™ plate at a density of 4.8x106 cells per millilitre, topped 
up with complete growth medium, and incubated overnight (± 20 hours). On Day 1, the cell 
aggregates/clusters were gently dislodged from the AggreWell™ plate using a plastic Pasteur 
pipette and transferred to the growth chamber of the bioreactor to produce spheroids. The 
bioreactor was then returned to the incubator and rotated on the lowest speed (approximately 
14.5 rpm). The speed was adjusted to create a microgravitational environment, whereby the 
spheroids remain in the same position without colliding with the sides of the vessel, or each 
other. Incubators for bioreactors were set at 5% CO2, 95% air, and 37ºC for a minimum of 18 
days, with growth media being exchanged every 2 days, and the speed being adjusted 
according to growth of the spheroids. Once treatment began, treatment media was replaced 
daily. 
 
Eighteen-day-old spheroids were exposed to a 500 µM palmitate pre-treatment for 96 hours. 
Thereafter, treatment with 0.1 mg/mL GRT, 10 µM ATV, or a combination thereof, began for 
a further 14 days. Treatment concentrations were extrapolated from 2D culture. An untreated 
control bioreactor served as the negative control and was exposed only to complete growth 
medium, while the palmitate-only bioreactor served as the positive control. Three other 
bioreactors were used and treated with palmitate and 0.01 mg/mL GRT, palmitate and              
10 µM ATV, or a combination of palmitate, 0.01 mg/mL GRT, and 10 µM ATV. 
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Figure 4.8.1: Schematic representation of 3D culturing timeline. 
 
4.9 Glucose utilisation 
 
As an indication of cellular respiration, glucose levels in the growth media was measured using 
a One Touch® Select® glucometer (Roche Diabetes Care South Africa). Media and treatment 
media was aspirated from the bioreactors with a 10 mL syringe. A sample (5 µL) of fresh and 
aspirated media was tested on a glucose test strip and measured in mmol/L. Glucose 
remaining in the media was calculated as a percentage relative to the fresh media added, set 
at 100%. 
 
4.10 Electron microscopy 
 
4.10.1 Tissue preparation 
 
(Method: NHLS Department of Electron Microscopy Laboratory, Department of Anatomical 
Pathology, Tygerberg Hospital – Mrs. N Muller) 
 
Harvested C3A spheroids were fixed in 2.5% glutaraldehyde in 0.1M phosphate buffer pH 7.2 
at 4°C for 8 - 12 hours. After a 5 min wash in phosphate buffer, spheroids were post-fixed in 
3% osmium tetroxide in Palade’s buffer for 1 hour. Thereafter, the osmium tetroxide was 
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removed and the spheroids washed in distilled water and processed in processing vials 
according to an established protocol (Table 4-1). 
 
Table 4-1: Tissue processing schedule. 
Reagent Time (min) 
10% uranyl acetate 15 
70% alcohol 10 
70% alcohol 10 
10% uranyl nitrate 20 
100% alcohol 15 
100% alcohol 20 
100% alcohol 30 
100% alcohol: Spurr’s resin 90 
Spurr’s resin 60 
Spurr’s resin 60 
 
Spheroids were then embedded with Spurr’s resin into gelatin capsules and allowed to 
polymerize overnight at 60°C. 
 
4.10.2 Ultra-thin sectioning 
 
Ultra-thin (100 nm) sections of the spheroids were cut from the resin blocks using a glass knife 
fitted with a water-trough using a Leica EM UC7 ultramicrotome (Vienna, Austria).  The ultra-
thin ribbon sections were collected from the water surface onto 200G grids, and allowed to dry 
on filter paper before staining. The grids were first stained with 2% uranyl acetate in 70% 
alcohol for 10 minutes, rinsed in 70% alcohol and distilled water. Thereafter the grids were 
stained with Reynold’s lead acetate for 5 minutes, washed in distilled water and allowed to dry 
on filter paper. The spheroid sections were imaged using a Joel JEM 1011 (Akishima, Tokyo) 
transmission microscope. 
 
4.11 Spheroid viability assessment 
 
See Chapter 11: Appendices: 11.8 
 
The luminescent assessment of ATP allows for luciferin, adenosine triphosphate (ATP) and 
co-factor Mg2+ to be metabolised by luciferase to produce oxyluciferin and energy in the form 
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of luminescence. ATP is a co-factor for the reaction, and the luminescence produced is 
proportional to the amount of ATP present, representative of metabolically active cells 
(Hannah et al, 2015). 
  
Spheroid viability was assessed using a CellTiter-Glo® Luminescent Cell Viability Assay 
(Catalogue no.: G7571; Promega, Anatech Instruments Pty. Ltd, Johannesburg, South Africa). 
Spheroids from each treatment group were sampled at Day 0, 3, 7, and 14 in a white-walled 
96-well clear bottom plate (0.32 cm2) (catalogue no.: M1062; Greiner CELLSTAR®, Sigma, 
Stanheim, Germany). The CellTiter-Glo® lysis buffer was added to each well and incubated 
at 37°C for 1 hour on a microtiter plate shaker. Luminescence readings were measured with 
a SpectraMax i3x multi-mode microplate reader (Molecular Devices, LLC, Sunnyvale, CA, 
USA) Results were generated on SoftMax Pro 7 software, version 7.2 (Molecular Devices, 
LLC, Sunnyvale, CA, USA). Three technical replicates were performed with three spheroids 
per repeat. ATP production was normalised to average spheroid volume (µm3) and expressed 
as luminescence (arbitrary units; AU) per µm3. 
 
4.12 Adenylate kinase assessment  
 
See Chapter 11: Appendices: 11.9 
 
Damage to the mitochondrial membrane causes a loss of cellular integrity and allows for the 
leakage of mitochondrial proteins and enzymes into the cytosol and culture media. 
Compromised mitochondria have been shown to non-selectively release mitochondrial 
proteins into the cytosol, such as cytochrome c. Adenylate kinase has been shown to be 
concomitantly released with cytochrome c (Single et al, 1998; Köhler et al, 1999). Adenylate 
kinase is present in all mitochondria and can be measured bioluminescently to sensitively and 
accurately determine cytolysis and cytotoxicity. A luciferase reaction occurs due to the 
enzymatic production of ATP by adenylate kinase substrate and ADP, allowing for a directly 
proportional luminescent measurement of the presence of adenylate kinase (Olsson et al, 
1983). 
 
Culture and treatment medium were sampled upon refreshing the bioreactors and stored at    
-20°C until required. Using the ToxiLight™ bioassay kit (catalogue no.: LT07-217; Lonza, MD, 
USA), the presence of adenylate kinase in the medium was measured. All reagents were 
thawed to room temperature and 5 µL of sampled medium was transferred into a clean white-
walled 96-well clear bottom plate (0.32 cm2) (catalogue no.: M1062; Greiner CELLSTAR®, 
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Sigma, Stanheim, Germany), followed by the addition of 100 µL of reconstituted adenylate 
kinase detection reagent, incubated at room temperature for 5 minutes. Luminescence 
readings were taken on a SpectraMax i3x multi-mode microplate reader (Molecular Devices, 
LLC, Sunnyvale, CA, USA). Results were generated on SoftMax Pro 7 software, version 7.2 
(Molecular Devices, LLC, Sunnyvale, CA, USA). Three technical replicates were performed 
per sample medium per time point. Adenylate kinase production was measured as 
luminescence (RLU), normalised to average spheroid volume per treatment (µm3), and 
calculated as a percentage relative to the first sample, set at 100%.  
 
4.13 Statistical analysis 
 
Statistical analysis was performed using GraphPad Prism 8.0.0 (GraphPad Software, La Jolla, 
California, United States of America) and data were compared using a one-way or two-way 
(where appropriate) Analysis of Variance (ANOVA), followed by a Tukey post hoc test. Data 
are presented as mean ± standard deviation (SD) and p-values of ≤ 0.05 were considered 
statistically significant. 
 
  
Stellenbosch University  https://scholar.sun.ac.za
 50 
 
5 Results 
 
5.1 Acute GRT, ATV, and palmitate cytotoxicity assessment in 2D culture 
(MTT) 
 
By assessing the activity of mitochondria in live cells with an MTT assay, the concentration- 
and time-dependent assessment of ATV and Afriplex GRT (hereafter referred to as GRT) on 
cytotoxicity was determined. 
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Figure 5.1.1: MTT assay for the assessment of cell viability in GRT-treated cells. Cells were exposed to ten 
different concentrations of GRT (0.0 mg/mL, 0.01 mg/mL, 0.02 mg/mL, 0.05 mg/mL, 0.1 mg/mL, 0.2 mg/mL, 0.25 
mg/mL, 0.5 mg/mL, 1 mg/mL, and 2 mg/mL) and assessed at 4 different time points, namely 3, 6, 12, and 24 hours. 
Data is normalised against the relevant control for each time point set at 100%. Data are mean ± SD derived from 
four independent experiments each with three technical repeats (n = 4). A Two-way Analysis of Variance was 
performed with a Tukey post hoc test. ** = p<0.01. 
 
An MTT assay was used to assess cell viability based on mitochondrial dehydrogenase activity 
in a time- and concentration-dependent fashion. Ten concentrations of GRT (0.0 mg/mL,        
0.01 mg/mL, 0.02 mg/mL, 0.05 mg/mL, 0.1 mg/mL, 0.2 mg/mL, 0.25 mg/mL, 0.5 mg/mL,            
1 mg/mL, and 2 mg/mL) were tested at 4 time points, namely: 3 hours, 6 hours, 12 hours, and 
24 hours, as shown in Figure 5.1.1. Cytotoxicity was observed only at 24 hours for the highest 
concentration of GRT. 
 
Stellenbosch University  https://scholar.sun.ac.za
 51 
 
0 3 6 9 12 15 18 21 24
80
100
120
140
0.01 mg/mL
0.1 mg/mL
Time (Hours)
%
 R
e
la
ti
v
e
 M
T
T
 A
c
ti
v
it
y
0.00 mg/mL
 
Figure 5.1.2: Selection of GRT concentrations and time points based on an MTT assay. Based on the 
concentration curves in Figure 5.1.1, two concentrations of GRT (0.01 and 0.1 mg/mL) showing the most positive 
effect on mitochondrial dehydrogenase activity at 24 hours were selected as the optimal GRT treatment 
concentrations in the C3A cells. Data is normalised against the relevant control for each time point set at 100%. 
Data are mean ± SD derived from four independent experiments each with three technical repeats (n = 4). A Two-
way Analysis of Variance was performed with a Tukey post hoc test. 
 
Figure 5.1.2 shows the MTT activity effect of GRT on C3A cells, concentrations of 0.01 mg/mL 
and 0.1 mg/mL of GRT for the 24 hours treatment period was selected based on their positive 
effect on mitochondrial dehydrogenase activity of the C3A cells. Afriplex GRT™ is formulated 
to contain 12% aspalathin. 
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Figure 5.1.3: MTT assay for the assessment of cytotoxicity and cell growth inhibition by ATV-treated C3A 
cells. Cells were exposed to 10 concentrations of ATV (0 µM, 0.5 µM, 1 µM, 2.5 µM, 5 µM, 10 µM, 12.5 µM,            
25 µM, 50 µM, and 100 µM) and assessed at 4 different time points, namely 3, 6, 12, and 24 hours (Figure 5.1.3). 
Data is normalised against the relevant control for each time point set at 100%. Data are mean ± SD derived from 
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four independent experiments each with three technical repeats (n = 4). A Two-way Analysis of Variance was 
performed with a Tukey post hoc test. * = p<0.05; *** = p<0.001.  
Figure 5.1.3 shows that ATV was cytotoxic to the cells from a concentration of 25 µM over the 
24 hour period tested. At the higher concentrations of 50 µM and 100 µM ATV, significant 
cytotoxicity was apparent from 6 hours (p<0.001) at 76.02% ± 11.09 and 48.92% ± 11.61 
respectively. 
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Figure 5.1.4: Semi Log concentration response curves and calculated IC50 values of ATV in C3A cells. 
Remaining MTT activity was determined at 12 (Figure 5.1.4.A) and 24 hours (Figure 5.1.5.B). Error bars: ± SD. 
Data from four independent experiments each with three technical repeats (n = 4). 
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Figure 5.1.5: Selection of ATV concentrations and time points based on MTT assay. Comparison of four 
selected ATV concentrations to illustrate the rationale for selection of 10 and 25 µM ATV for 24 hours as optimal 
treatment options. Data is normalised against the relevant control for each time point set at 100%. Data from four 
independent experiments each with three technical repeats (n = 4), presented as mean ± SD. A two-way Analysis 
of Variance was performed with a Tukey post hoc test. * = p<0.05; *** = p<0.001. 
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As seen in Figures 5.1.3 and 5.1.5, the two highest concentrations tested (50 µM and 100 µM) 
of ATV induced noticeable toxicity in C3A cells after 12 hours (53.88% ± 11.71 and 14.28% ± 
5.60 respectively) and 24 hours (36.53% ± 20.14 and 5.96% ± 1.24 respectively) and were 
thus deemed too toxic to fit the model being used, which called for the induction of hepatic 
injury. Based on the 12- and 24-hour MTT IC50 values (48.13 µM ± 2.08 and 41.41 µM ± 3.67 
respectively), two lower concentrations of 10 µM and 25 µM, were considered the more 
intermediate, physiologically and literature-relevant concentrations for further experiments. 
 
Palmitate treatment was used to mimic a hyperlipidaemic physiological state in vitro as 
previously described by Hu et al (2014). This was verified by assessing the CYP3A4 activity 
as Shu et al (2016b) showed that CYP3A4 activity is increased in the hyperlipidaemic state. 
Cells were expected to react differently to the statin treatment as a result of the varying 
metabolic status of the cells. The introduction of a palmitate pre-treatment noticeably 
decreased cell viability, as shown in Figure 5.1.6. Hu et al (2014) made use of 200 µM 
palmitate treatment for 24 hours. 
 
 
Figure 5.1.6: MTT assay for the assessment of cell viability in palmitate-treated C3A cells. Cells were 
exposed to three different concentrations of palmitate (200µM, 500µM, and 750µM) for 24 hours, as this was the 
pre-treatment period before 24 hours of ATV and/or GRT treatment. Data are mean ± SD derived from three 
independent experiments each with three technical repeats (n = 3). A Two-way Analysis of Variance was performed 
with a Tukey post hoc test. Comparative statistics were between each concentration of palmitate in each treatment 
group and the respective palmitate negative control. ** = p<0.01; *** = p<0.001. 
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Figure 5.1.7: MTT assay for the assessment of GRT and atorvastatin (ATV) treatment on C3A cell viability 
in palmitate pre-treated cells. C3A cells were exposed to three different concentrations of palmitate (200µM, 
500µM, and 750µM) for 24 hours before 24 hours of ATV and GRT treatment. Data are mean ± SD derived from 
three independent experiments each with three technical repeats (n = 3). Data are normalised against the relevant 
control set at 100%. Data are mean ± SD. A Two-way Analysis of Variance was performed with a Tukey post hoc 
test. Comparative statistics were between each concentration of palmitate in each treatment group and the 
respective palmitate negative control. ** = p<0.01; *** = p<0.001. GRT1 = 0.01 mg/mL; GRT2 = 0.1 mg/mL; ATV1 
= 10 µM and ATV2 = 25 µM. 
 
C3A cells were exposed to three different concentrations of palmitate pre-treatment, followed 
by a 24 hour treatment with GRT or ATV. Pre-treatment of C3A cells with 200 µM palmitate 
did not significantly reduce cell viability when compared to the cells not treated with palmitate 
in each treatment group (Figure 5.1.7). Treatment with 750 µM palmitate showed a significant 
decrease (p<0.001) in cell viability in all treatment groups as compared to their respective 
controls, with viability decreasing by approximately half in each treatment group. Viability was 
significantly decreased (p<0.01 and p<0.001) compared to the control in the treatment groups 
when cells were treated 500 µM palmitate, however, being an intermediate and literature-
relevant concentration, it was chosen as an appropriate concentration for an in vitro model of 
hepatic injury.  
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5.2 Assessment of CYP3A4 induction by palmitate 
 
 
Figure 5.2.1: Western blot analysis assessing the modulation of CYP3A4 activity in palmitate-treated C3A 
cells. Cells were exposed to different treatments (24 hours) and the protein expression of CYP3A4 (~52 kDa) and 
GAPDH (~37 kDa) was quantified by Western blot gel electrophoresis: Medium Control = culture medium; Palmitate 
Control = 500 µM palmitate; Medium + Rifampicin = culture medium + 10 µM Rifampicin; Palmitate + Rifampicin = 
500 µM palmitate + 10 µM Rifampicin. CYP3A4 protein expression was normalised to the housekeeping gene, 
GAPDH, and expressed in arbitrary units (AU). n = 1. Statistical analysis not performed. 
 
Literature shows that the hyperlipidaemic state increases CYP3A4 activity when compared to 
the healthy condition. Rifampicin is used as a positive control as it is an inducer of CYP3A4 
activity. As seen in Figure 5.2.1, the Medium Control showed the lowest CYP3A4 expression 
(0.008 AU). Palmitate treatment showed increased CYP3A4 expression (0.057 AU) compared 
to the Medium Control, and the Rifampicin-treated combination cells both showed further 
increased protein expression (0.062 AU for the Medium + Rifampicin group, and 0.065 AU for 
the Palmitate + Rifampicin group).  
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5.3 Viability assessment in C3A cells not exposed to palmitate (normal 
condition) and exposed to palmitate pre-treatment (hyperlipidaemic 
condition). 
 
An MTT assay was used to assess mitochondrial function as an indication of cell viability in 
C3A cells not exposed to palmitate (normal condition), as well as pre-treated with palmitate 
(hyperlipidaemic condition), and subsequently treated with the previously selected 
concentrations of GRT or ATV or combination treatment.  
 
 
Figure 5.3.1: MTT assay assessment of cell viability in C3A cells not exposed to palmitate (normal 
condition) treated with GRT, atorvastatin, and combinations thereof. C3A cells were exposed to the following 
treatments and combinations (24 hours). Vehicle control = media with 0.25% DMSO; ATV1 = 10 µM; ATV2 = 25 
µM; GRT1 = 0.01 mg/mL; GRT2 = and 0.1 mg/mL; ATV1 + GRT1 = 10 µM ATV + 0.01 mg/mL GRT; ATV1 + GRT2 
= 10 µM ATV + 0.1 mg/mL GRT; ATV2 + GRT2 = 25 µM ATV + 0.1 mg/mL GRT. Data are mean ± SD derived from 
three independent experiments each with three technical repeats (n = 3). A One-way Analysis of Variance was 
performed with a Tukey post hoc test. All results were calculated as percentage relative absorbance normalised to 
the vehicle control at 100%. * = p<0.05; ** = p<0.01; *** = p<0.001. 
 
Figure 5.3.1 shows that GRT treatment at the concentrations tested (GRT1 = 0.01 mg/mL and 
GRT2 = 0.1 mg/mL) had no significant effect on cell viability in C3A cells not exposed to 
palmitate (normal condition).  In contrast, ATV reduced C3A cell viability in a concentration 
dependent manner. A significant decline in C3A cell viability was demonstrated between         
10 µM versus a 25 µM 24 hour treatments (75.66% ± 15.52 vs 36.77% ± 16.45; p<0.001). 
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Combination treatment of ATV (10 µM and 25 µM) with GRT (0.01 mg/mL and 0.1 mg/mL) did 
not ameliorate ATV-induced cytotoxicity.  
 
Figure 5.3.2: MTT assay assessment of cell viability in C3A cells pre-treated with 500 µM palmitate for 24 
hours (hyperlipidaemic condition), treated with GRT, atorvastatin and combinations thereof. Cells exposed 
to 500 µM palmitate pre-treatment were subsequently treated with the following treatments and combinations (24 
hours). Palmitate control = palmitate pre-treated cells exposed to media with 0.25% DMSO for 24 hours; ATV1 = 
10 µM; ATV2 = 25 µM; GRT1 = 0.01 mg/mL; GRT2 = and 0.1 mg/mL; ATV1 + GRT1 = 10 µM ATV + 0.01 mg/mL 
GRT; ATV1 + GRT2 = 10 µM ATV + 0.1 mg/mL GRT; ATV2 + GRT2 = 25 µM ATV + 0.1 mg/mL GRT. %. Data are 
mean ± SD derived from three independent experiments each with three technical repeats (n = 3). A one-way 
Analysis of Variance was performed with a Tukey post hoc test. All results were calculated as percentage relative 
absorbance normalised to the palmitate control at 100%. ** = p<0.01; *** = p<0.001. 
 
In C3A cells treated with 500 µM palmitate for 24 hours, used to simulate a hyperlipidaemic 
condition, GRT did not significantly reduce cell viability. As was seen in the normal condition, 
atorvastatin induced cytotoxicity in C3A cells in a concentration-dependent manner. A 
significant decline in C3A cell viability was demonstrated between 10 µM versus 25 µM 
treatments for 24 hour (53.78% ± 23.20 vs 16.58% ± 13.99; p<0.001). The adverse effect of 
atorvastatin was not improved by the combination treatment with GRT at either concentration.  
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5.4 Oxidative stress assessment in 2D culture 
 
Reactive oxygen species (ROS) production, relative to cell viability was assessed to elucidate 
the effect of oxidative stress. This was analysed in the normal condition as well as the 
hyperlipidaemic condition. 
 
5.4.1 Intracellular ROS production in the normal condition 
Determination of cellular ROS production was assessed by the DCF assay that determined 
the rate of deacetylation of DCFDA by cellular esterases, and by its oxidation by intracellular 
ROS, generating a highly fluorescent DCF product. 
 
Figure 5.4.1: DCF assay assessment of oxidative stress in C3A cells not exposed to palmitate (normal 
condition) treated with GRT, atorvastatin and combinations thereof. C3A cells were treated with GRT, 
atorvastatin and combinations (24 hours). Vehicle control = media with 0.25% DMSO; ATV1 = 10 µM; ATV2 = 25 
µM; GRT1 = 0.01 mg/mL; GRT2 = and 0.1 mg/mL; ATV1 + GRT1 = 10 µM ATV + 0.01 mg/mL GRT; ATV1 + GRT2 
= 10 µM ATV + 0.1 mg/mL GRT; ATV2 + GRT2 = 25 µM ATV + 0.1 mg/mL GRT. %. Data are mean ± SD derived 
from three independent experiments each with three technical repeats (n = 3). A one-way Analysis of Variance was 
performed with a Tukey post hoc test. All results were calculated as percentage relative fluorescence normalised 
to the vehicle control at 100%. *** = p<0.001. 
 
In the normal condition as shown in Figure 5.4.1, GRT had no significant effect on intracellular 
ROS production; whist ATV increased intracellular ROS in a concentration related manner. 
Co-treatment with GRT has a significant (p<0.001) additive effect on ATV-induced intracellular 
ROS production compared to ATV2 monotherapy. 
Stellenbosch University  https://scholar.sun.ac.za
 59 
 
5.4.2 Intracellular ROS production in the hyperlipidaemic condition 
 
Figure 5.4.2: DCF assay assessment of oxidative stress in C3A cells exposed to 500 µM palmitate for 24 
hours to simulate hyperlipidaemia, treated with GRT, atorvastatin and combinations thereof. Palmitate-
treated C3A cells were exposed to the following treatments and combinations (24 hours): Palmitate control = 
palmitate pre-treated cells exposed to media with 0.25% DMSO for 24 hours; ATV1 = 10 µM; ATV2 = 25 µM; GRT1 
= 0.01 mg/mL; GRT2 = and 0.1 mg/mL; ATV1 + GRT1 = 10 µM ATV + 0.01 mg/mL GRT; ATV1 + GRT2 = 10 µM 
ATV + 0.1 mg/mL GRT; ATV2 + GRT2 = 25 µM ATV + 0.1 mg/mL GRT. Data are mean ± SD derived from three 
independent experiments each with three technical repeats (n = 3). A one-way Analysis of Variance was performed 
with a Tukey post hoc test. All results were calculated as percentage relative fluorescence normalised to the 
palmitate control at 100%. * = p<0.05; *** = p<0.001. 
 
Under the simulated hyperlipidaemic condition (Figure 5.4.2) ATV showed a concentration 
dependent increase in intracellular ROS, with 25 µM ATV greatly increasing (>10-fold) 
intracellular ROS production (1431.00% ± 504.20). The increase in intracellular ROS induced 
by the higher concentration of ATV was more than double than what was induced under the 
normal condition. In combination, GRT at the concentrations used did not moderate an ATV-
induced increase in ROS production. 
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5.5 Mitochondrial membrane potential assessment 
 
Mitochondrial membrane potential was assessed for the accumulation of JC-1 J-aggregates 
by active mitochondria, represented by red fluorescence, derived from a green fluorescent 
monomer of the JC-1 dye. Red J-aggregates accumulate in the mitochondria due to higher 
mitochondrial membrane integrity, whereas green monomers are present when there is 
decreased mitochondrial membrane potential. Increased red fluorescence signal is due to 
higher mitochondrial membrane potential, while the presence of the green fluorescence is due 
to decreased mitochondrial membrane potential. This dual-emission JC-1 dye allows for the 
fluorescent determination of mitochondrial integrity changes. Cell populations were measured 
in terms of mean fluorescence (FL2-A) intensity, where increased fluorescence intensity is 
indicative of increased presence of red aggregates as an indication of mitochondrial 
membrane integrity, and in terms of JC-1 inactive cells, where “inactive” cells represents the 
percentage of the cell population that fall beneath the minimum red fluorescence threshold of 
the measurement of J-aggregates. 
 
5.5.1 JC-1 fluorescence in the normal condition 
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Figure 5.5.1: JC-1 flow cytometric assessment of mitochondrial polarisation (activity) in C3A cells not 
exposed to palmitate (normal condition) treated with GRT, atorvastatin and combinations thereof. 
Representative flow cytometry dot plots of JC-1 J-aggregates (FL2-A; red fluorescence) versus JC-1 monomers 
(FL1-A; green fluorescence). C3A cells were treated with GRT, atorvastatin and combinations (24 hours). Vehicle 
control = media with 0.25% DMSO; ATV1 = 10 µM; ATV2 = 25 µM; GRT1 = 0.01 mg/mL; GRT2 = and 0.1 mg/mL; 
ATV1 + GRT1 = 10 µM ATV + 0.01 mg/mL GRT; ATV1 + GRT2 = 10 µM ATV + 0.1 mg/mL GRT; ATV2 + GRT2 = 
25 µM ATV + 0.1 mg/mL GRT.  
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Figure 5.5.2: Mean FL-2 (red) fluorescence intensity in C3A cells not exposed to palmitate (normal 
condition) as an indication of mitochondrial membrane potential. C3A cells were treated with GRT, 
atorvastatin and combinations (24 hours). Vehicle control = media with 0.25% DMSO; ATV1 = 10 µM; ATV2 = 25 
µM; GRT1 = 0.01 mg/mL; GRT2 = and 0.1 mg/mL; ATV1 + GRT1 = 10 µM ATV + 0.01 mg/mL GRT; ATV1 + GRT2 
= 10 µM ATV + 0.1 mg/mL GRT; ATV2 + GRT2 = 25 µM ATV + 0.1 mg/mL GRT. Data are mean ± SD derived from 
three independent experiments each with three technical repeats (n = 3). A one-way Analysis of Variance was 
used with a Tukey post hoc test. All results were expressed as a percentage relative fluorescence intensity 
normalised to the vehicle control at 100%. * = p<0.05. 
 
In terms of mitochondrial function in the normal condition, Figure 5.5.2 shows the effect of 24 
hours’ treatment on mitochondrial membrane potential (Δψm). There was a difference in the 
mean fluorescence intensity measured between GRT1 (90.62% ± 21.45) and GRT2 (64.28% 
± 13.16), however this was not significant. The ATV1 group (66.99% ± 22.73) showed a 
significantly greater (p<0.05) mean fluorescence intensity compared to the ATV2 group 
(32.48% ± 11.55). 
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5.5.2 JC-1 fluorescence in the hyperlipidaemic condition 
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Figure 5.5.3: Percentage of JC-1 J-aggregate formation in the hyperlipidaemic condition as an indication 
of mitochondrial membrane potential. Representative flow cytometry dot plots of JC-1 J-aggregates (FL2-A; red 
fluorescence) versus JC-1 monomers (FL1-A; green fluorescence). C3A cells were treated with GRT, ATV and 
combinations (24 hours) after a 500 µM palmitate pre-treatment for 24 hours. Palmitate control = palmitate pre-
treated cells with media with 0.25% DMSO; ATV1 = 10 µM; ATV2 = 25 µM; GRT1 = 0.01 mg/mL; GRT2 = 0.1 
mg/mL; ATV1 + GRT1 = 10 µM ATV + 0.01 mg/mL GRT; ATV1 + GRT2 = 10 µM ATV + 0.1 mg/mL GRT; ATV2 + 
GRT2 = 25 µM ATV + 0.1 mg/mL GRT. 
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Figure 5.5.4: Mean FL-2 (red) fluorescence intensity in the hyperlipidaemic condition as an indication of 
mitochondrial membrane potential. C3A cells were treated with GRT, ATV and combinations (24 hours) after a 
24 hour 500 µM palmitate pre-treatment. Palmitate control = palmitate pre-treated cells with media with 0.25% 
DMSO; ATV1 = 10 µM; ATV2 = 25 µM; GRT1 = 0.01 mg/mL; GRT2 = 0.1 mg/mL; ATV1 + GRT1 = 10 µM ATV + 
0.01 mg/mL GRT; ATV1 + GRT2 = 10 µM ATV + 0.1 mg/mL GRT; ATV2 + GRT2 = 25 µM ATV + 0.1 mg/mL GRT. 
Data are mean ± SD derived from three independent experiments each with three technical repeats (n = 3). A one-
way Analysis of Variance was used with a Tukey post hoc test. All results were expressed as a percentage relative 
fluorescence intensity normalised to the palmitate control at 100%. ** = p<0.01. 
 
Figure 5.5.4 shows that, in the hyperlipidaemic condition, ATV1 (106.90% ± 20.81) showed a 
significantly greater (p<0.01) mean fluorescence intensity ATV2 (63.02% ± 16.17). No other 
significant differences were noted between any other groups. 
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5.6 Apoptosis assessment 
 
The extent of apoptosis related hepatotoxic damage was measured using an annexin V and 
a propidium iodide stain. Annexin V is a protein, conjugated to fluorochromes, that has a high 
affinity for phosphatidylserine (PS). Phosphatidylserine is translocated outside the membrane 
due to the loss of plasma membrane asymmetry. This translocation precedes the loss of 
plasma membrane integrity which is a crucial part of apoptotic and necrotic cell death. The 
loss of plasma membrane integrity causes the membrane to be permeable, allowing for vital 
dyes, such as propidium iodide, to enter the cell. Therefore, annexin V positive, PI negative 
cells indicate cells in early apoptosis, whereas annexin V positive, PI positive cells have 
undergone cell death (late apoptotic/necrotic).  
 
5.6.1 Annexin V/PI apoptosis assessment in the normal condition 
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Figure 5.6.1: Representative scatter plots of annexin V/PI flow cytometry assessment in the normal 
condition. Representative flow cytometry scatter plots of C3A cells were treated with GRT, atorvastatin and 
combinations (24 hours). Vehicle control = media with 0.25% DMSO; ATV1 = 10 µM; ATV2 = 25 µM; GRT1 = 0.01 
mg/mL; GRT2 = and 0.1 mg/mL; ATV1 + GRT1 = 10 µM ATV + 0.01 mg/mL GRT; ATV1 + GRT2 = 10 µM ATV + 
0.1 mg/mL GRT; ATV2 + GRT2 = 25 µM ATV + 0.1 mg/mL GRT. 
 
5.6.2 Viable 
 
Annexin V negative, propidium iodide negative cells were considered viable cells. All results 
were calculated as a percentage of the cell population in the lower left quadrant, averaged 
over three experiments. 
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Figure 5.6.2: Quantification of the percentage of viable cells in the normal condition. C3A cells were treated 
with GRT, atorvastatin and combinations (24 hours). Vehicle control = media with 0.25% DMSO; ATV1 = 10 µM; 
ATV2 = 25 µM; GRT1 = 0.01 mg/mL; GRT2 = and 0.1 mg/mL; ATV1 + GRT1 = 10 µM ATV + 0.01 mg/mL GRT; 
ATV1 + GRT2 = 10 µM ATV + 0.1 mg/mL GRT; ATV2 + GRT2 = 25 µM ATV + 0.1 mg/mL GRT. Data are mean ± 
SD derived from three independent experiments each with two technical repeats (n = 3). A one-way Analysis of 
Variance was used with a Tukey post hoc test. All results were expressed as a percentage of the cell population 
falling in the lower left quadrant. *** = p<0.001. 
 
Figure 5.6.2 shows that, in the normal condition, there was a significant difference (p<0.001) 
in viable cells between GRT1 (86.83% ± 11.81) and ATV1 + GRT1 (56.67% ± 17.68). The 
combination of ATV2 + GRT2 (34.67% ± 9.4) compared to GRT2 (78.17% ± 9.09) showed a 
significant (p<0.001) decrease in the percentage of viable cells. There was a significant 
(p<0.001) decrease in the percentage of viable cells when ATV1 and ATV2 were compared 
(57.67% ± 10.41 and 18.00% ± 5.62 respectively). The combination ATV2 + GRT2 showed 
almost twice the percentage of viable cells compared to ATV2 alone (34.67% ± 9.4 vs 18.00% 
± 5.62) although this was not significant. 
 
5.6.3 Early apoptosis 
Apoptotic cells were annexin V positive, PI negative cells. All results were calculated as a 
percentage of the cell population in the upper and lower right quadrants, averaged over three 
experiments. 
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Figure 5.6.3: Quantification of the percentage of early apoptotic cells in the normal condition. C3A cells 
were treated with GRT, atorvastatin and combinations (24 hours). Vehicle control = media with 0.25% DMSO; 
ATV1 = 10 µM; ATV2 = 25 µM; GRT1 = 0.01 mg/mL; GRT2 = and 0.1 mg/mL; ATV1 + GRT1 = 10 µM ATV + 0.01 
mg/mL GRT; ATV1 + GRT2 = 10 µM ATV + 0.1 mg/mL GRT; ATV2 + GRT2 = 25 µM ATV + 0.1 mg/mL GRT. Data 
are mean ± SD derived from three independent experiments each with two technical repeats (n = 3). A one-way 
Analysis of Variance was used with a Tukey post hoc test All results were expressed as a percentage of the cell 
population falling in the upper and lower right quadrants. ** = p<0.01; *** = p<0.001. 
 
There was a significant difference (p<0.001) in the percentage of early apoptotic cells when 
GRT2 (9.17% ± 3.25) and ATV2 + GRT2 (0.33% ± 0.52) were compared.  The ATV1 group 
(5.67% ± 2.50) showed significantly greater (p<0.01) prevalence of early apoptosis as 
compared to ATV2 (0.33% ± 0.52). The ATV1 + GRT1 combination group (4.17% ± 0.41) 
showed a slightly decreased percentage of early apoptotic cells compared to ATV1 alone, 
while ATV1 + GRT2 (3.67% ± 0.52) showed a more than 1-fold decrease compared to ATV1. 
The ATV2 group showed only a marginally greater prevalence of early apoptotic cells as 
compared to ATV2 + GRT2 (0.33% ± 0.52). The combination of GRT1 and GRT2 did not 
significantly improve ATV1 or ATV2-induced apoptosis. 
 
5.6.4 Late apoptosis 
 
Late apoptotic cells were defined as annexin V dim, PI positive cells, where the proportion of 
PI positive fluorescence greatly overshadowed the annexin V fluorescence. All results were 
calculated as a percentage of the cell population in the upper left quadrant, averaged over 
three experiments. 
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Figure 5.6.4: Quantification of the percentage of late apoptotic cells in the normal condition. C3A cells were 
treated with GRT, atorvastatin and combinations (24 hours). Vehicle control = media with 0.25% DMSO; ATV1 = 
10 µM; ATV2 = 25 µM; GRT1 = 0.01 mg/mL; GRT2 = and 0.1 mg/mL; ATV1 + GRT1 = 10 µM ATV + 0.01 mg/mL 
GRT; ATV1 + GRT2 = 10 µM ATV + 0.1 mg/mL GRT; ATV2 + GRT2 = 25 µM ATV + 0.1 mg/mL GRT. Data are 
mean ± SD derived from three independent experiments each with two technical repeats (n = 3). A one-way 
Analysis of Variance was used with a Tukey post hoc test. All results were expressed as a percentage of the cell 
population falling in the upper left quadrant. *** = p<0.001. 
 
Compared to ATV1 + GRT1 (35.17% ± 19.28), GRT1 (8.00% ± 9.90) showed a significant 
(p<0.01) decrease in the prevalence of late apoptotic cells. The GRT2 group (12.50% ± 6.06) 
showed an insignificant decrease in the percentage of late apoptotic cells compared to ATV1 
+ GRT2 (26.33% ± 13.40), and a significant (p<0.001) decrease compared to ATV2 + GRT2 
(64.83% ± 8.98). The ATV1 group (36.50% ± 10.93) showed significantly (p<0.001) less late 
apoptotic cells compared to ATV2 (81.67% ± 5.57), which showed the greatest percentage of 
late apoptotic of all the treatment groups in the normal condition. 
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5.6.5 Annexin V/PI apoptosis assessment in the hyperlipidaemic condition 
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Figure 5.6.5: Representative scatter plots of annexin V/PI flow cytometry assessment in the 
hyperlipidaemic condition. Scatter plots subjected to the appropriate gating and colour compensation were used 
for analysis and comparison. 
 
5.6.6 Viable 
 
Annexin V negative, propidium iodide negative cells were considered viable cells. All results 
were calculated as a percentage of the cell population in the lower left quadrant, averaged 
over three experiments. 
 
Figure 5.6.6: Quantification of the percentage of viable cells in the hyperlipidaemic condition. C3A cells 
were treated with GRT, ATV and combinations (24 hours) after a 24 hour 500 µM palmitate pre-treatment. Palmitate 
control = palmitate pre-treated cells with media with 0.25% DMSO; ATV1 = 10 µM; ATV2 = 25 µM; GRT1 = 0.01 
mg/mL; GRT2 = 0.1 mg/mL; ATV1 + GRT1 = 10 µM ATV + 0.01 mg/mL GRT; ATV1 + GRT2 = 10 µM ATV + 0.1 
mg/mL GRT; ATV2 + GRT2 = 25 µM ATV + 0.1 mg/mL GRT. Data are mean ± SD derived from three independent 
experiments each with two technical repeats (n = 3). A one-way Analysis of Variance was used with a Tukey post 
hoc test. All results were expressed as a percentage of the cell population falling in the upper left quadrant. 
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In terms of the percentage of viable cells, there was no statistical differences between any of 
the different treatment groups. Although insignificant, GRT1 showed the lowest percentage of 
viable cells (65.00% ± 10.04) while ATV1 + GRT2 showed the greatest percentage of viable 
cells (82.50% ± 5.09). 
 
5.6.7 Early apoptosis 
 
Early apoptotic cells were annexin V positive, PI negative cells. All results were calculated as 
a percentage of the cell population in the upper and lower right quadrants, averaged over three 
experiments. 
 
Figure 5.6.7: Quantification of the percentage of early apoptotic cells in the hyperlipidaemic condition. C3A 
cells were treated with GRT, ATV and combinations (24 hours) after a 24 hour 500 µM palmitate pre-treatment. 
Palmitate control = palmitate pre-treated cells with media with 0.25% DMSO; ATV1 = 10 µM; ATV2 = 25 µM; GRT1 
= 0.01 mg/mL; GRT2 = 0.1 mg/mL; ATV1 + GRT1 = 10 µM ATV + 0.01 mg/mL GRT; ATV1 + GRT2 = 10 µM ATV 
+ 0.1 mg/mL GRT; ATV2 + GRT2 = 25 µM ATV + 0.1 mg/mL GRT. Data are mean ± SD derived from three 
independent experiments each with two technical repeats (n = 3). A one-way Analysis of Variance was used with 
a Tukey post hoc test. All results were expressed as a percentage of the cell population falling in the upper and 
lower right quadrants. ** = p<0.01. 
 
In terms of early apoptosis in the hyperlipidaemic condition, only GRT2 (11.67% ± 2.58) and 
ATV2 + GRT2 (3.17% ±0.98) showed significantly different results (p<0.01). The Palmitate 
Control treatment group showed the greatest percentage of early apoptotic cells (13.00% ± 
5.73) while ATV2 showed the least early apoptotic cells (1.75% ± 0.50), although this was 
insignificant. 
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5.6.8 Late apoptosis 
 
Late apoptotic cells were annexin V positive, PI positive cells, where the proportion of PI 
positive fluorescence greatly overshadowed the annexin V fluorescence. 
 
Figure 5.6.8: Quantification of the percentage of late apoptotic cells in the hyperlipidaemic condition. C3A 
cells were treated with GRT, ATV and combinations (24 hours) after a 24 hour 500 µM palmitate pre-treatment. 
Palmitate control = palmitate pre-treated cells with media with 0.25% DMSO; ATV1 = 10 µM; ATV2 = 25 µM; GRT1 
= 0.01 mg/mL; GRT2 = 0.1 mg/mL; ATV1 + GRT1 = 10 µM ATV + 0.01 mg/mL GRT; ATV1 + GRT2 = 10 µM ATV 
+ 0.1 mg/mL GRT; ATV2 + GRT2 = 25 µM ATV + 0.1 mg/mL GRT. Data are mean ± SD derived from three 
independent experiments each with two technical repeats (n = 3). A one-way Analysis of Variance was used with 
a Tukey post hoc test. All results were expressed as a percentage of the cell population falling in the upper left 
quadrant. 
 
The ATV1 + GRT2 group showed the least number of late apoptotic cells (11.67% ± 4.13) 
while the ATV2 group showed the greatest percentage of late apoptotic cells (30.75% ± 13.45). 
None of the differences between any of the groups was significant.  
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5.7 Caspase activation assessment 
 
The cleavage of fluorogenic peptides allowed for the fluorescent measurement of the 
executioner caspases 3 and 7, confirming the extent of apoptosis-induced hepatotoxic 
damage. 
 
5.7.1 Caspase 3/7 assessment in the normal condition 
 
Figure 5.7.1: Caspase 3/7 activity as a marker of apoptosis in the normal condition. Cells were exposed to 
various treatments and combinations (24 hours). Vehicle control = media with 0.25% DMSO for 24 hours; GRT1 = 
0.01 mg/mL; GRT2 = and 0.1 mg/mL; ATV1 = 10 µM; ATV2 = 25 µM; ATV1 + GRT1 = 10 µM ATV + 0.01 mg/mL 
GRT; ATV1 + GRT2 = 10 µM ATV + 0.1 mg/mL GRT; ATV2 + GRT2 = 25 µM ATV + 0.1 mg/mL GRT. Data are 
mean ± SD derived from three independent experiments each with three technical repeats (n = 3). A one-way 
Analysis of Variance was used with a Tukey post hoc test. All results were expressed as a percentage relative 
fluorescence normalised to the vehicle control at 100%. *** = p<0.001. 
 
Figure 5.7.1 shows that, in the normal condition, there was a negligible difference in caspase 
3/7 activity of GRT1 (100.90% ± 4.44) and GRT2 (101.80% ±5.32). The ATV1 (158.50% ± 
41.78) group alone showed significantly less caspase 3/7 activity compared to ATV2 (441.00% 
± 169.20; p<0.001). The difference between ATV1 and ATV1 + GRT1 (168.70% ± 45.81) was 
slight, but insignificant, as was the difference between ATV1 and ATV1 + GRT2 (153.50% ± 
39.40). There was a significant (p<0.001) difference between ATV2 and ATV2 + GRT2 
(283.20% ± 135.00). 
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5.7.2 Caspase 3/7 assessment in the hyperlipidaemic condition 
 
Figure 5.7.2: Caspase 3/7 activity as an indication of late apoptosis in the hyperlipidaemic condition. Cells 
were exposed to various treatments and combinations (24 hours) subsequent to a 500µM palmitate pre-treatment 
for 24 hour. Palmitate control = palmitate pre-treated cells exposed to media with 0.25% DMSO for 24 hours; GRT1 
= 0.01 mg/mL; GRT2 = and 0.1 mg/mL; ATV1 = 10 µM; ATV2 = 25 µM; ATV1 + GRT1 = 10 µM ATV + 0.01 mg/mL 
GRT; ATV1 + GRT2 = 10 µM ATV + 0.1 mg/mL GRT; ATV2 + GRT2 = 25 µM ATV + 0.1 mg/mL GRT. Data are 
mean ± SD derived from three independent experiments each with three technical repeats (n = 3). A one-way 
Analysis of Variance was used with a Tukey post hoc test. All results were expressed as a percentage relative 
fluorescence normalised to the palmitate control at 100%. ** = p<0.01; *** = p<0.001. 
 
Figure 5.7.2 shows that the GRT1 group showed significantly less caspase 3/7 activity 
compared to the GRT2 group (144.20% ± 40.45 and 174.20% ± 43.65 respectively; p<0.001) 
in the hyperlipidaemic condition. The ATV1 and ATV2 groups showed similar values (92.24% 
± 16.85 and 91.85% ± 13.82 respectively). The ATV1 + GRT2 combination group showed 
greater activity (126.20% ± 29.90), while the ATV1 + GRT1 combination group showed 
significantly greater caspase 3/7 activity (p<0.001) when compared to ATV1. The ATV2 + 
GRT2 combination group (114.70% ± 21.82) showed significantly greater activity than the 
ATV2 group (p<0.01).   
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5.8 In vitro culturing of C3A spheroids 
 
Three-dimensional culturing allows for long-term culturing and, as such, the assessment of 
the implications of exposure to chronic treatment. Further, it has been shown that cultured 
spheroids regain a degree of hepatic functionality (Wrzesinki et al, 2013). This allows for a 
more in-depth analysis of the effects of chronic treatment in a model that is truer to in vivo 
models than traditional culturing methods. 
 
5.9 Transmission electron micrographs 
 
Transmission electron microscopy is a technique that contributes to the field of molecular 
microscopy as it allows for the visualisation and identification of cellular components on a 
subcellular level. Further, this contributes to the understanding of the specialisation of cells 
and tissue in order to sense the extracellular environment and adjust functionality accordingly 
(Hayat, 1986). Untreated control spheroids were sampled for transmission electron 
microscopy in order to assess the cellular changes on a structural and molecular level, 
demonstrating ultrastructural features of the cells. 
 
Figure 5.9.1: Transmission electron micrograph of C3A liver spheroids. N = nucleus; Nu = nucleolus; M = 
mitochondria (black arrows); Mv = microvilli; L = lipid droplets (white arrow). Scale bar = 10 000 nm. 
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Figure 5.9.2: Transmission electron micrograph of C3A liver spheroids showing the cellular specialisation 
of the hepatocytes. N = nucleus; Nu = nucleolus; M = mitochondria (white arrows); Mv = microvilli; L = lipid 
droplets; RER = rough endoplasmic reticulum; TJ = tight junction (blue arrows); A = autophagosome (black arrow). 
Scale bar = 5 000 nm. 
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Figure 5.9.3: Transmission electron micrograph of C3A liver spheroids showing the cellular specialisation 
of the hepatocytes. N = nucleus; Nu = nucleolus; M = mitochondria; Mv = microvilli (black arrows); L = lipid 
droplets; RER = rough endoplasmic reticulum; PR = polyribosomes; D = desmosome (white arrows). Scale bar = 
2 000 nm. 
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Figure 5.9.4: Transmission electron micrograph of C3A liver spheroids showing the cellular specialisation 
of the hepatocytes. N = nucleus; Nu = nucleolus; M = mitochondria; Mv = microvilli (black arrows); RER = rough 
endoplasmic reticulum; TJ = tight junction (white arrows); PR = polyribosomes; Mem = nuclear membrane (blue 
arrow); Eu = euchromatic DNA; He = heterochromatic DNA. Scale bar = 1 000 nm. 
 
Structural hepatic-specific changes were evident in all micrographs. Extracellularly, microvilli 
were present, increasing the cellular surface area for the transfer of nutrients. Further, tight 
junctions were present, preventing the intercellular exchange of fluids, as well as the presence 
of desmosomes, contributing to the cellular strength. Intracellularly, lipid droplets were found 
in the hepatocytes due to active lipid synthesis. The presence of autophagosomes, 
polyribosomes, and rough endoplasmic reticulum showed the functionality of normal cell and 
protein turnover mechanisms. Further evidence of active protein synthesis is shown by the 
presence of euchromatic nuclei.  
 
An untreated control spheroid was sampled for electron microscopy. As such, the above 
micrographs serve as representative images of this form of 3D culture, and the structural 
differences in the cells as a result of the culturing method, as compared to 2D-cultured C3A 
cells. 
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5.10 Spheroid size 
 
Sampled spheroid diameter length was measured in micrometres (µm) longitudinally and 
latitudinally and the values were averaged. The time points selected for measurement were 
as follows: Day 0, the day the spheroids were dislodged from the AggreWell™ plate and 
introduced to the bioreactors; Day 7, a week after being introduced to the bioreactors; Day 14, 
two weeks of culturing in the bioreactors; Day 18, the literature-determined time that spheroids 
were considered mature enough to survive the introduction of treatment and, as such, became 
Day 0 of treatment; Day 36, the day of termination of the culturing, post treatment. 
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Figure 5.10.1: Average spheroid size. Sampled spheroid diameters were measured longitudinally and 
latitudinally in micrometres at Day 0, 7, 14, 18, and 36 and measurements were averaged. Data are mean ± SD 
derived from five time points each with three sampled spheroids (n = 3). A two-way Analysis of Variance was used 
with a Tukey post hoc test. ** = p< 0.01; ** = p<0.001 compared to Day 0. 
 
Figure 5.10.1 shows that the average spheroid size at Day 7 (530.80 µm ± 23.63) was 
significantly (p<0.001) greater than Day 0 (255.30 µm ± 16.69), and Day 14 (751.20 µm ± 
50.44) was significantly (p<0.01) greater than Day 7. Day 14 and Day 18 (818.80 µm ± 30.69) 
showed similar results, and Day 36 (1470.00 µm ± 162.40) was signficantly (p<0.001) greater 
than both Day 14 and Day 18. 
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Figure 5.10.2: Representative images of spheroids sampled for measurement. Spheroids were sampled at Day 0, 7, 14, and 18 of the growth period. Spheroid diameters 
were measured longitudinally and latitudinally in micrometres at 40X magnification. Scale bar = 500 µm. 
 
 
Stellenbosch University  https://scholar.sun.ac.za
Stellenbosch University  https://scholar.sun.ac.za
 83 
 
 
 
Figure 5.10.3: Representative images of treated spheroids sampled for measurement. Spheroids were sampled from each treatment group at Day 36. Spheroid diameters 
were measured longitudinally and latitudinally in micrometres at 40X magnification. Scale bar = 500 µm. 
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Figure 5.10.4: Comparison of average spheroid size between start and end of treatment. Sampled spheroid 
diameters were measured longitudinally and latitudinally in micrometres at Day 0 and Day 18 of treatment and 
measurements in µm were averaged. GRT = 0.01 mg/mL; ATV = 10 µM; ATV+GRT = 10 µM ATV + 0.01 mg/mL 
GRT. Data are mean ± SD derived from two time points each with three sampled spheroids (n = 3). A two-way 
Analysis of Variance was used with a Tukey post hoc test. * = p<0.05; ** = p<0.01; *** = p<0.001 compared to ATV 
at Day 18. 
 
Before treatment, varying numbers of spheroids were grown in individual bioreactors. For 
treatment purposes, all spheroids were removed from all bioreactors and placed in a Petri 
dish. From there, a calculated number of spheroids were individually counted and re-
introduced into a bioreactor. As such, the average size of the spheroids at Day 0 of treatment 
was the same (818.80 µm ± 30.69), however the average size of the spheroids significantly 
(p<0.001) increased between Day 0 and Day 18 in each treatment group. The average size 
of the Control and ATV+GRT groups were almost identical (1491 µm ± 175.50 and 1486 µm 
± 160.80, respectively), while the palmitate group showed a decrease in average spheroid 
size (1380 µm ± 108.70), as did the GRT group (1324 µm ± 144.10), although neither of these 
decreases were significant. The ATV group, however, showed a significant (p<0.001) increase 
in average spheroid size (1805 µm ± 264.40) compared to all the other treatment groups. 
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5.11 Glucose utilisation 
 
The measurement of glucose concentration in the growth media acts as an indication of 
cellular respiration of the spheroids. Refreshing of growth and treatment media was performed 
using a 10 mL syringe, from which 5 µL of the aspirated media was tested using a One Touch® 
Select® glucometer. The glucose concentration of a sample of the fresh media was also 
tested. Increased cellular respiration resulted in decreased glucose concentration values. The 
concentration of the fresh media was taken as 100% and the glucose concentration of the 
sampled aspirated media was calculated as a percentage relative to the fresh media. 
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Figure 5.11.1: Average glucose utilisation for all bioreactors monitored for 36 days of culturing. Glucose 
concentration was measured in mmol/L when growth media was refreshed and calculated as a percentage relative 
to the freshly added media at 100%. Data are mean ± SD. 
 
Initially, growth media was refreshed every two days and the average concentration of glucose 
in the media was measured concurrently. Figure 5.11.1 gives an indication in the continuation 
of cellular respiration of the spheroids over 36 days of culturing. From Day 18, growth or 
treatment media was refreshed daily and the average glucose concentration was therefore 
also measured daily. 
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Figure 5.11.2: Average glucose utilisation for all spheroids monitored for 18 days of treatment. Glucose 
concentration was measured in mmol/L when growth or treatment media was refreshed and calculated as a 
percentage relative to the fresh medium, in which the treatments were made up daily, at 100%. Data are mean ± 
SD. A two-way Analysis of Variance was used with a Tukey post hoc test.  
 
Day 18 of culturing was Day 0 of treatment. On Day 0, spheroids were exposed to a palmitate 
pre-treatment which was refreshed with fresh palmitate treatment every day, for four days. As 
such, glucose utilisation in old media, relative to the fresh media added, was measured daily 
as treatment medium was replenished. Figure 5.11.2 shows that spheroids were treated for 4 
days with palmitate, and then a further 14 days with various treatments, and shows the glucose 
utilisation of the spheroids over the total 18 day treatment period. The pre-treatment and 
treatment periods are two different phases. The last day of pre-treatment, Day 4, was 
considered the first day of treatment, Day 0.   
 
In terms of the effect of individual treatments on the spheroids, the control, palmitate, and GRT 
treated spheroids showed a similar trend in terms of glucose utilisation over the 14 day 
treatment period. By Day 7, ATV noticeably increased glucose utilisation, whereas ATV+GRT 
noticeably decreased glucose utilisation. By Day 14, however, there was a steep decrease in 
glucose utilisation in the ATV treated group, although this was insignificant. The ATV and 
ATV+GRT (91.83% and 94.68% respectively) groups showed decreased glucose utilisation 
0 1 2 3 4/0 3 7 14
25
50
75
100
Day
%
 G
lu
c
o
s
e
 r
e
m
a
in
in
g
Pre-treatment Treatment
Control
Palmitate
GRT
ATV
ATV + GRT
Palmitate
Stellenbosch University  https://scholar.sun.ac.za
 87 
 
 
 
 
at Day 14, with results approaching the glucose concentration of the fresh media. However, 
none of these changes in glucose utilisation were significant.   
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5.12 Spheroid viability assessment  
 
The luminescent intensity measured, indicative of the production of ATP, is directly 
proportional to the number of viable and active cells. The normalisation of this luminescence 
to the average volume of the spheroid allows for quantification of the viability of treated 
spheroids. 
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Figure 5.12.1: Comparison of average ATP production in treated spheroids at Day 0, 3, 7, and 14 of 
treatment. Average ATP production of spheroids was luminescently measured in arbitrary units (AU) and 
normalised to average spheroid volume (µm3) at each time point. GRT = 0.01 mg/mL; ATV = 10 µM; ATV+GRT = 
10 µM ATV + 0.01 mg/mL GRT. Data are mean ± SD derived from five treatments at four time points each with 
three sampled spheroids (n = 3). A two-way Analysis of Variance was used with a Tukey post hoc test.  
 
Changes in ATP production started as early as Day 3 after treatment, however none of the 
differences between the treatment groups was significant. Throughout the treatment period, 
the control and palmitate-treated spheroids showed similar ATP fluorescence which stayed 
relatively constant. By Day 14, the ATV, and ATV+GRT groups’ ATP production plummeted 
to almost non-existent (1.45 AU/µm3 ± 1.00, and 3.79 AU/µm3 ± 2.32 respectively).  
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5.13 Adenylate kinase production 
 
Adenylate kinase is an enzyme present in the inter-mitochondrial membrane space and leaks 
into the cytosol and culture media when the cellular and mitochondrial membranes are 
compromised. The presence of adenylate kinase in treatment or culture medium can be 
luminescently tagged and measured. Expressed luminescence is proportional to the number 
of compromised cells. The normalisation of the luminescent readings to the average spheroid 
volume at the relevant time points allows for the quantification of damage done to the integrity 
of the cells. 
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Figure 5.13.1: Adenylate kinase luminescence relative to average spheroid volume at different time points. 
Media collected as various time points were assessed for the presence of adenylate kinase. GRT = 0.01 mg/mL; 
ATV = 10 µM; ATV + GRT = 10 µM ATV + 0.01 mg/mL GRT. Data are mean ± SD derived from five treatments at 
ten time points each with three technical repeats (n = 3). Results are expressed as percentage luminescence per 
average spheroid volume, normalised to the control at the first time point set at 100%. A two-way Analysis of 
Variance was used with a Tukey post hoc test. *** = p<0.001. 
 
Adenylate kinase levels decreased steadily in the control group for the duration of the study. 
The addition of palmitate significantly (p<0.001) damaged the spheroids as was seen by an 
increase in adenylate kinase at Day 1 of pre-treatment with palmitate compared to the control 
(28.72% ± 3.72 vs 115.27% ± 6.60). Similarly, as shown in Figure 5.13.1, Day 2 of pre-
treatment also showed a significant increase (p<0.001) in luminescence in the palmitate group 
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(55.92% ± 19.55) compared to the control group (20.48% ± 3.64). Thereafter, the adenylate 
kinase levels were similar in both treatment groups until the end of pre-treatment. There was 
an increase in the adenylate kinase levels in all treatment groups, however this was 
insignificant (p>0.05), followed by a steady decrease in the levels in all treatment groups from 
Day 3 to Day 14. 
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6 Discussion 
 
6.1 Background 
 
Statins are one of the most frequently prescribed therapeutic drugs for the treatment of 
dyslipidaemia and hypercholesterolaemia. Through competitive inhibition of 
hydroxymethylglutaryl coenzyme-A (HMG-CoA), statins inhibit cholesterol synthesis at a rate-
limiting step of the mevalonate pathway. Statins are prescribed to patients who have 
dyslipidaemia, hypercholesterolaemia (familial, acquired, or combined), or patients who are at 
risk of cardiovascular disease, such as patients with an unfavourable LDL/HDL ratio. The need 
for such therapeutic interventions is increasing due to the rising prevalence of a sedentary 
lifestyle, Westernised diet, and its consequent metabolic perturbations (Metabolic Syndrome) 
and Type 2 Diabetes Mellitus. The reduction in plasma lipid levels of cholesterol allows for a 
decrease in potential cardiovascular disease and associated complications. For example, a 
decrease in the progression of atherosclerosis, the formation of atherosclerotic plaques, and 
the potential for myocardial infarction.  
 
Approximately 38.6 million Americans were using statins in 2016 (Adedinswo et al, 2016). A 
retrospective cohort study published in 2016 showed that, in the United Kingdom between 
1997 and 2006, moderate to severe hepatotoxicity occurred in 0.44% of patients on high dose 
(40 – 80 mg per day) atorvastatin, compared to 0.07% of patients on low dose (10 – 20 mg 
per day) atorvastatin. By comparison, 0.09% of high dose (40 – 80 mg per day) simvastatin 
patients and 0.05% of low dose (10 – 20 mg per day) simvastatin patients exhibited moderate 
to severe hepatotoxicity (Clarke et al, 2016). 
 
Statin associated side-effects cannot be ignored, specifically the potential for statin-induced 
hepatotoxicity. Typically, statin-related adverse effects include an increased incidence of 
diabetes, myopathy, and an increase in serum transaminases. Save for the possibility of new 
onset diabetes mellitus, cessation of statin treatment has shown to rectify these side-effects. 
However, in the majority of cases, continued and prolonged use of statins has been shown to 
reduce the severity of the side-effects (Zhang et al, 2013). 
 
Statin-induced hepatotoxicity is attributed mainly to an increased ROS production causing 
oxidative stress and promoting the activation of inflammatory, autophagic, and apoptotic 
pathways (Pal et al, 2015; Wang et al, 2015). Chronically elevated oxidative stress is likely to 
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cause complications in all normal cellular functioning and signalling, and possible eventual 
organ failure.  
 
A patient undergoing statin treatment is likely to have other metabolic aberrations apart from 
dyslipidaemia. The presence of this risky metabolic profile could potentiate statin-induced 
hepatotoxicity (Koh et al, 2011). The hyperlipidaemic condition, characterised by chronic high 
plasma concentrations of free fatty acids and triglycerides, is also associated with hepatic 
conditions such as steatosis and Non-Alcoholic Fatty Liver Disease (NAFLD). In this study, to 
mimic hyperlipidaemic conditions in vitro, palmitate, a naturally occurring long chain saturated 
fatty acid, was added to the culture media. The addition of palmitate has been used to study, 
for example, induced: insulin resistance in a) C3A cells by Abu Baker et al (2017); b) C2C12 
myotubes by Abu Baker and Tan (2017); hyperlipidaemia, NAFLD, ER stress, and lipotoxicity 
in a) primary hepatocytes and H4IIEC3 cells by Egnatchik et al (2014), and b) primary mouse 
hepatocytes and HepG2 cells by Feldstein et al (2004); and as a model of CYP3A4 activity in 
Fa2N-4 and HepG2 cells by Hu et al (2014). 
 
 
Figure 6.1.1: Proposed mechanism of lipotoxicity in Type 2 Diabetes. Oxidative stress and calcium 
dysregulation form a vicious cycle that disturbs critical organelle function. Lipotoxicity resulting from ER stress and 
mitochondrial dysfunction contributes to pancreatic β-cell failure, insulin resistance in target tissues and diabetic 
complications. (Adapted from Ly et al, 2017). 
 
The hyperlipidaemic condition leads to altered liver function due to the onset of a pro-
inflammatory state, increasing the activity of cell death mechanisms and promoting a state of 
excess ROS and oxidative stress (Figure 6.1.1). The relationship between CYP450 
modulation and diabetes has been found to be time-dependent with long-term diabetes 
resulting in more significant CYP450 modulation, suggesting that treating cells with high levels 
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of fatty acids for a longer time may be more demonstrative when studying the effects of 
elevated concentrations of fatty acids in an in vitro study (Hu et al, 2014; Shu et al, 2016a; 
Shu et al, 2016b). The hyperlipidaemic condition has also been shown to increase the activity 
of CYP3A4 which is an enzyme responsible for atorvastatin metabolism. An increase in 
CYP3A4 activity would alter the metabolism and pharmacokinetics of atorvastatin, potentially 
resulting in an incorrect and/or ineffective concentration of atorvastatin in the circulation, 
leaving the liver susceptible to toxicity. Patel et al (2016) showed that GRT is metabolised by 
CYP3A4, suggesting that concurrent administration of GRT and ATV would result in 
competitive inhibition of CYP3A4 and altered pharmacokinetics of ATV. Patel et al (accepted 
manuscript) demonstrated a 300% increase in ATV serum concentrations in mice following 
concurrent administration of ATV and GRT. 
 
Often, the philosophy of ‘prevention is better than cure’ is employed by patients and healthcare 
professionals alike. It is well-known that statins can result in unwanted side-effects, and it has 
been shown that patients stop using statins as a result of unwanted side-effects. A 
retrospective study (between 2000 and 2008) by Zhang et al (2013) showed that, of a cohort 
of 107 835 patients, 17.4% experienced statin-related side-effects, and 59.2% of which 
discontinued statin treatment as a result (Zhang et al, 2013). As such, patients with increased 
cholesterol levels will often supplement statin treatment with alternative “holistic” medication 
in order to prevent or lessen the side-effects associated with statin usage. Such preventative 
measures include dietary changes or the use of nutraceuticals, herbal, or indigenous 
medicines. Natural products, nutraceuticals, and herbal medicines are generally presumed to 
be safe. However, taken in conjunction with a therapeutic pharmaceutical agent may alter their 
metabolism and lead to adverse herb-drug interactions (reviewed by Awortwe et al, 2018).  
 
Rooibos is traditionally consumed as a hot or cold beverage, favoured for its high polyphenol 
content and lack of caffeine, and has gained popularity not only for its taste but for its health 
promoting properties. As such, numerous health products containing Rooibos are available, 
including extracts with increased phenolic content. With the increased prevalence of metabolic 
perturbations, specifically dyslipidaemia, the likelihood of combining statin usage and Rooibos 
supplementation is increased as it is presumed that Rooibos will safely limit side-effects while 
positively modulating the lipid profiles of patients. These assumptions are based on pre-clinical 
publications in the public domain that demonstrate hepatoprotective effects of Rooibos against 
known hepatotoxins such as CCl4- (Kucharská et al, 2004), LPS (Ajuwon et al, 2014), and t-
BHP (Canda et al, 2014).  
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Given the increase in probability of the concomitant therapy of statins and Rooibos, the effects 
of Rooibos on statin-induced hepatotoxicity warrants investigation as two cases exist that 
show chronic Rooibos consumption, with atorvastatin or maintenance treatment of rituximab 
and daily administration of prednisolone, was associated with hepatotoxicity. Statin-induced 
hepatotoxicity is rare, but it has occurred. This study aimed to assess whether the addition of 
GRT would improve or worsen induced toxicity, especially in patients with dyslipidaemia. 
 
6.2 Toxicity Study 
 
The human-derived hepatocarcinoma cell line C3A is a derivative of the HepG2 cell line and 
has been shown to express human proteins, secrete albumin, and have increased CYP450 
activity compared to HepG2 cells (Baquerizo et al, 2015). For the in vitro toxicity study, 
HepG2/C3A cells were used to establish a model of hepatotoxicity in a normal and an induced 
hyperlipidaemic state. HepG2/C3A cells are frequently used in toxicity studies (reviewed by 
Baquerizo et al, 2015) and have also successfully been used in the culturing of 3D spheroids 
(Wrzesinski et al, 2013; Wrzesinski et al, 2014; Wrzesinski & Fey, 2018; reviewed by Calitz et 
al, 2018). 
 
Atorvastatin was assessed for potential toxicity and doses above 25 µM (50 µM and 100 µM) 
showed significant toxicity as early as 6 hours after treatment, which decreased cell viability 
in a dose- and time-dependent manner. These results complement data published by Dorcat 
et al (2018) showing that ATV treatment dose-dependently decreases cell viability in terms of 
MTT activity in HepG2 cells at a concentration of 1.2 mM. Tolosa et al (2015) showed that 24 
hours treatment with of six different statins (atorvastatin, cerivastatin, fluvastatin, lovastatin, 
pravastatin, and simvastatin) showed a significant decrease in cell viability, and a significant 
increase in mitochondrial mass at doses of above 50 µM in HepG2 cells. In this study, doses 
of under 25 µM showed no toxicity at 24 hours. Subsequent IC50 values were calculated to be 
48.13 µM ± 2.08 and 41.41 µM ± 3.67 at 12 and 24 hours respectively. Two intermediate 
concentrations (10 µM and 25 µM) were thus chosen for future experiments.  
 
A 2011 letter to the editor of the British Journal of Clinical Pharmacology by Björkhem-
Bergman et al highlighted a discrepancy in the ATV concentrations tested in vivo and in vitro 
compared to human serum concentrations and Cmax values. It was shown that toxicity studies 
and studies assessing the pleiotropic effects of statins, made use of concentrations typically 
>1000-fold than those found in humans. Although there are differences between the 
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metabolism in humans, rodents, and cultured cells, it is still important to note that these 
differences exist (Björkhem-Bergman et al, 2011). The Cmax of ATV has been shown to range 
between 1.95 µg/L and 252 µg/L in dosages between 2.5 mg and 80 mg (Lea & McTavish, 
1997; Lennernӓs, 2003). Both 10 µM and 25 µM are more than twice the maximum recorded 
Cmax values. However, as this study was an assessment of acute toxicity, the concentrations 
and time points of ATV used were acceptable and aligned with those used in previous studies 
(Youssef et al, 2002; Hoffart et al, 2011; Phulukdaree et al, 2015; Tolosa et al, 2015; Kim et 
al, 2016; Shu et al, 2016a). Youssef et al (2002) found that treatment with 10 µM ATV exerted 
immunomodulatory pleiotropic effects on microglia EOC 20 cells and may be beneficial for 
multiple sclerosis or other Th1-mediated autoimmune diseases. Hoffart et al (2011) found that 
30 µM ATV and its metabolites are PXR ligands and induce various metabolising enzymes. 
Gaunidinoaceto-N-methyltranserase is a critical enzyme in the creatine synthesis pathway 
and its expression in hepatocytes is regulated by miR-124a. Phulukdaree et al (2015) found 
that 20 µM ATV treatment upregulated miR-124a levels in HepG2 cells. Tolosa et al (2015) 
assessed a range of statin concentrations (5 µM to 100 µM) and the consequent drug-induced 
mitochondrial impairment in HepG2 cells, and found that ATV resulted in mitochondrial 
membrane hyperpolarisation, decreased calcein levels, and increased superoxide production. 
Kim et al (2016) found that treatment of glomerular mesangial cell line SV40 MES 13 with      
10 µM rosuvastatin decreased plasminogen activator inhibitor-1 (PAI-1); a protein that, when 
present in high levels, has been linked to the development of atherosclerosis and thrombosis. 
Shu et al (2016a) showed that treatment of HepG2 cells with 10 µM and 30 µM ATV resulted 
in oxidative stress-induced hepatotoxicity. The same study by Shu et al (2016a) used a low 
(10 mg/kg), medium (20 mg/kg), and high dose (40 mg/kg) of atorvastatin in a single dose 
streptozotocin-induced diabetic Sprague-Dawley rat model. Within 8 days of atorvastatin 
treatment, all the high dose atorvastatin rats died and suffered from hepatomegaly and 
hepatorrhagia. The low and medium doses also caused severe liver damage, however this 
was not lethal (Shu et al, 2016a). It is important to note the lethality of the dosage of 
atorvastatin; however it is also important to note that STZ is hepatotoxic specifically to rodents 
and could also contribute to the toxicity of atorvastatin. 
 
Similar to what has been described above, in this study, GRT was assessed for potential 
toxicity at a range of doses from 0 mg/mL to 2 mg/mL on C3A cells. The cell viability results 
suggested that mild toxicity occurred only at the highest dose after 24 hours of treatment. 
Literature relevant concentrations of 0.01 mg/mL and 0.1 mg/mL GRT were chosen for further 
experiments (Muller et al, 2012; Mazibuko et al, 2013; Mazibuko et al, 2015).  
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As previously stated, the hyperlipidaemic state in animals and humans exerts its own toxic 
effects on the system. Therefore, in order to prevent a state of excessive lipotoxicity, the model 
was optimised for the induction of hepatic dysfunction as a result of hyperlipidaemia induced 
by palmitate allowing for the assessment of ATV toxicity. Optimisation of the hyperlipidaemic 
state was achieved through the evaluation of three palmitate concentrations (200 µM, 500 µM, 
and 750 µM). Zezina et al (2018) showed that treatment with 500 µM palmitate resulted in 
increased mitochondrial fragmentation in macrophages, however this was found to be a 
defence mechanism employed by the cells to reduce ROS production and lipotoxicity as 
opposed to being as a result of lipotoxicity itself. Further, it was shown that this fragmentation 
was neither toxic nor irreversible in the macrophages. In untreated cells in this study, it was 
shown that 750 µM resulted in a significant decrease (p<0.001) in cell viability (48.96% ± 22.16 
compared to 100% ± 2.26 in the untreated control). A similar pattern of viability was shown in 
cells exposed to palmitate pre-treatment and then either of two concentrations of GRT or ATV 
monotherapy: 750 µM was deemed too toxic for the model. Abu Baker and Tan (2017) showed 
that exposure to 750 µM palmitate for 24 hours elicited numerous detrimental effects in C3A 
cells, such as oxidative stress, mitochondrial dysfunction, and impaired fatty acid oxidation. 
The present study showed that the addition of 500 µM palmitate greatly increased the toxicity 
of ATV. The difference in viability in both GRT treated groups as compared to the untreated 
control showed that GRT alone was not able to modulate the toxic effect of palmitate. 
 
In the normal condition, in cells not pre-treated with palmitate, both 10 µM and 25 µM ATV 
caused a significant decrease in relative MTT activity, while GRT alone showed no difference 
at the concentrations used after 24 hours. In combination, GRT did not modulate the toxicity 
induced by ATV in terms of MTT activity. The same trend was noted in the hyperlipidaemic 
condition. Taken together, this suggests that GRT did not have a modulating effect on ATV-
induced toxicity in terms of MTT activity.  
 
6.3 Induction of Simulated Hyperlipidaemia 
 
As mentioned previously, it has been shown that the presence of metabolic perturbations such 
as T2DM causes altered drug metabolism due to increased expression and activity of 
cytochrome P450 isozymes (Hu et al, Shu et al, 2016a; Shu et al, 2016b). Of particular 
importance, in terms of statin-induced hepatotoxicity, is CYP3A4, which has been shown to 
increase statin metabolism resulting in decreased plasma concentrations and accelerated 
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clearance of the CYP3A4-metabolised drugs (Nobuo et al, 1994; Xu et al, 2014; Shu et al, 
2016a; Shu et al, 2016b). As such, the expression of CYP3A4 in C3A cells would allow for 
validation of CYP3A4 induction in the simulated hyperlipidaemic condition induced by 500 µM 
palmitate pre-treatment. Although present, CYP3A4 expression is significantly decreased in 
HepG2/C3A cells compared to primary hepatocytes (Barnett et al, 1990; Yu et al, 2005; Baek 
et al, 2006; Borbás et al, 2006; Westerink & Schoonen, 2007). However, rifampicin, a known 
potent CYP3A4 inducer (Lin & Lu, 1998; Lu & Li, 2001), was used as a positive control to 
induce CYP3A4 expression in C3A cells. Literature has shown that 14 hour treatment with a 
mixture of a high concentration of fatty acids, decreased CYP3A4 activity. However, Hu et al 
(2014) showed that a 48 hour treatment of hepatocytes with 100 and 200 µM palmitate 
induced CYP3A4 activity, demonstrating that CYP3A4 can be differentially expressed in a 
time- and concentration-dependent manner. Despite these high concentrations, fatty acids 
have been shown to induce apoptosis and the accumulation of lipids in hepatocytes, 
supported by the preliminary study by Hu et al (2014) showing that concentrations higher than 
200 µM of palmitate could significantly decrease cell viability after 48 hours. As expected, the 
results of the present study showed that the untreated control cells showed low CYP3A4 
expression, and the addition of rifampicin resulted in a >7-fold increase in CYP3A4 expression. 
The addition of palmitate alone resulted in a marked increase in CYP3A4 expression 
compared to the untreated control, and this appeared to be slightly increased, albeit not 
significantly, with the addition of rifampicin to the palmitate treatment. This shows that CYP 
activity, specifically CYP3A4 in this study, was up-regulated in palmitate-treated cells. As 
such, these results, in conjunction with the literature, suggest that the addition of 500 µM 
palmitate pre-treatment induced a simulated hyperlipidaemic condition in this model.  
 
Pharmacokinetic and toxicity studies are performed in order to understand the therapeutic 
margin of a drug in pre-clinical trials, thereby decreasing the risk of adverse effects or toxicity 
and establishing effective therapeutic margins, consequently decreasing the risk of drug 
failure. Pharmacokinetic studies assess the absorption, distribution, metabolism, and 
excretion (ADME) of a drug to understand at which point the potential for adverse reactions 
lies in the overall metabolism of a drug. Increased understanding of the biochemistry of CYPs 
has altered the way ADME research is conducted. The CYP system plays an essential role in 
drug metabolism, and CYP phenotype, CYP inhibition, and CYP induction all alter drug 
pharmacokinetics (Vrbanac & Slauter, 2017). As such, in vitro analysis of these parameters 
provides early predictive information relative to drug metabolism, however in vivo assessment 
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of ADME processes, remains the gold standard for drug pharmacokinetic and 
pharmacodynamic assessment.  
 
6.4 Oxidative Stress 
 
The overproduction of ROS in the presence of insufficient antioxidant defences results in a 
state of oxidative stress, creating an environment where cells are particularly susceptible to 
injury. The fluorescence of DCF occurs due to the oxidation of the DCFDA substrate by free 
radicals and is a measure of the extent of ROS production in the cell. 
 
Results of the toxicity study were supported by the oxidative stress experiments performed. 
In the normal condition, GRT alone at any concentration did not induce ROS production. The 
higher concentration of ATV (25 µM) induced significant amounts of ROS production, and co-
treatment with 0.1 mg/mL GRT further exacerbated this effect. In the hyperlipidaemic 
condition, a similar trend was seen: GRT alone did not induce ROS production, however 
significant ROS production was found with 25 µM ATV treatment, both alone (1431.00% ± 
504.20) and in combination with GRT (1493% ± 278.40). Shu et al (2016) showed that ATV-
induced hepatotoxicity in the hyperlipidaemic condition is as a result of increased ROS 
production. 
 
The antioxidant potential of Rooibos has been well documented and has been shown to 
increase the activity of endogenous antioxidant systems, as well as having ROS scavenging 
capabilities (Marnewick et al, 2003; Uliĉná et al, 2003, Kucharská et al, 2004; Ajuwon et al, 
2013; Ajuwon et al, 2014). In this study, GRT was unable to ameliorate the ATV-induced ROS 
production in either condition, suggesting that GRT was unable to protect the cells against 
ATV-induced ROS production. ATV acts by inhibiting mevalonate which, apart from being a 
precursor of cholesterol, is also a precursor of the mitochondrial ubiquinone (CoQ10), an 
important redox component of the mitochondrial electron transport chain, responsible for 
synthesising ATP. Reducing the biosynthesis of CoQ10 in the liver affects mitochondrial 
oxygen consumption and liver cell function, and increases cellular ROS production. Although 
GRT is known to affect cholesterol synthesis, it is likely that its mechanism of action does not 
involve the mevalonate pathway and, as such, does not protect against ATV-induced ROS 
production.  
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In terms of hepatotoxicity, it can be speculated that the contrast of the results of this study to 
those in other studies may be as a result of fundamental experimental differences. Carbon 
tetrachloride (CCl4-) (Kucharská et al, 2004), LPS (Ajuwon et al, 2014), and t-BHP (Canda et 
al, 2014) have been used to chemically induce hepatic injury, inflammation, and acute 
oxidative stress in vivo. Treatment with Rooibos has shown to modulate the induced hepatic 
injury in these models. Previously, Rooibos has been shown to protect against CCl4- induced 
toxicity. However, the mechanism of toxicity induced by CCl4- is different to that of ATV as it 
involves the production of trichloromethylperoxy radicals inducing lipid peroxidation, oxidising 
polyunsaturated fatty acids and phospholipids, and consequently affecting the permeability of 
the mitochondria, ER, and the cellular membrane. The endotoxins LPS are inducers of 
inflammation and cytokine-mediated cell damage, whereas t-BHP causes hydroperoxide-
induced oxidative stress as it generates free radicals such as t-butoxyl and t-methyl radicals 
which cause DNA damage, depletion of glutathione, and cell membrane permeabilisation, via 
various mechanisms. It can be speculated that the mechanism of action of ATV-induced 
toxicity is due to the chronic inhibition of the mevalonate pathway, consequently hindering the 
fluidity and permeability of the mitochondrial membrane. 
 
6.5 Mitochondrial Membrane Integrity 
 
The dual emission JC-1 dye allows for the assessment of the formation of fluorescent red “J-
aggregates” that accumulate in the mitochondria as a result of high mitochondrial membrane 
potential, and fluorescent green J monomers which form due to decreased mitochondrial 
membrane potential. The overall mitochondrial membrane integrity of the cells is measured in 
terms of the mean red fluorescence intensity, where an increased mean value is indicative of 
a stronger red fluorescence as a result of greater J-aggregate formation. The relative 
percentage of JC-1 inactive cells is indicative of the proportion of the population with increased 
green fluorescence as a result of the presence of J monomers and decreased membrane 
integrity.  
 
In the normal condition, ATV dose-dependently decreased mean red fluorescence intensity, 
whereas GRT treatment alone showed no difference to mean red fluorescence intensity. 
Although insignificant, the co-treatment groups showed a similar range of results compared to 
the ATV monotherapy groups, suggesting that GRT could not attenuate the toxicity of the ATV 
in terms of mitochondrial membrane potential changes. In the hyperlipidaemic condition, in 
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comparison to ATV1, ATV2 significantly reduced mean fluorescence intensity. This effect was 
not ameliorated by GRT treatment.  
 
Taken together, these results show that ATV has a negative effect on mitochondria. As 
mentioned previously, the ATV-induced oxidative stress was associated with mitochondrial 
alterations which, in terms of oxidative stress, was not ameliorated by GRT. In terms of 
membrane potential, these results support the previous findings whereby ATV reduced 
mitochondrial dehydrogenase activity, increased oxidative stress, in a dose-related fashion. 
These effects were not attenuated by the addition of GRT. To date, similar studies have not 
been performed. 
 
Previously, Johnson et al (2016) showed that aspalathin, the major dihydrochalcone C‐
glucoside in Rooibos, was able to protect mitochondrial membrane integrity of H9c2 cells 
under hyperglycaemic conditions by shifting the substrate preference from fatty acid oxidation 
to glucose oxidation. It can be speculated that, in the present study, GRT is unable to 
overcome the damage caused by hyperlipidaemic condition, whereas a model of 
hyperglycaemia is more easily rectified by GRT. 
 
6.6 Apoptosis Assessment 
 
Annexin V and PI are used concurrently in order to assess plasma and nuclear membrane 
integrity. Annexin V and PI negative cells have intact plasma membranes and, as such, are 
deemed viable. Annexin positive, PI negative cells indicate a decrease in the integrity of the 
plasma membrane and are considered to be in early apoptosis. The membrane phospholipid 
phosphatidylserine (PS) is translocated out of the plasma membrane and exposed to the 
extracellular environment upon the loss of plasma membrane symmetry. In this early stage of 
cell death, the membrane is compromised and PS flipped, allowing for the conjugation of 
annexin V fluorochromes to the exposed PS. Propidium iodide is a DNA-intercalating dye. 
Propidium iodide positive cells are in a state of late apoptosis as the plasma membrane 
integrity is lost and the cells’ ability to exclude PI dye is compromised. Results will be 
discussed in terms of viable, early apoptosis, and late apoptosis in the normal state and in the 
hyperlipidaemic state. 
 
The value of flow cytometry is to assess the current rate of apoptosis from within the remaining 
“normal” population of C3A cells: cells are selected (gated) based on their 
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physical/morphological characteristics. The selection of cells based on their forward/side 
scatter characteristics means that cells in advanced stages of apoptosis, apoptotic bodies, 
karyorrhectic and necrotic cells are excluded from the analysis due to their reduced size and 
increased side scatter densities. Further, the gating was selected according to the dispersion 
of viable cells in an untreated, normal population, thereby excluding cells that had already 
been affected by the toxic effects of palmitate. Cells assessed in the hyperlipidaemic condition, 
therefore, allowed for the assessment of the viability status of the remaining cells falling into 
the parameters of “normal” cells. An MTT assay assesses cell viability in totality, considering 
the mitochondrial dehydrogenase activity of the entire cellular population as opposed to a 
select population. Cell viability, metabolism, and proliferation, as assessed by MTT assay, is 
a rudimentary indication of functional mitochondria within the cell. As such, the two methods 
should be regarded as complementary: MTT provides an overall impression of the toxicity and 
cell viability, whereas flow cytometry provides an indication of cell loss to apoptosis at a 
specific time i.e. 24 hours. Based on this, looking at the MTT, there were dramatic losses of 
cell viability, particularly in high dose ATV, while, after 24 hours, the effects of ATV and GRT 
on apoptosis was significantly different to the controls, suggesting that the cells exposed to 
palmitate were more susceptible and cells were lost to apoptosis before this time point. 
 
In the normal condition, in terms of annexin V/PI assessment, the results of the viable cells 
(annexin neg., PI neg.) supported the MTT activity of different treatment groups. In terms of 
apoptotic cells, cells in early apoptosis (annexin V pos., PI neg.) showed no significant 
differences between the treatment groups and the control. The evaluation of late apoptosis 
confirmed results of the DCF assay where treatment with ATV, particularly 25 µM ATV, 
resulted in significant amounts of late apoptosis. After 24 hours with treatment, the increased 
number of cells in late apoptosis relative to those in early apoptosis indicates that the toxic 
effects of ATV (especially at a high dose 25uM) had a rapid onset. This is evident by the 
number of viable cells, which are almost depleted (18.00% ± 5.62 for ATV2 vs 57.67% ± 10.41 
for ATV1), cells entering apoptosis (0.33% ± 0.52 for ATV2 vs 5.67% ± 2.50 for ATV1), and 
those in late apoptosis (81.67% ± 5.57 for ATV2 vs 36.50% ± 10.93 for ATV1) after 24 hours.  
GRT was unable to modulate the apoptotic effects of 10 µM or 25 µM ATV on hepatocytes. 
Taken together, these results are consistent with previous results, supporting the idea that 
ATV-induced hepatotoxicity is dose-dependent in the normal condition. 
 
The hyperlipidaemic condition showed contrasting results to the normal condition, in terms of 
cell viability where the majority of the assessed gated population under all treatment conditions 
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were viable, further highlighting the experimental design in terms of assessing a population 
that is considered “normal” or healthy according to morphological characteristics alone. The 
results of the apoptotic cells, however, showed complementary results to that found in the 
normal condition, where cells treated with ATV2 showed the fewest early apoptotic cells, 
although differences were insignificant. There was no significant difference between any of 
the treatment groups in terms of late apoptotic cells, however the ATV2 group showed the 
greatest percentage thereof (30.75% ± 13.45). To date, similar studies have not been 
performed. 
 
The discrepancy between these results and those of the MTT assay illustrates limitations of 
different experimental designs, although the results should be considered complementary.  
 
6.7 Caspase Assessment 
 
Apoptosis can be initiated through either the extrinsic or intrinsic pathways. Caspase-3, -7, 
and -9 are executioner caspases and activated by both the intrinsic and extrinsic apoptotic 
pathways in the final part of each pathway, committing the cell to apoptosis. As such, the 
activity of these caspases is an indication of the state of apoptosis of the cells and, therefore, 
an overall measurement of cell viability.  
 
Caspase 3/7 activity was significantly increased by ATV, particularly 25 µM. These results are 
in agreement with the 2015 study by Pal et al that showing a significant increase in caspase 
activation in healthy rats from ATV concentrations of 10 mg/kg/day. Similarly, Docrat et al 
(2018) noted a significant increase in ATV-induced caspase activation in HepG2 cells, of 
which C3A cells are a sub-clone, treated with 1.2 mM ATV. Further, Docrat et al (2018) made 
use of a similar assay to assess caspase activity. The combination of ATV2 + GRT2 showed 
significantly less caspase 3/7 activity compared to the ATV2 group alone, suggesting that GRT 
had a modulating effect on caspase activity in the normal condition. GRT alone did not activate 
caspase activity.  
 
In the hyperlipidaemic condition, although there are significant differences and GRT dose-
dependently increases caspase activity, the increase is relatively small (<1-fold), which is 
below a biologically significant change, generally regarded as >1.5-fold. Further, it is important 
to consider the activity relative to the time point assessed. Another variable compared to the 
cells in the normal condition is that the cells had already been pre-treated with palmitate which 
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could account for the differences observed in terms of ATV toxicity in the cells in the normal 
condition relative to the cells in the hyperlipidaemic condition. Further, GRT at the relatively 
high dose of 0.1 mg/mL could have pro-oxidant effects under the hyperlipidaemic condition. 
The antiapoptotic/antioxidant effects of Rooibos and aspalathin has been previously shown to 
be optimal at doses of 0.001 mg/mL and 0.01 mg/mL.  
 
As with an MTT assay, the fluorescent measurement of caspase activity allows an average at 
a specific time-point as opposed to a cell-specific result. The experimental time point may miss 
the point at which the caspase cascade is initiated. Further, the preference of necrosis as a 
mechanism of cell death results in caspase activation being avoided altogether.  
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6.8  3D Spheroid Culturing of C3A Cells 
 
Three-dimensional culturing has become increasingly popular for assessing pharmacokinetics 
in vitro as a means of an intermediate technology between cell culture and animal studies. 
This form of culturing C3A cells allows for the regaining of functionality after trypsinisation, 
specific to hepatocytes, in an in vitro model, and allows the culture to grow “undisturbed” and 
unharmed by trypsinisation, with a constant “flow” of nutrients. These culturing conditions 
mean that hepatocellular specialisation, within the spheroids, occurs. Further, multiple 
spheroids are produced in each experimental repeat (approximately 600 in this study). As a 
result, even one experimental repeat yields multiple technical repeats per subsequent assay 
or analysis. 
 
Transmission electron micrographs of an untreated control spheroid showed the specialisation 
of the cells within the spheroid. Microvilli increase the cellular surface area, increasing the 
efficiency of nutrient transfer, while tight junctions and desmosomes increase cellular strength 
and integrity. The presence of rough endoplasmic reticulum, autophagosomes, and 
polyribosomes showed normal cellular protein synthesis and turnover, further supported by 
the presence of heterochromatic and euchromatic DNA. As further confirmation of the 
specialisation of the hepatocytes, lipid droplets were present intracellularly due to restored 
hepatocellular cholesterol synthesis.  
 
The C3A spheroids produced followed the growth and doubling time as previously observed 
by Wrzesinski, et al (2013) and Wrzesinski & Fey (2013). Growth and cellular function of the 
spheroids was measured in terms of average spheroid size as well as in terms of glucose 
utilisation. In this study, spheroids grew at a constant rate from approximately 250 µm at Day 
0 to approximately 800 µm at Day 18, the first day of treatment. By Day 36, spheroids were 
approximately 1500 µm. Similar results were found in the study by Wrzesinski, et al (2013). In 
terms of projected growth, the growth curve of the spheroids would tend towards a plateau 
from Day 35 onward. Due to time constraints, it was not possible to assess this further in the 
current study. In this study, the addition of the various treatments resulted in alterations in the 
macroscopic appearance of the treated spheroids, suggesting changes in the structural 
integrity of the spheroids. Palmitate treatment adversely effected the spheroids in terms of 
their spherical shape and surface morphology, with potential loss of cells or cell clusters from 
the spheroids, which was confirmed with increased cell debris within the surrounding media. 
This is in keeping with the MTT which showed that there is significant cell loss with the addition 
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of palmitate and ATV, and, by implication, a loss of cluster integrity in 3D culture. The ATV 
treated spheroids showed the most severe alterations as was evident in the compromised 
structural integrity of the spheroids. This resulted in a significant overall increase in the 
average diameter measured in the ATV treated spheroids as compared to all other treatments 
after 18 days of treatment. Although there were slight differences in the average diameter 
measured for the other treatment groups, there was no significant difference in the average 
diameters. 
 
Glucose is used for the maintenance of normal cellular functions. As such, changes in the 
utilisation of glucose rudimentarily indicates alterations in normal cellular function. Glucose 
concentration was measured at each medium change and calculated relative to the glucose 
concentration of the fresh treatment, set at 100%. The changes in the remaining glucose were 
a simple indication of metabolism and the viability. The glucose utilisation fluctuated, but the 
remaining concentration was always less than the fresh medium. The addition of the 
treatments decreased the average glucose utilisation, suggesting a decrease in spheroid 
integrity and viability as a result of the treatment. This was further confirmed by the 
assessment of glucose utilisation measurement of each treatment bioreactor. By Day 7, the 
ATV+GRT treated spheroids showed decreased glucose utilisation (86.16%), which 
decreased further by Day 14 (94.68%). Day 14 also showed a decreased utilisation by the 
ATV-treated spheroids (91.84%).  
 
6.9 ATP 
 
As with glucose utilisation, ATP is indicative of normal cellular functioning, with a decrease in 
ATP production suggesting compromised cellular functioning and consequently decreased 
viability of the spheroids. The results of ATP production as shown by Wrzesinski, et al (2013), 
showed fluctuations in the initial growth phase of the spheroids, followed by a trend towards 
a plateau after 25 days of growth. In the present study, the ATP production was normalised to 
the spheroid size. A similar trend in ATP production was noted in the present study for the 
Control and Palmitate-treated spheroids. At Day 0 of treatment, the ATP levels were 
comparable between all the different groups. The Control and Palmitate-treated spheroids 
fluctuated marginally, although insignificantly, but overall maintained a stable, almost 
plateaued, rate of ATP production. At Day 3, there was an increase in the ATP production in 
the GRT, ATV, and ATV+GRT spheroids. Day 7 showed a notable increase in ATP production 
in the GRT, ATV, and ATV+GRT spheroids, with the ATV treated spheroids showing a 
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significant difference compared to the control spheroids. Day 14 showed a severe decline in 
the ATP production in the GRT, ATV, and ATV+GRT spheroids, all with values approaching 
0. These results support the results of the average glucose utilisation as well as the 
ultrastructural changes in the spheroids, confirming that there is a decline in the viability and 
integrity of the spheroids as a result of the treatments administered, supporting, preliminarily, 
the two-dimensional in vitro results. 
 
6.10 Adenylate Kinase 
 
The degradation of the mitochondrial membrane causes the leakage of the mitochondrial 
intermembrane enzyme, adenylate kinase, into the cytosol. A study by Wrzesinski & Fey 
(2013) showed that the extension of culturing time decreased the adenylate production of the 
spheroids, however insignificant erratic fluctuations were noted occasionally. In the present 
study, adenylate kinase production decreased exponentially over the initial 18-day growth 
period. The Control spheroids continued to decrease towards a plateau, in keeping with the 
study by Wrzesinski & Fey (2013). The addition of palmitate pre-treatment significantly 
increased adenylate kinase production for the first two days, before decreasing to levels 
comparable with the Control spheroids. The addition of the various treatments increased the 
adenylate kinase production at Day 3, before decreasing at Day 7 and Day 14. This 
insignificant erratic fluctuation is in keeping with those found by Wrzesinski & Fey (2013). 
Control, GRT, and Palmitate spheroids had the lowest adenylate kinase production by the end 
of the treatment period, although this was statistically insignificant.  
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7 Conclusion  
 
This study hypothesised that an aspalathin-enriched Rooibos extract (GRT) ameliorates 
statin-induced hepatotoxicity and aimed to investigate the potential hepatoprotective effects 
of Rooibos against statin-induced hepatotoxicity in vitro. 
 
ATV was dose- and time-dependently hepatotoxic and this hepatotoxic effect was 
exacerbated by the addition of palmitate pre-treatment. ATV toxicity was associated with 
decreased mitochondrial membrane potential, and increased ROS production as well as 
caspase 3/7 activity. Increased cell death was confirmed by MTT and annexin V. GRT on its 
own was not toxic but could not mitigate the toxicity induced by palmitate or ATV. The findings 
from the current study suggest that concurrent supplementation with GRT appears to be less 
effective at protecting hepatocytes against ATV- and/or palmitate-induced toxicity as 
compared to the toxicity of other exogenous toxins.  
 
A single observational 3D culture experiment was conducted, acting as basic confirmation of 
the use of a chronic model without using animals. The results of 3D culturing should be 
reviewed in conjunction with the 2D model as it is not possible to infer possible conclusions 
drawn from the above work alone. It is not possible to make assumptions after Day 7 of ATV 
or ATV+GRT treatment as it was shown that the spheroids started dying from Day 7. This 
could be due to the ATV dosages used being too great or too toxic for chronic exposure in 
vitro. At the concentrations tested, palmitate and ATV treatment, as a monotherapy and in 
combination with GRT, decreased viability. In the parameters assessed, GRT was unable to 
attenuate the ATV-induced toxicity. 
 
This study found that GRT alone was not toxic. However, even at the highest concentration 
tested, GRT was unable to protect against the ATV-induced mitochondrial dysfunction and the 
consequent induced toxicity. These findings were observed in the normal and hyperlipidaemic 
conditions. However, GRT did not exacerbate the effects of ATV, suggesting that concomitant 
use of GRT and ATV is safe in terms of hepatotoxicity. These results are in contrast with 
studies on the hepatoprotective effects of Rooibos (Marnewick et al, 2003; Uliĉná et al, 2003, 
Kucharská et al, 2004; Ajuwon et al, 2013; Ajuwon et al, 2014), however it is speculated that 
this is because ATV induces mitochondrial dysfunction and toxicity through a different 
mechanism of action to other hepatotoxins. By extension, the mechanism by which GRT 
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exerts its antioxidant and hepatoprotective effects is not associated with the mechanism of 
ATV-induced hepatotoxicity. 
 
The present study assessed ATV (10 µM and 25 µM) as a hepatotoxin and the effects that the 
hepatoprotectant GRT (0.01 mg/mL and 0.1 mg/mL) could have on the induced toxicity, under 
normal and hyperlipidaemic conditions. It was shown that GRT was unable to modulate the 
hepatotoxic effects induced by ATV or palmitate in an acute or a chronic model. These findings 
support the null hypothesis of this study. 
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8 Limitations & Future Outlook 
 
The present study focused on the hepatotoxic effects of ATV in C3A cells exposed to standard 
media conditions and cells exposed to media treated with palmitate. The palmitate treatment 
served as an in vitro model mimicking a hyperlipidaemic condition. To achieve this aim, it was 
essential to select ATV dose concentrations that were “safe”. The lower ATV dose (10 µM) 
did not induce significant toxicity whilst the higher dose (25 µM) induced significant cytotoxicity 
after 24 hours. Based on MTT mitochondrial dehydrogenase activity and CYP3A4 activity, 
pre-treatment with 500 µM palmitate for 24 hours followed by 24 hours’ treatment with 10 µM 
and 25 µM ATV was selected. However, the addition of a low dose of ATV in conjunction with 
the palmitate pre-treatment decreased viability significantly. A more toxic effect was seen with 
the addition of high dose ATV. Whilst GRT slightly increased cell survival, this was not 
significant. As such, the study could have benefitted from reducing the palmitate 
concentration, shifting the primary hepatotoxic effect to ATV toxicity rather than palmitate 
toxicity.  
 
Based on initial MTT results, the addition of GRT treatment (0.01 mg/mL and 0.1 mg/mL) had 
no effect on ATV-induced toxicity at 10 µM or 25 µM ATV. Therefore, for technical reasons, 
such as fitting treatments and controls onto a single 96-well multiplate to ensure standard 
culture conditions per experiment, only the highest concentration GRT was used as a 
combination treatment with ATV2.  
 
Moving forward with the study, it would be beneficial to assess cholesterol synthesis ([14C] 
acetate incorporation), mitochondrial activity and biosynthesis (CoQ10 synthesis and activity), 
several markers of apoptosis (e.g. PARP and caspase-1), and to assess parameters of 
endogenous antioxidant defence systems (SOD and GSH/GSSG activity). Evaluation of the 
mevalonate pathway could also elucidate potential mechanism(s) by which ATV induces 
toxicity, as well as the potential influence GRT may have on cholesterol synthesis at a 
mechanistic level. This elucidation could be relevant not only in liver cells, but also in skeletal 
muscle cells, and could illustrate the potential influence GRT may have on mitochondrial 
electron transport chain function. Understanding these parameters could provide insight into 
the serious muscular side-effects of ATV treatment. Assessing the bioenergetics of the 
mitochondria using a Seahorse platform would allow for the real time assessment of oxygen 
consumption rate (OCR) and the extracellular acidification rate (ECAR), thereby dissecting 
the precise effects both on and of the mitochondria in this context. 
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It has been shown that GRT inhibits CYP3A4 and increases the Cmax of ATV and its 
metabolites. As such, GRT interferes with ATV pharmacokinetics. This study investigated ATV 
cytotoxicity, and as such, therapeutic and/or realistic doses were not considered. Moving 
forward with the study, these aspects should be considered.  
 
Although standard cell culture methodologies allow for the dissection of functional and 
mechanistic effects of drugs, a large gap exists between what can be achieved in culture and 
what happens in the in vivo environment (i.e. the ADME of the substances). Recently, the use 
of 3D culture as a tissue-specific intermediate has gained interest in pharmacology research 
which, due to ethical pressures, are exploring non-animal-based testing of drugs and 
cosmetics. Following the findings in 2D culture, the potential for applying this model in 3D 
culture was pursued as a single observational 3D culture experiment. 
 
In terms of the model, it was possible to successfully grow multiple C3A liver spheroids over 
36 days and recreate the conditions and treatments used in 2D culture. The results of this 
preliminary study would determine whether or not the research topic would be worth pursuing 
further (i.e. as part of a larger PhD study). The seeding and structure of the technique means 
that more than 600 spheroids were grown at a time, with multiple spheroids sampled per assay 
and time point, resulting in multiple technical repeats despite there only being a single 
experimental repeat. A shortcoming in the present study, however, was the limitation in the 
number of bioreactors available for the study, thereby limiting the treatments and combinations 
that could be assessed. The maintenance of bioreactors and spheroids is a reagent-heavy 
process, increasing the experimental cost. Further, the time constraints of an MSc limited the 
repetition of this experiment as one experimental repeat takes over a month to complete.  
 
The adenylate kinase assessment showed that there was initial cell damage, however the 
spheroids were able to acclimatise to the culturing conditions and were able to adapt to 
palmitate concentration used. Thereafter, the spheroids remained viable for an extended 
period. This is important in terms of highlighting the stark differences between acute and 
chronic models and their associated toxicity as the models provide different insights. In the 
present study, the addition of ATV at the concentrations tested induced severe toxicity which 
proved to be fatal to the spheroids, both alone and in combination with GRT. 
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This study has shown that 3D culturing technology can be used as a model, and the presence 
of tissue-specification specialisations, crucial to tissue functioning and cellular viability, means 
that data generated is likely to be more reliable than that of 2D culturing. This cellular 
specialisation allowed the spheroids to better adapt to the treatment environment created. 
Three-dimensional culturing, as an intermediate between in vitro and in vivo models, allows 
for refinement prior to in vivo experimentation in a model that is safer, more ethical to animals, 
as well as more cost-effective. Further, the 3D culturing technique allows for testing of 
drugs/substances in human-derived cells that express human metabolising enzymes such as 
CYP3A4. Rodents express a different isozyme of CYP3A, creating an uncertainty in the 
validity of assessing CYP3A metabolism in rodents and extrapolating the results to humans. 
The use of 3D culture and human-specific tissue narrows the translational gap between 
rodents and human metabolism of a drug/substance/ATV. 
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10 Supplementary Data 
 
Table 10-1: Quantification of JC-1 FACS analysis in the normal condition. C3A cells were exposed to various 
treatments and combinations (24 hours). Vehicle control = media with 0.25% DMSO; GRT1 = 0.01 mg/mL; GRT2 
= and 0.1 mg/mL; ATV1 = 10 µM; ATV2 = 25 µM; ATV1 + GRT1 = 10 µM ATV + 0.01 mg/mL GRT; ATV1 + GRT2 
= 10 µM ATV + 0.1 mg/mL GRT; ATV2 + GRT2 = 25 µM ATV + 0.1 mg/mL GRT. Data are mean ± SD derived from 
three independent experiments each with two technical repeats (n = 3). All results were expressed as a percentage 
normalised to the vehicle control at 100%. A one-way Analysis of Variance was performed with a Tukey post hoc 
test. 
 
 
 
 
 
 
 
 
 
 
 
 
Table 10-2: Quantification of JC-1 FACS analysis in the hyperlipidaemic condition. C3A cells were exposed 
to various treatments and combinations (24 hours). Palmitate control = palmitate pre-treated cells with media with 
0.25% DMSO; GRT1 = 0.01 mg/mL; GRT2 = and 0.1 mg/mL; ATV1 = 10 µM; ATV2 = 25 µM; ATV1 + GRT1 = 10 
µM ATV + 0.01 mg/mL GRT; ATV1 + GRT2 = 10 µM ATV + 0.1 mg/mL GRT; ATV2 + GRT2 = 25 µM ATV + 0.1 
mg/mL GRT. Data are mean ± SD derived from three independent experiments each with two technical repeats (n 
= 3). All results were expressed as a percentage normalised to the palmitate control at 100%. A one-way Analysis 
of Variance was performed with a Tukey post hoc test. 
 
 
 
 Mean Red (FL2-A) Fluorescence Intensity 
Vehicle Control 100.00% ± 8.76 
GRT1 90.62% ± 21.45 
GRT2 64.28% ± 13.16 
ATV1 66.99% ± 22.73 a 
ATV2 32.48% ± 11.55 a 
ATV1 + GRT1 73.95% ± 19.46 
ATV1 + GRT2 56.22% ±11.62 
ATV2 + GRT2 38.44% ± 20.66 
 a = p<0.05 
 Mean Red (FL-2) Fluorescence Intensity 
Palmitate Control 100.00% ± 17.52 
GRT1 69.03% ± 22.77 
GRT2 74.38% ± 25.03 
ATV1 106.90% ± 20.81 a 
ATV2 63.02% ± 16.17 a 
ATV1 + GRT1 75.87% ± 20.28 
ATV1 + GRT2 81.00% ± 20.27 
ATV2 + GRT2 57.67% ± 11.79 
 a = p<0.01 
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10.1 JC-1 staining in the hyperlipidaemic condition 
 
Figure 10.1.1: Representative images of JC-1 stained C3A cells in the hyperlipidaemic condition. Images were captured at 40X magnification. Scale bar = 100 µm.
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Table 10-3: Quantification of annexin V/PI FACS analysis in the normal condition. C3A cells were exposed 
to various treatments and combinations (24 hours). Vehicle control = media with 0.25% DMSO; GRT1 = 0.01 
mg/mL; GRT2 = and 0.1 mg/mL; ATV1 = 10 µM; ATV2 = 25 µM; ATV1 + GRT1 = 10 µM ATV + 0.01 mg/mL GRT; 
ATV1 + GRT2 = 10 µM ATV + 0.1 mg/mL GRT; ATV2 + GRT2 = 25 µM ATV + 0.1 mg/mL GRT. Data are mean ± 
SD derived from three independent experiments each with two technical repeats (n = 3). A one-way Analysis of 
Variance was performed with a Tukey post hoc test.  
 
 
Table 10-4: Quantification of annexin V/PI FACS analysis in the hyperlipidaemic condition. Cells were 
exposed to various treatments and combinations (24 hours) subsequent to a 24 hour 500µM palmitate pre-
treatment. Palmitate control = palmitate pre-treated cells exposed to media with 0.25% DMSO for 24 hours; GRT1 
= 0.01 mg/mL; GRT2 = and 0.1 mg/mL; ATV1 = 10 µM; ATV2 = 25 µM; ATV1 + GRT1 = 10 µM ATV + 0.01 mg/mL 
GRT; ATV1 + GRT2 = 10 µM ATV + 0.1 mg/mL GRT; ATV2 + GRT2 = 25 µM ATV + 0.1 mg/mL GRT. Data are 
mean ± SD derived from three independent experiments each with two technical repeats (n = 3). A one-way 
Analysis of Variance was performed with a Tukey post hoc test.  
 Viable Early Apoptosis Late Apoptosis 
Vehicle Control 86.33% ± 4.63 5.83% ± 2.04 7.83% ± 2.79 
GRT1 86.83% ± 11.81 a 5.33% ± 2.50 8.00% ± 9.90 a 
GRT2 78.17% ± 9.09 b 9.17% ± 3.25 a 12.50% ± 6.06 b 
ATV1 57.67% ± 10.41 c 5.67% ± 2.50 b 36.50% ± 10.93 c 
ATV2 18.00% ± 5.62 c 0.33% ± 0.52 b 81.67% ± 5.57 c 
ATV1 + GRT1 56.67% ± 17.68 a 7.83% ± 3.76 35.17% ± 19.28 a 
ATV1 + GRT2 68.67% ± 13.74 5.00% ± 0.89 26.33% ± 13.40 
ATV2 + GRT2 34.67% ± 9.40 b 0.33% ± 0.52 a 64.83% ± 8.98 b 
 
a = p<0.001; b = p<0.001; 
c = p<0.001 
a = p<0.001; b = p<0.01 
a = p<0.01; b = p<0.001; c 
= p<0.001 
 Viable Early Apoptosis Late Apoptosis 
Palmitate Control 67.00% ± 5.06 13.00% ± 5.73 19.83% ± 8.66 
GRT1 65.00% ± 10.04 12.17% ± 4.92 23.00% ± 12.60 
GRT2 73.33% ± 10.29 11.67% ± 2.58 a 14.67% ± 9.16 
ATV1 72.00% ± 6.54 5.00% ± 2.45 22.83% ± 5.35 
ATV2 67.75% ± 14.01 1.75% ± 0.50 30.75% ± 13.45 
ATV1 + GRT1 71.17% ± 10.94 7.00% ± 5.55 21.83% ± 7.73 
ATV1 + GRT2 82.50% ± 5.09 5.50% ± 3.21 11.67% ± 4.13 
ATV2 + GRT2 76.33% ± 10.15 3.17% ±0.98 a 20.50% ± 9.81 
  a = p<0.01  
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11 Appendices 
 
11.1 Tissue Culture 
 
11.1.1 Aseptic Technique 
o In order to maintain sterility, all experiments and procedures took place in a biosafety 
class 2 cabinet. Micropipette tips and serological pipettes used were filtered and 
sterile. Before being placed in the biosafety class 2 cabinet, all equipment (centrifuge 
tubes, flasks, etc.), as well as the surface of the hood itself, were sprayed down with 
70% ethanol.  
 
11.1.2 Maintenance of Cell Line 
o Cell name: C3A [HepG2/C3A, derivative of HepG2 (ATCC HB-8065)] (ATCC® 
CRL-10741™)  
o ATCC #: HB-8065 
o Aggregating cell line, therefore care must be taken so as not to allow cultures to 
become over-confluent 
o Growth medium: EMEM with 10% FBS and 0.1% 200 mM L-Glutamine (the 
combination of which referred to as complete growth medium) 
o Temperature: 37°C and 5% CO2 
o Freeze medium: Complete growth medium supplemented with 7% DMSO 
o Storage medium: Liquid nitrogen (vapour phase) 
o Number of times the cells have been trypsinized and reseeded was indicated by 
passage numbers in order to avoid phenotypic drift. 
o Complete growth medium, PBS, and treatments were always pre-warmed in a water 
bath at 37°C prior to use. 
 
11.1.3 Preparation of Complete Growth Media 
o 10% FBS (50 mL) was added to 500 mL EMEM 
o 200 mM L-glutamine (5 mL) was added to 500 mL EMEM 
o Complete medium was then aliquoted into 50 mL centrifuge tubes for routine use 
o Aliquoted centrifuge tubes containing medium were stored at 4°C 
 
11.1.4 Cell thawing 
o 50 mL centrifuge tube of growth medium was pre-warmed in water bath at 37°C 
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o Cryopreservation vial storing C3A cells was removed from liquid nitrogen storage tank 
and allowed to thaw 
• NOTE: complete thawing of cells was not allowed 
o Once partially thawed, cryopreservation vial was aseptically transferred the biosafety 
class 2 cabinet 
o 14 – 18 mL pre-warmed growth medium was added to a T75 flask 
o Cell suspension in the flask was slowly re-suspended and incubated (37°C with 5% 
CO2) 
o Confluency of the cells was assessed regularly and growth medium was refreshed 
every 2 days 
o Cells were considered ready to be sub-cultured at 70% - 80% confluency 
 
11.1.5 Cell sub-culturing and seeding 
o Fresh growth medium and PBS is pre-warmed to 37°C in a water bath 
o Trypsin was brought to room temperature 
o Growth medium was aspirated from the cell monolayer 
o The monolayer was washed with 5 mL pre-warmed PBS 
o PBS was aspirated and 3 mL trypsin was added to the flask and incubated (37°C) for 
5 minutes to ensure loosening of cells. Sufficient loosening of the cells was assessed 
using a microscope. 
• NOTE: cells were very adherent so gently tapping the culture flask 
against the base of one’s palm helped to loosen the cells 
o Once cells had sufficiently loosened, trypsin was inactivated with at least twice the 
volume of pre-warmed growth medium (i.e.: ≥6 mL) 
o Cell suspension was aspirated from the flask and decanted into a 50 mL centrifuge 
tube and centrifuges for 5 minutes at 1500rpm 
o Without disturbing the pellet, the supernatant was discarded and the pellet was re-
suspended with pre-warmed medium 
o A 10 µL sample of the cell suspension was counted and the required volume given the 
appropriate seeding density was calculated (See Counting of Cells) 
o The calculated volume of cell suspension was added to the applicable growth surface 
(flask or plate) and the required volume of fresh growth medium was added 
o Gently swirl plate or flask to ensure uniform cell distribution over growth surface 
o Cells were then incubated as normal (37°C with 5% CO2) 
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11.1.6 Counting of Cells 
o Haemocytometer was cleaned with 70% ethanol before use 
o 10 µL of cell suspension was added to 10 µL of Trypan blue 
o 10 µL of the Trypan blue cell suspension was added to one half of the haemocytometer 
(covering one grid) 
o Haemocytometer was placed on the stage of an Olympus CKX31 inverted light 
microscope  
o Cells were counted in four of the nine quadrants (A, B, C, D see image below) 
 
 
Example of a haemocytometer: 
 
  
o Calculate the number of cells 
• Total volume of each quadrant = 10-4cm3 therefore the conversion factor is 
10 000 
𝐶𝑒𝑙𝑙𝑠 𝑝𝑒𝑟 𝑐𝑚3 =  (
# 𝑐𝑒𝑙𝑙𝑠 𝑡𝑎𝑙𝑙𝑖𝑒𝑑
# 𝑞𝑢𝑎𝑑𝑟𝑎𝑛𝑡𝑠 𝑐𝑜𝑢𝑛𝑡𝑒𝑑
) × 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 × 10 000 
= 𝑥 𝑐𝑒𝑙𝑙𝑠 𝑝𝑒𝑟 𝑚𝑙 
▪ NOTE: multiplied by the Trypan blue dilution factor in order to calulate 
accurate number of cells relative to the volume 
• Cells resuspended in 𝑦 μl of medium 
𝑉𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑐𝑒𝑙𝑙 𝑠𝑢𝑠𝑝𝑒𝑛𝑠𝑖𝑜𝑛 𝑟𝑒𝑞𝑢𝑖𝑟𝑒𝑑 =  
𝑦
𝑥
 × 𝑟𝑒𝑞𝑢𝑖𝑟𝑒𝑑 𝑠𝑒𝑒𝑑𝑖𝑛𝑔 𝑑𝑒𝑛𝑠𝑖𝑡𝑦 
▪ NOTE: Seeding density for C3A cells is 1,10x105 cells per millilitre 
 
11.1.7 Freezing cells 
o Cells were generally frozen  at a concentration >1X106 cells/mL per cryopreservation 
vial 
o After centrifugation, the supernatant was aspirated without disturbing the pellet 
o Each pellet was carefully re-suspended in complete growth medium supplemented 
with 7% (v/v) DMSO 
A 
C 
B 
D 
Stellenbosch University  https://scholar.sun.ac.za
 11-iv 
 
o 1 mL of cell suspension was added to each cryopreservation vial 
o Vials were labelled with the cell line, passage number, and date 
o Cryopreservation vials were stored at -80°C overnight 
o The following day, cryopreservation vials were transferred to liquid nitrogen for proper 
storage for future use  
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11.2 Cytotoxicity and Cell Viability 
 
11.2.1 MTT reagents 
11.2.1.1 MTT 
o 90 mg MTT was dissolved in 45 mL 1x PBS 
 
11.2.1.2 Sorenson’s Glycine Buffer 
o 0.3755 g glycine (0.1 M) 
o 0.292 g NaCl (0.1 M) 
o 50 mL USP WFI 
o pH to 10.5 with NaOH 
 
11.2.2 MTT protocol 
o PBS pre-warmed 
o Medium aspirated 
o Washed with 200 µL PBS 
o Added 50 µL MTT to each well 
o Incubated for 30 minutes at 37°C 
o Aspirated MTT 
o Added 200 µL DMSO and 25 µL Sorenson’s Buffer 
o Read at OD570nm using Microtiter plate reader 
 
11.3 Modulation of CYP3A4 activity 
 
11.3.1 Western blot reagent preparation 
11.3.1.1 10x Tris-buffered saline (TBS) stock solution 
o 48.44 g Trizma-Base 
o 160.12 g NaCl 
o 1.8 L dH2O 
o pH to 7.6 
o Made up to 2 L with dH2O 
o Stored at 4°C 
 
11.3.1.2 1x TBS-T working solution 
o 200 mL 10x TBS stock solution 
o 1800 mL dH2O 
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o 2 mL Tween-20 
o Stored at 4°C 
 
11.3.1.3 Transfer buffer 
o 200 mL 5x Bio-Rad Transfer Buffer  
o 200 mL absolute ethanol 
o 600 mL d2H2O 
o Stored at room temperature 
 
11.3.2 Protein extraction 
o Cells scraped in 300 µL radioimmunoprecipitation assay (RIPA) lysis buffer 
supplemented with phenylmethylsulfonyl fluoride (PMSF) and a protease inhibitor 
o Lysate collected in Eppendorf microcentrifuge tube 
o Lysate homogenised in a tissue ribolyser 
• Homogenise at 25 Hz for 60 seconds 
• Incubate 60 seconds on ice 
• Repeat 4 times 
o Centrifuged at 30000 rpm at 4°C for 10 minutes 
o Supernatant collected in new Eppendorf microcentrifuge tube 
 
11.3.3 Protein concentration determination (RC DC protein assay) 
o Samples were diluted 1:10 in nanopore water 
o Samples were compared to a BSA standard curve 
• Standard curve concentrations were 0.0 mg/mL, 0.125 mg/mL, 0.25 mg/mL, 
0.5 mg/mL, 0.75 mg/mL, 1.0 mg/mL, 1.5 mg/mL, and 2.0 mg/mL 
o 25 µL of reagent A’ + 200 µL of reagent B were added to each well containing 
standards and samples 
o Multi-well plate was mixed on a plate shaker (500 rpm; 10 seconds) then incubated for 
10 minutes at room temperature 
o Absorbance was read on a SpectraMax i3x at OD630 
o Protein concentration of each sample was extrapolated from the BSA standard curve 
generated and multiplied by the dilution factor 
 
11.3.4 Sample preparation and gel electrophoresis 
o 4x SDS sample buffer was prepared (900 µL Laemmli Sample Buffer + 100 µL β-
mercaptoethanol) 
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o 60 µg protein lysate was mixed with SDS sample buffer in a ratio of 1:4 
o Samples were denatured by heating (5 minutes at 95°C) 
o Samples were then immediately transferred to ice 
o Mini-PROTEAN® TGX™ 12% Precast Gels placed in gel tank 
o Tank and buffer dam filled with 1x Tris/Glycine/SDS running buffer 
o 5 µL Precision Plus ProteinTM Western CTM marker and 60 µg protein sample was 
loaded onto the gel 
o PowerPac HC was run at 150 V for 70 minutes 
 
11.3.5 Western blot analysis 
11.3.5.1 Transfer to Nitrocellulose membrane 
o Transfer sandwich and nitrocellulose membrane were submerged in 1x Transfer Buffer 
for 3 minutes 
o Transfer sandwich was assembled in a Trans-Blot® TurboTM transfer cassette 
o Proteins were transferred to membrane by semi-dry transfer 
• Bio-Rad mixed molecular weight transfer for 10 minutes at 25 V and 2.5 A 
 
11.3.5.2 Ponceau S stain 
o Membrane was removed and submerged in Ponceau S stain to assess protein transfer 
o Membrane was incubated on an orbital shaker for 10 minutes 
o Membrane was rinsed in dH2O until the background was clear 
o Protein bands imaged on Bio-Rad ChemiDoc MP System 
o Membrane was counterstained in TBS-T on an orbital shaker for 5 minutes at room 
temperature 
 
11.3.5.3 Membrane labelling 
o Membrane blocked in 5% (w/v) skim milk powder in TBS-T on an orbital shaker for 120 
minutes at room temperature 
o Membrane rinsed 3 x 10 minutes in TBS-T 
o Membrane incubated in primary antibody overnight on an orbital shaker at 4°C 
• CYP3A4 1:500 in 5% (w/v) BSA in TBS-T 
• GAPDH 1:2500 in TBS-T 
o Membrane rinsed 3 x 10 minutes in TBS-T 
o Membrane blocked in HRP-conjugated secondary antibody (1:4000) + StrepTactin 
(1:10000) in 2.5% (w/v) skim milk powder in TBS-T on an orbital shaker for 90 minutes 
at room temperature 
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o Membrane rinsed 3 x 10 minutes in TBS-T 
o Membrane immersed in ECL (1:1 parts A and B) and incubated for 5 minutes in the 
dark at room temperature 
o Membrane imaged on Bio-Rad ChemiDoc MP System 
 
11.4 Oxidative stress (DCF assay) 
 
o 20 µM DCF added to each well 
o Incubated for 30 minutes at 37°C 
o Readings taken (Ex 485/20nm; Em 528/20nm) 
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11.5 Apoptosis assessment using flow cytometry 
 
11.5.1 JC-1 mitochondrial membrane potential stain 
o Aspirated treatment medium into Eppendorf micro centrifuge tubes in order to retain 
detached cells and stored at 4°C temporarily  
o Added 200 µL trypsin to each well 
o Incubated at 37°C for 15 minutes 
o Neutralised the trypsin with 500 µL medium 
o Added trypsinised cells to Eppendorf micro centrifuge tubes stored at 4°C  
o Centrifuged at 200xg for 5 minutes 
o Aspirated supernatant 
o Re-suspended in 250 µL PBS 
o Counted (untreated unstained control) with a Trypan blue stain 
• Calculated viability and adjusted to 1x106 cells/mL 
o Stained with 2 µM JC-1 
• NOTE: JC-1 is light-sensitive 
o Incubated for 30 minutes at 37°C 
o Centrifuged at 200xg for 5 minutes 
o Washed with 300 µL PBS 
o Centrifuged at 200xg for 5 minutes 
o Re-suspended in 300 µL PBS 
o Read on flow cytometer 
 
11.5.2 Annexin V/propidium Iodide (PI) stain 
o Aspirated treatment medium into Eppendorf micro centrifuge tubes in order to retain 
detached cells and stored at 4°C temporarily 
o Added 200 µL trypsin to each well 
o Incubated at 37°C for 15 minutes 
o Neutralised the trypsin with 500 µL medium 
o Added trypsinised cells to Eppendorf micro centrifuge tubes stored at 4°C  
o Centrifuged at 200xg for 5 minutes 
o Aspirated supernatant 
o Re-suspended in 250 µL PBS 
o Stained with 100 µL Annexin V/PI per sample 
• NOTE: Annexin V/PI is light-sensitive 
• 1.5 µL/100 µL Annexin V 
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• 10 µL/100 µL PI 
▪ Working concentration of PI is 100 µg/mL 
o Incubated for 30 minutes at 37°C 
o Centrifuged at 200xg for 5 minutes 
o Washed with 300 µL PBS 
o Centrifuged at 200xg for 5 minutes 
o Re-suspended in 300 µL PBS 
• NOTE: Samples kept on ice 
o Read on flow cytometer 
 
11.6 Caspase 3/7 activation assessment 
 
o 2 mM stock solution (made up in DMSO – 100 µL → already prepared) 
o Diluted stock in complete medium to final concentration of 10 µM working solution 
o Aspirated treatment 
o Added 100 µL working solution to each well 
o Read on SpectraMax i3x 
• Ex/Em: 502nm/530nm 
• Incubated for 60 minutes at 37°C 
• Read from the bottom of the well every 15 minutes 
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11.7 3D culturing 
 
11.7.1 Day 0 
 
Bioreactors and AggreWell™ plate were prepared 
 
11.7.1.1 Setting up of 10 mL bioreactors 
o Bioreactor was removed from sterile packaging in the hood 
o Balanced in a sterile Petri dish, the bioreactor ports were plugged with appropriate 
plugs 
o Humidity chamber was filled 40 mL with pre-warmed TC grade water 
o Growth chamber was filled with 9 mL pre-warmed DPBS 
o Apical growth chamber port area was cleaned with ~200 µL 70% ethanol 
o Bioreactor was firmly attached to a rotor switched on to reverse 
 
11.7.1.2 Preparation of AggreWell™ plate 
o Centrifuge plate carrier was wiped with ethanol and appropriate programme was set 
o 500 µL complete growth medium was added to two wells of the AggreWell™ plate 
• Used wells were marked accordingly 
o AggreWell™ plate was centrifuged with an appropriately prepared counter balance 
plate at room temperature at 2200 RCF for 9 minutes 
o Plate was carefully removed from the centrifuge and placed in the incubator until 
needed 
o Semi-confluent cells were removed from T75 flask by trypsinisation 
o Cells were gently re-suspended to achieve a single cell suspension 
o A sample of approximately 100 µL of cell suspension was removed for quantification 
of cells with a haemocytometer 
o Cells were centrifuged at room temperature in a sterile 50 mL centrifuge tube for 5 
minutes at 100 RCF 
o Cells were re-suspended at 4.8x106 cells/mL 
• A minimum of 2 mL of this cell suspension was prepared 
o 500 µL of the cell suspension was added to each of the two previously prepared 
AggreWell™ plate wells. Caution was taken to disperse the cell suspension as evenly 
as possible throughout each well, as well as avoiding the formation of bubbles 
o Each of the newly seeded wells was topped up with 1000 µL of pre-warmed growth 
medium 
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o AggreWell™ plate was centrifuged at room temperature at 100 RCF for 3 minutes 
o Distribution of the cells and absence of bubbles was assessed visually with the aid of 
an inverted microscope 
o AggreWell™ plate was carefully transferred to the incubator and the plate was left to 
incubate for approximately 20 hours 
 
11.7.2 Day 1 
o Heating blocks were pre-warmed to ~37°C 
o Mother bioreactors were prepared as follows: 
• One bioreactor prepared on Day 0 was detached 
• PBS was aspirated from the growth chamber 
• 3.5 mL pre-warmed complete growth medium was added to the chamber 
• Bioreactor was reattached to the rotor and incubated at 37°C until required 
o 500 µL pre-warmed complete growth medium was added to a Petri dish (on heating 
block; 35mm x 10mm; clearly labelled) 
o AggreWell™ plate was placed on the second heating block. Spheroids were gently 
dislodged from within the micro-wells using a disposable Pasteur pipette.  
• NOTE: in order to be very gentle, a maximum volume equivalent to 2 cm from 
the tip of the pipette was taken up and pipetted incredibly slowly 
o Process was observed continuously under the microscope 
o Dislodged spheroids were transferred to the Petri dish when approximately 50% of the 
spheroids had been dislodged 
o Fresh medium was added to the well to and remaining spheroids were dislodged and 
transferred to the Petri dish 
o Spheroids were observed under the microscope for uniformity. Any distinctly aberrant 
spheroids or cell clusters were removed 
o Petri dish was gently swirled to aggregate the spheroids in the centre. Using a 
disposable Pasteur pipette, spheroids were transferred to the growth chamber of the 
bioreactor via the large port on the face of the bioreactor 
o The front port was securely fastened and the growth chamber was topped up via the 
apical port with pre-warmed complete growth medium using a 10 mL pipette 
o Bioreactor was gently tapped to release any bubbles close to the apical port 
o Excess medium was removed from the external apical port areas and bioreactor was 
checked again for bubbles. 
o If no bubbles were found, external apical port was cleaning with ~200 µL 70% ethanol 
o Bioreactor was returned to the incubator and rotated at the lowest speed (~14.5 rpm) 
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o Bioreactors were checked for bubbles approximately 1 hour later 
 
11.7.3 Change of growth/treatment media 
o For the first 18 days of growth, media was changed every two days. Treatment media 
was changed every day 
o Media was carefully aspirated using a 10 mL syringe with an 18G hypodermic needle 
from the apical port of the bioreactor 
o Fresh media/treatment added slowly using a 10 mL serological pipette 
o The fastened apical port was cleaned thoroughly with 70% ethanol 
 
11.7.4 Sampling of spheroids 
o Approximately half of the media in the bioreactor was carefully aspirated using a          
10 mL syringe with an 18G hypodermic needle from the apical port of the bioreactor  
o Apical port was fastened and bioreactor placed with front port facing up 
o Spheroids were sampled from the front port and transferred to applicable sample 
surface (plate or microcentrifuge tube) and front port was fastened 
o Remaining media/treatment media was removed and replaced with fresh 
media/treatment media as previously described 
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11.8 ATP production 
 
o Stored plate with sampled spheroids and CellTiter-Glo® detection kit left to equilibrate 
to room temperature before use 
o Lyophilized CellTiter-Glo® Substrate reconstituted in CellTiter-Glo® buffer 
o 125 µL CellTiter-Glo® Reagent added to each well 
o Incubated for 60 minutes at 37°C on plate shaker 
o Read on SpectraMax i3x 
 
11.9 Adenylate kinase assessment 
 
o All reagents equilibrated to room temperature before use 
o Adenylate kinase detection reagent reconstituted in 10 mL assay buffer and allowed 
to equilibrate for 15 minutes (at room temperature) 
o 5 µL of each treatment was added to a white-walled plate 
o 100 µL reconstituted adenylate kinase detection reagent was added to each well 
o Incubated at room temperature for 5 minutes 
o Read on SpectraMax i3x 
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